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Glycosyltransferases (GTs) are a large enzyme family that are involved in the biosynthesis of 
complex carbohydrates and glycoconjugates. These glycosylation reactions are essential to 
many fundamental biological processes, including cellular adhesion, cell signalling and 
bacterial cell wall biosynthesis. The aim of this project was the development of operationally 
simple assays for GTs and their application for the identification and characterisation of novel 
GT inhibitors. The main focus was on the bacterial GT, α1,4-galactosyltransferase C (LgtC) 
which transfers galactose from uridine-diphosphate-galactose to the terminal lactose on the 
cell wall lipooligopolysacharide of Neisseria meningitidis. 
 
A fluorescence-based ligand displacement assay (LDA) was optimised and validated for 
compound library screening. Additionally, the applicability of the LDA was investigated with 
three other GTs: bovine β1,4-galactosyltransferase, TcdB from Clostridium difficile and NGT 
from Actinobacillus pleuropneumoniae. The validated LDA was used for screening two 
compound libraries (c. 400 compounds in total) against LgtC for the first time. Positive hits 
were identified from both screening campaigns and selected compounds from two structural 
classes were characterised. One of these inhibitor classes was identified as molecular 
aggregators, which inhibit LgtC non-specifically. Results from the enzymological 
characterisation of the second class of hit compounds suggest that these inhibitors were 
mixed-type inhibitors and inhibit LgtC in micromolar range with considerable potential for 
further development. 
 
Development of a novel biochemical assay was attempted, in order to characterise potential 
inhibitors from the compound screening. This assay was based on an unnatural fluorescent 
acceptor and coupling of the GT reaction to a glycosidase reaction. During the development of 
this novel biochemical assay, unexpected enzymological features of LgtC were discovered. LC-
MS/MS was used to investigate unknown products originating from the LgtC-catalysed 
reaction. The results suggest LgtC transfers more than one sugar moiety to the unnatural 
acceptor. Additionally two existing biochemical assays: HPLC-based assay and phosphatase 
coupled assay were successfully optimised and validated for determining the kinetic 
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Carbohydrates (also called glycans) are the most diverse biological compound class in nature. 
Initially, carbohydrates were identified as energy storage molecules (e.g. cellulose and 
glycogen), but since 1960s carbohydrates have also been found to be involved in numerous 
biological processes such as pathogen infections, inflammation, cell adhesion and cancer.1  
Carbohydrates are represented in many forms from single saccharides to complex 
polysaccharides and glycoconjugates (when mono- or disaccharide is covalently linked to a 
non-carbohydrate moiety such as protein or lipid2). Glycosyltransferases and glycosidases are 
two major classes of carbohydrate-active enzymes that modify these carbohydrate structures.3 
Glycosyltransferases catalyse the glycan synthesis (e.g. oligosaccharides) whereas glycosidases 
hydrolyse glycosidic linkages. 
 
Specific inhibitors of glycosyltransferases could serve as therapeutic leads in drug discovery 
and could be utilised as useful tools in analysing glycan function and assembly. Therefore, 
robust and sensitive assays are essential for identifying novel inhibitors, monitoring enzymatic 
activity and inhibitor potency. The main focus of the thesis is to develop both a high-
throughput assay for inhibitor identification and a biochemical assay for investigation of 
activities of GTs.  
 
This chapter will introduce glycosyltransferases, their classification, mechanisms, biological 
function and potential drug targets. This will be followed with a brief review of the analytical 
techniques utilised for GT characterisation. Glycosidases, the second main carbohydrate-active 















Glycosyltransferases (GTs) represent a large family of enzymes that are involved in the 
biosynthesis of glycoconjugates, oligosaccharide and polysaccharides.1, 4, 5 These enzymes 
catalyse the transfer of a sugar moiety from an activated donor sugar substrate onto specific 
acceptor molecules forming glycosidic bonds (Figure 1.1).5 The acceptors are most commonly 
saccharides but can also be lipids, natural products, DNA, proteins or glycoconjugates.5 
Generally, GTs elongate the glycan chains by transferring sugar moieties producing a preferred 
acceptor substrate for another GT. The glycosidic linkage between each sugar moiety can have 
two anomeric configurations (α or β),5 therefore, the potential number of structures that can 
exist is vast. 
 
 
Figure 1.1. Glycosyltransferase catalysed reaction  
 
Most of the GTs are nucleotide sugar-dependent enzymes and they are usually referred to as 
Leloir enzymes.6, 7 The donor substrates consist of a sugar moiety which is linked to a 
nucleotide via a mono-or diphosphate.  The high-energy bond between the anomeric centre of 
the sugar ring and phosphate activates the sugar for the transfer reaction. In mammalian 
metabolism there are nine main nucleotide donors (Table 1.1): uridine diphosphate galactose 
(UDP-Gal), uridine diphosphate glucose (UDP-Glc), uridine diphosphate N-acetylglucosamine 
(UDP-GlcNAc), uridine diphosphate N- acetylgalactose (UDP-GalNAc), uridine diphosphate 
xylose (UDP-Xyl), uridine diphosphate glucuronic acid (UDP-GlcA), guanosine diphosphate 
mannose (GDP-Man), guanosine diphosphate fucose (GDP-Fuc) and cytidine 5’-monophospho-








Table 1.1. Nucleotide sugar donors in mammalian metabolism 
 
Nucleotide sugar R1 R2 R3 R4 R5 R6 
UDP-Gal (A) -OH -H -OH -CH2OH   
UDP-Glc (B) -H -OH -OH -CH2OH   
UDP-GlcNAc (C) -H -OH -NHAc -CH2OH   
UDP-GalNAc (D) -OH -H -NHAc -CH2OH   
UDP-Xyl (E) -H -OH -OH -H   
UDP-GlcA (F) -H -OH -OH -COOH   
GDP-Man (G) -OH -H   -CH2OH -H 
GDP-Fuc (H) -H -OH   -H -CH3 
CMP-NeuAc (I)       
 
 
GTs are highly specific for both the donor and the acceptor substrates, and generally, do not 
tolerate structural modifications of their natural substrates. However, some GTs can accept 
unnatural substrates and the reactions can occur in a non-stereospecific manner.9-13 Recently, 
substrate engineering studies have shown that a bifunctional α2,3/α2,8 sialyl transferase CstII 
from Campylobacter jejuni (C. jejuni) is able to use unnatural donors and acceptors. CstII strain 
OH4384 naturally catalyses the transfer of sialic acid moiety from CMP-NeuAc to the terminal 
position 3’ hydroxyl of terminal lactose-containing acceptors. The second step, sialic acid is 
transferred to the 8’ hydroxyl of the α2,3’-sialylated lactose.14 Lairson and co-workers 
investigated donor flexibility of CstII with α-linked para-nitrophenyl (pNP) sialic acid where it 
could serve as an alternative donor.13 They demonstrated that CstII catalysed the transfer of 
sialic acid with α2,3-linkage but only in the presence of the natural donor CMP-NeuAc.13  
27 
 
Recent investigations with a derivative of galactose, (β-linked pNP-Gal), demonstrated that it 
served as a specific acceptor for CstII, and also for bovine α1-3-galactosyltransferase (α1,3-
GalT)12 which naturally catalyses the transfer of galactose from UDP-Gal to terminal N-
acetyllactosamine-containing glycoconjugates.15 A non-stereospecific outcome of the GT 
catalysed reaction has also been reported. Acceptor specificity studies of LgtC (α1,4-
galactosyltrasferase) demonstrated that the transfer of galactose to unnatural acceptors 
formed α1,2/3/4 linkages.12 LgtC naturally forms an α1,4-linkage between donor sugar and 
acceptor molecule.16 These properties can be exploited as tools for the enzymatic synthesis of 
various oligosaccharides.  
 
1.1.1. Classification of glycosyltransferases 
 
Glycosyltransferases have been classified into families based on their amino acid sequence 
similarities along with the stereochemical outcome of their reactions and three-dimensional 
structure.5, 17  To date 94 GT families based on their amino acid similarities are listed in the 
Carbohydrate Active Enzymes Database (CAZy).5, 18 The majority of the known GTs can be 
divided into two classes with the GT-A and GT-B folds based on their three-dimensional crystal 
structures.5, 18 However, no correlation is found between the GT folds and the stereochemical 
outcome of the catalysed reaction. GT-A and GT-B folds are formed of two Rossmann-like folds 
which is typical for nucleotide-binding proteins.1, 5 The Rossmann-like fold consists of βαβ 
units, usually 6 parallel β- strands linked to 4 α- helices.19  
 
The GT-A proteins contain two closely associated Rossmann-like folds, as a single domain.5 The 
first GT-A fold was identified when the crystal structure of SpsA from Bacillus subtilis was 
described in 1999 (Figure 1.2, left).20 Most GT-A folded GTs have an Asp-x-Asp (or DXD, x is any 
amino acid) motif in the catalytic site, which is involved in metal ion binding, such as Mn2+ or 
Mg2+, and is essential for enzymatic activity.5 The GT-A fold also contains a small flexible loop 
region that changes conformation during the catalytic cycle by creating an acceptor binding 
site.21 The first described GT crystal structure was the β-glycosyltransferase from 





The GT-B proteins contain two Rossmann-like folds, however, in this case the two domains are 
less associated and the active site is predicted as lying in the cleft (Figure 1.2, right).5 Instead of 
using a divalent metal ion to stabilise the nucleotide phosphate, the joined helices of the 
subdomain of the Rossmann folds create a binding site for the acceptor. 
 
 
Figure 1.2. Overall folds observed for GTs. The GT-A fold is represented by the inverting GT SpsA from 
Bacillus subtilis in the presence of UDP (Protein Data Bank, PDB: 1QGQ)
20
 and the GT-B fold, by 
bacteriophage T4 β-glucosyltransferase in the presence of UDP (PDB: 1JG7)
23
. α-helixes are in blue, β-
strands in red and donor substrates are presented in stick form (yellow)  
 
A GT-C fold has been recently proposed for hydrophobic integral membrane GTs and this fold 
is proposed to bind lipid phosphate-activated donor sugar substrates.5 The membrane 
enzymes are difficult to express and crystallise, and only two crystal structures have been 
reported.24, 25 Most GTs with known structure possesses the GT-A, GT-B or GT-C fold, however, 
some GTs still remain unclassified.  
 
1.1.2. Mechanism of GTs 
 
GTs catalyse the formation of a glycosidic bond between the sugar from the nucleotide donor 
and the acceptor. The released glycosylated product can have the same or opposite 
configuration at the anomeric carbon as the donor substrate (Figure 1.3).5 Functionally, GTs 
can be separated into retaining or inverting enzymes depending on the outcome of the 
reaction. The mechanism for inverting GTs is well established while the retaining mechanism is 








The inverting GTs follow a single SN2-like displacement mechanism.
5 A base (usually asparagine 
or glutamic acid) in the active site of the enzyme, protonates the hydroxyl group of the 
acceptor, assisting its direct nucleophilic attack onto the anomeric carbon of the sugar donor 
(Figure 1.4, a). Retaining GTs are proposed to use a double displacement mechanism which 
involves two sequential SN2-like reactions that lead to a covalently bound glycosyl-enzyme 
intermediate (Figure 1.4, b).1, 5 The mechanism requires a nucleophile and divalent cation or 
charged side chain in an appropriate location within the active site. The first step occurs 
similarly to the inverting mechanism and the hydroxyl group of the incoming acceptor is 
probably activated for the nucleophilic attack by the base catalyst of the leaving group or the 
enzyme. 
 
Figure 1.4. Direct-displacement mechanisms of inverting GTs (A) and a proposed double-displacement 
mechanism for retaining GTs (B). R1 would generally be a nucleoside mono- or diphosphate of the donor 




Alternatively, SNi-like and SNi mechanisms have been proposed for retaining GTs which involves 
an ion pair intermediate or oxocarbenium ion-like transition state, respectively.5, 26 Studies of 
the reaction mechanism of retaining GTs can be controversial. For example, SNi-like and SNi 
mechanisms have been proposed for α1,4-galactosyltransferase (LgtC) based on experimental 
and computational studies.16, 27, 28  
 
1.1.3. Glycosyltransferases in biological systems 
 
The products of GT catalysed reactions such as glycolipids and glycoproteins mediate many 
essential biological processes. These complex glycan chains are generally located on the cell 
wall of eukaryotic cells where they play an important role as receptors in recognition events 
such as cell signalling and cellular adhesion, and provide receptors for viruses, bacteria or 
hormones.29 GTs are involved in the biosynthesis of N-/O-liked glycoproteins and glycolipids in 
both prokaryotic and eukaryotic organisms.29-31 Glycosylation in eukaryotic cells is initiated in 
the endoplasmic reticulum and further modified in the Golgi apparatus.29  Whereas in 
prokaryotic cells glycosylation occurs in the cytoplasm and in the periplasm.32 
 
Glycosylation plays a significant role for human health and disease.33-35 Changes in 
glycosylation can cause under- and over expression of naturally occurring glycans. In diseases 
such as cancer, glycosylation of the cell surface proteins change from normal and the immune 
system initiates the construction of abnormal cells when the wrong type of glycans are 
recognised. For example, N-acetylglucosaminyltransferase V (GlcNAc-TV, also known as 
MGAT5: mannoside-acetylglucosaminyltransferase 5) has been found to be associated in the 
branching of N-linked oligosaccharides.33, 36 These extensively β1,6-GlcNAc branched glycans 
create additional sites for terminal sialic acid residues on the cell surface, which can lead to an 
elevated activity of sialyltransferases in cancerous cells. Many polysaccharide structures, such 
as sialyl Lewis isomers that are present on O- and N-linked oligosaccharides, have been found 
to be associated in various human malignancies. Increasing activity of fucosyltransferases, such 
as FucT I-VIII which transfers fucose in α 1,2/3/4 or 6-linkages to terminal galactose or GlcNAc 
residues can lead to an over expression of various terminal glycans, such as sialyl Lewis X and 
Lewis Y (Figure 1.5).36 For example, increasing activity of α1,2-fucosyltransferase in human 
colorectal cancer cells have shown to be linked to the formation of Lewis B (Fuc-α1,2-Gal-β1, 
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3-[Fuc-α1,4]-GlcNAc-β1,3-Gal-β1,4-Glc) and Lewis Y37 and, increased activity of β1,6-N-
acetylglucosaminyltransferase (C2GnT) in breast carcinoma, sialyl Lewis A (NeuAc-α2,3-Gal-β1, 








Almost all bacteria cell walls consist of a peptidoglycan layer which is formed of linear glycan 
strands cross-linked by short peptides.39 The peptidoglycan layer is essential for shape and 
protects the bacteria from turgidity. The outer cell membrane of the Gram-negative bacteria is 
covered with polysaccharides (Figure 1.6) and this sugar layer is responsible for the protection 
of the bacteria from the host’s immune system, as well as acting as a virulence factor for 
the infection of the host.32, 40 Unusual monosaccharides such as di-N-acetylbacillosamine 
(BacAc2), 2,4-diacetamido-2,4,6-trideoxyhexose (DATH), N-acetylfucosamine and pseudaminic 
acid have been found in bacterial glycosylation that are not present in the eukaryotic 
systems.30 Both O-linked and N-linked protein glycosylation pathways are found in bacteria 
and the first bacterial N-glycosylation pathway was described with C. jejuni.41 In C. jejuni, five 
different glycosyltransferases (i.e. PglC, PglA, PhlJ, PglH and PglI) are involved in the 
biosynthesis of heptasaccharide (GalNAc-α1,4-GalNAc-α1,4-(Glc-β1,3)-GalNAc-α1,4-GalNAc-
α1,4-GalNAc-α1,3-BacAc2) on a lipid carrier which is then transferred to an asparagine residue 
of the protein by PglB. In addition, unusual monosaccharides are found in O-glycosylation in 
Neisseria gonorrhoeae where DATH containing trisaccharide (Gal-β1,4-Gal-α1,3-DATH) is 









A range of GTs play an important role in the biosynthesis of Gram-negative bacterial 
lipopolysaccharides (LPSs) and lipooligosaccharides (LOSs). LOS differs from LPS by lacking the 
O-antigen (O-polysaccahride) repeating units. LPS and LOS are located in the outer membrane 
of the bacterial cell surface (Figure 1.6) where they are attached to lipid A which is a key factor 
for virulence.40 The outer oligosaccharide core of LPS and LOS is an important factor for the 
interaction between the bacteria and the environment. For example, various α-chains can be 
formed in the biosynthesis of LOS in Neisseria meningitidis (N. meningitidis) that are crucial for 
bacterial survival in the host. The biosynthesis of meningococcal LOS is initiated in the 
cytoplasm by the synthesis of an inner oligosaccharide core that is attached to lipid A, 
containing two KDO (3-deoxy-D-manno-2-octulosonic acid) and two HEP (L-glycero-D-manno-
heptose) residues.43 Synthesis of the outer oligosaccharide core (α-chain) is initiated by LgtF 
(β1,4-glucosyltransferase) that first adds glucose to the HEP1 residue, followed by the 
sequential addition of additional sugar residues (Figure 1.7). The completed α-chain is 
translocated to the periplasmic surface of the inner membrane, transported across periplasm 
and integrated into the outer membrane.43 Various GTs are responsible for the sequential 
addition of sugars to the α-chain. Depending on the phase variable expression of lgtA and lgtC 
(LgtA and LgtC encoding genes, respectively) different α-chains can be formed.44, 45 If LgtA (1,3-
N-acetylglucosaminetransferase) is not expressed then the α-chain can terminate at the Gal-
β1,4-Glc-β1,4-HEP1. Alternatively, if LgtC is expressed then addition of α1,4-Gal at the Gal of 
the Gal-β1,4-Glc-β1,4-HEP1 of LOS occurs and a short α-chain (Gal-α1,4-Gal-β1,4-Glc, 
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globotriaose) is formed.46, 47 Synthesis of lacto-N-neotetraose (Gal-β1,4-GlcNAc-β1,3-Gal-β1,4-
Glc, LNT)  occurs in the presence of LgtA, transferring GlcNAc to the terminal galactose 
followed by LgtB (β1,4 galactosyltransferase) to terminate the LNT structure.48, 49  
 
 
Figure 1.7. LOS of N. meningitidis. LgtC transfers galactose to the terminal end of the α-chain if LgtA is 




Globotriaose and LNT chains on N. meningitidis LOS are major virulence determinants. These 
α-chains can be sialylated and they form a capsular polysialic acid structure that camouflages 
N. meningitidis from the human immune system.46, 47 In addition, sialylation increases survival 
of N. meningitidis in the blood stream that can lead to fatal septicaemia.50  
 
1.1.4. Inhibitors of glycosyltransferases 
 
GTs are involved in the biosynthesis of complex glycoconjugates that participate in 
fundamental properties of cells such as signalling, immune response, microbial adhesion and 
infection. Because the glycosylation is essential for the survival of organisms, GT inhibitors are 
potential chemical tools for studying the behaviour of these enzymes, such as their 
mechanism, their role in glycan synthesis and also as potential lead compounds in drug 
discovery. Different strategies have been used in order to design potent GT inhibitors. 
Generally, the designed structure analogues are based on donor or acceptor substrates and 
potency as an inhibitor against a certain GT is investigated by a biochemical assay.51 In 
addition, three-dimensional structures of the enzymes are used to design potential inhibitors 
based on docking simulations.52-54 Another approach for inhibitor discovery is high-throughput 
screening (HTS) of large compound libraries. HTS has been shown to be an effective technique 
for the discovery of small molecule inhibitors and novel GT inhibitors have been identified 
(Figure 1.8, D-F).55-57 
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Different types of GT inhibitors have been developed to date, including acceptor and donor 
analogues, transition-state analogues and small molecule inhibitors.51, 58, 59 A disadvantage of 
the donor analogues (e.g. carbasugar analogues of nucleoside diphosphate sugars, Figure 1.8, 
A).60) is a poor cell membrane permeability due to their polar and charged nature, therefore, 
they generally cannot be used for in vivo studies. Recently, membrane permeable inhibitors of 
GTs have been developed.61, 62 A sugar analogue of GlcNAc, 2-naphthyl 2-butanamido-2-deoxy-
1-β-D-glucopyranoside (Figure 1.8, B) was found to be a specific inhibitor of β1,4-
Galactosyltransferase in cell homogenates (human airway cells; H292, human colonic cancer 
cells; CaCo-2 and mouse lymphocytic cells; MOPC).61 Brown and co-workers discovered an 
acceptor analogue of GlcNAc-β1,2-Man-β1,6-Man. Deacetylated GlcNAc-β1,3-Gal-β-O-
naphthalenemethanol inhibited the activity of β1,4-Galactosyltransferase T1 and the in vivo 
studies indicated the formation of sialyl Lewis x was blocked in U937 monolytic leukemia cells 
(Figure 1.8, C).62 
 
 
Figure 1.8. A) UDP-carba-Glc, a donor substrate analogue B) An acceptor analogue, 2-naphthyl 2-
butanamido-2-deoxy-1-β-D-glucopyranoside inhibitor of β1,4-GalT
61
, C) An acceptor analogue, per-O-
acetylated GlcNAc-β1,3-Gal-β-O-naphtalenemethanol, inhibitor of β1.4-GalT T1
62
, D-F) small molecular 







A small number of drug-like GT inhibitors have been discovered and some of these inhibitors 
have reached clinical study stage.59, 63 Currently in clinical use, Miglustat, N-butyl-
deoxynojirimycin (Figure 1.9), has been used for treatment of type 1 Gaucher's disease which 
is a glycosphingolipid lysosomal storage disorder.64 Gaucher's disease is caused by a lack of 
glucocerebrosidase which leads to an accumulation of glucosylceramide in several organs. 
Miglustat is an imino sugar inhibitor that lowers the activity of glucosylceramide synthase 
which catalyse the first step in the biosynthesis of glucosphingolipids.64, 65 
 
 




Searching for potent inhibitors of GTs is challenging due the low binding affinity of glycosyl 
donors and acceptors to GTs, the lack of three-dimensional protein structures and the complex 
reaction mechanism, which includes a transition state where a nucleotide sugar, an acceptor 
and often, a metal ion are involved. In addition, the lack of sensitive, robust and operationally 
simple compound screening methods due to non-chromophore containing substrates, further 
complicate this process. 
 
1.2. Glycosyltransferase assays  
 
Numerous diverse assays have been developed to study GTs.63, 66 These assays allow the 
determination of GT activity during and after enzyme purification in cellular systems, and can 
be used for mechanistic studies, for high through-put screening of GT inhibitors as well as for 
the directed evolution of GTs.    
 
GT assays can be designed either as biochemical or binding affinity assays.63 The biochemical 
assays are carried out with saturated substrate concentrations and progress of the enzymatic 
reaction can be monitored either by the depletion of the substrates (i.e. sugar-nucleotide or 
acceptor) or the formation of the products (i.e. nucleoside diphosphate (NDP) or glycosylated 
acceptor). These assays provide essential information about the biological activity of the used 
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GT. Therefore, the biochemical assays are generally used for inhibitor validation and substrate 
specificity studies. A disadvantage of the biochemical assays is the poor availability of many 
substrates, particularly acceptors. In contrast to the biochemical assay, the binding assays 
(Scheme 1.1. D)63 are designed to monitor the binding affinity of a labelled donor substrate. 
The acceptors are not required in this assay format, and therefore, the conversion of the donor 
to product is not monitored. The binding assay can be developed as HTS assays where the 
binding affinity of small molecular inhibitors can be monitored effectively without acceptors. 
The advantage of the binding affinity assays compared to the biochemical assays is the 
applicability for HTS of inhibitor candidates, cost effectiveness and simple assay protocols.  
 
Natural GT acceptor substrates are generally (poly) saccharides which do not contain a 
chromophore or a fluorophore. However, the natural GT catalysed reaction can be monitored 
by detecting the formation of the glycosylated product (primary product) by mass 
spectrometry (MS) or the NDP (secondary product) with various detection methods, e.g. 
coupled enzymatic assays, chromatographic methods with UV detection, chemosensors and 
immune assays (Scheme 1.1. A). Methods such as high performance liquid chromatography 
(HPLC), capillary electrophoresis (CE) or ion exchange chromatography with a 
spectrophotometric detection are generally used for the monitoring of the depletion of the 
sugar donor or formation of the NDP, due to the UV-active nucleobase. If the method is based 
on detection of the NDP then it is essential to determine the enzymatic or chemical hydrolysis 
of the sugar donor under the assay conditions. Another approach for monitoring GT activities 
is to use labelled donors or acceptors which allow the detection of the primary product 
(Scheme 1.1. B). The labelled product can then be detected with spectrophotometric 
techniques (UV or fluorescence) or radiochemical methods (scintillation counting). GT 
reactions can also be monitored by FRET (fluorescence resonance energy transfer), a 
technique where both the donor and the acceptor are fluorescently labelled (Scheme 1.1. C). A 
ligand displacement assay is based on a fluorescent donor analogue that binds to the active 
site which can be then displaced with a high affinity inhibitor (Scheme 1.1. D). The ligand 





Scheme 1.1. Principles of assays used for determination of GT activity and ligand binding. A) Native GT 
reaction; NDP can be detected by HPLC/UV, coupled enzymatic assay, immunodetection or 
chemosensor and primary product can be detected by MS, B) Labelled donor or acceptor: the product 
can be detected by  spectrophotometric or radiochemical methods, C) FRET based assay principle, D) 




Monitoring the GT reactions is challenging due to the complexity of the reaction which occurs 
in the presence of multiple, colourless substrates in low concentrations. Therefore, GT assays 
require a sensitive detection method for the monitoring of small concentration changes in the 
GT catalysed reactions. Limitations for the development of GT biochemical assays are the poor 
availability of natural substrates as well as labelled substrates and GTs may not be able to turn 
over unnatural substrates with bulky fluorescent substituents with useful reaction rates. 
Ideally, GT assay that monitor the reaction progress in real time are particularly valuable. In 
addition, accuracy, reproducibility and operational simplicity are important factors for an 
effective GT biochemical assay. Due to the complexity of the GT reaction a range of different 
assays have been developed to achieve these requirements. Therefore, GT assays will be 




1.2.1. Non fluorescence-based assays 
 
Radiometric assays are the most sensitive techniques for monitoring GT activities.66 Typically 
the radiometric assays involve incubation of the enzyme with radiolabelled donor substrate 
and acceptor. After the desired incubation time the reaction is stopped and unreacted 
radiolabelled substrates are then removed from the radiolabelled glycosylation product. This 
step usually requires chromatographic techniques (i.e. ion-exchange chromatography, 
electrophoresis66) and the radiolabelled glycosylated product is quantified by scintillation 
counting.67 Due to the separation and the washing steps, radiometric assays are difficult to 
adapt for HTS. Recently, von Ahsen and co-workers develop a miniaturised scintillation 
proximity assay with fucosyltransferase VII.68 The acceptor molecules were coated with 
scintillat-impregnanted microspheres which emit light when stimulated with radiolabelled 
molecules. Therefore, the reaction was monitored by incubating the coated acceptors with 
radiolabelled donor substrates. The assay was then applied to HTS and nearly 800000 
compounds were screened against human fucosyltransferase VII.68 Due to the detection 
technique, washing steps were not required. However, a significant disadvantage of this assay 
is the radioactive waste and the requirement for radiolabelled substrates.  
 
Many chromatographic methods have been used to determine activities of GTs and the most 
common techniques are HPLC69-72 and CE.73-76 A GT-catalysed reaction can be monitored 
without additional modifications by detecting the UV-active nucleobase containing sugar 
donor or/and the nucleobase containing secondary product. In this approach, when the 
detection is not based on monitoring the primary reaction product, it is imperative to 
determine the amount of hydrolysis of sugar nucleotide donor.  Alternatively, the acceptors 
can be post- or pre- derivatised with UV-active or fluorescent moieties which then allow the 
quantitative analysis of the primary product. Hayashi and co-workers utilised commercially 
available fluorescent acceptors C6-4-nitrobenzo-2-oxa-1,3-diazole (NBD)-ceramide and C6-
NBD-glucosylceramide to monitor the activity of GlcT and GalT respectively.71 The fluorescent 
products were then separated from the donor substrates and quantified with a HPLC-based 
method. Monegal and co-workers developed a fluorophore-assisted capillary electrophoresis 
method to monitor α1.3-GalT activity.74 The glycosylated product was post-derivatised with 8-
aminonaphthalene-1,3,6-trisulfonic acid that allowed both UV-detection and fluorescence 
detection of the product. In this assay format the GT catalysed reaction occurs in the presence 
of native substrates which is an advantage compared to the assay where pre-derivatised 
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acceptors, which may hamper the reaction progress, are used. The chromatographic methods, 
particularly CE with fluorescence detection,75 are very sensitive. However, the major 
disadvantage is the time-consuming procedures because the assays are performed in a 
discontinuous manner. 
 
Mass spectrometry (MS) offers an alternative as detection methodology in GT assays because 
it is applicable to monitoring the turnover of naturally occurring GT substrates. MS detection 
has been used for inhibitor screening77 and characterisation,78, 79 and also in HTS format. The 
HTS format has been employed for studying potential substrates for bovine β1,4-GalT and a 
plant glucosyltransferase, UGT72B1 form Arabidopsis thaliana.80 This method provided a rapid 
and reliable determination of kinetic parameters for these two enzymes and the assay format 
could be suitable for other GTs.  
 
An equivalent proton is released during the transfer of sugar molecule from sugar-nucleotide 
donor to the acceptor, causing a change in pH which can be detected by using pH indicators. 
Deng and co-workers developed an assay by exploiting this approach by detecting the pH 
change with phenol red pH indicator.81 The pH assay was applied to study the substrate 
specificities of three different galactosyltransferases. Palcic and Persson also developed a 
similar pH based assay with pH indicator bromothymol blue.82 They employed the assay in HTS 
format and screened 350 mutants of the blood group α1.3-galactosyltransferase (GTB). Two 
novel mutants were identified and the characterisation investigations with radiochemical assay 
displayed increased activity compared to the wild-type GTB. Advantages of these two assays 
are that labelled substrates are not required and the applicability to HTS and other GTs.  
 
Immunological methods are also applied to HTS. Hang and co-workers developed an enzyme-
linked lectin assay (ELLA) for polypeptide N-acetyl-α-galactosaminyltransferases (ppGalNAcTs) 
and they screened a small urine-based library against ppGalNAcTs.83 A disadvantage of such 
immunological methods is the availability of specific antibodies for each reaction product.  
 
Coupled enzyme assays are performed with natural GT substrates and generally on a 
microplate, therefore, they are applicable techniques for HTS. Gosselin and co-workers 
assayed GT activities by coupling the secondary reaction product, UDP, via pyruvate kinase and 
lactate dehydrogenase to NADH oxidation.84 The reaction progress was proportional to the 
decrease in absorbance at 340 nm. This continual coupled assay was developed for the 
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investigation of four different galactosyltransferases. The amount of UDP (or UMP) has also 
been detected by a coupled reaction with phosphatase which releases inorganic phosphate.85 
The inorganic phosphate can be then detected with colorimetric reagents. Advantage of these 
coupled assays is that they can be applied to a GT reaction that produces UDP or UMP. 
Conversely, these types of assays may consume large quantities of valuable reagents when 
they are applied to large compound library screening. In addition, both reported coupled 
assays utilise UV-detection which may not be enough for detecting small concentration 
changes in the GT-catalysed reactions. 
 
1.2.2. Fluorescence-based assays 
 
Fluorescence is a phenomenon where molecules absorb a photon and after a short time they 
emit a photon which has a longer wavelength and lower energy.86 Fluorescence intensity (FI), 
fluorescence anisotropy/polarisation (FP), fluorescence resonance energy transfer (FRET) can 
be used to monitor glycosylation when suitable fluorescently labelled substrates are found.63 FI 
is directly related to changes in fluorophore concentration and is typically used in enzyme 
assays to monitor substrate turnover.86 FP provides information on molecular orientation and 
is typically used for ligand binding reactions. The degree of polarisation is determined from 
measurements of fluorescence intensities parallel and perpendicular with respect to the plane 
of linearly polarised excitation light.87 FRET is a distance-dependent interaction between the 
electronically excited states of two fluorophores in which excitation is transferred from a 
donor molecule to an acceptor molecule.87 FRET can be used to assay interactions of 
biomolecules over a 1-5 nm scale.86, 88 Fluorescence quenching can occur by a variety of 
different processes. For example, molecules in solution, upon contact with the fluorophore can 
cause a quenching by deactivating the excited photon and emitted light is released as heat 
instead, or the fluorophore can form a complex with a quencher which has a different 
absorption spectrum.87 In addition, high fluorophore concentrations or impurities in sample 
can cause inner-filter interference.88 The inner filter is caused by a very high absorbance which 
prevents the excitation light penetrating deeply enough to the point at which the detection 





Fluorescence methods are generally performed on microplates and, because the read-outs are 
volume-independent, the assays can be developed in low reaction volumes and miniaturised. 
Additionally, fluorescence detection is more sensitive than UV-detection and does not require 
expensive instruments. However, an identical emission wavelength of the labelled substrates 
and tested inhibitors or possible impurities may cause false results in assays that are 
developed for inhibitor screening. This interference can be prevented by developing a long 
emission wavelength labelled substrates because most of the compounds in compound 
collections generally are fluorescent in the blue-green range.  
 
Fluorescence-based ligand displacement assays that monitor ligand binding are an attractive 
technique for large compound library screenings due to low reaction volume and sensitivity. 
Fluorescent donor analogues are essential to obtain detectable signals as naturally occurring 
sugar nucleotides do not contain a fluorophore. However, the assay protocols are generally 
very simple because acceptors are not required. Walker’s group demonstrated the 
effectiveness of a ligand displacement assay with two GlcNAc transferases, MurG and OGT. 89, 
90 They designed two fluorescently labelled UDP-GlcNAc analogues. They obtained a strong 
fluorescence polarisation signal with UDP-GlcNAc analogue (Figure 1.10, A) during binding to 
donor binding site of MurG. The same UDP-GlcNAc analogue was not directly suitable for 
investigating structurally related OGT. They hypothesised that short linker between the sugar 
and the fluorophore interfered with binding. Subsequently, they designed a fluorescent probe 
with longer linker which significantly changed fluorescence polarisation in the presence of 
OGT. A large commercial compound library was screened against both GTs using individual 
donor analogues in order to discover small molecular inhibitors. Potential inhibitors were 
identified from both screenings and then evaluated using a radiometric assay. Based on the 
same principle, Kiessling’s group developed fluorescently labelled UDP analogue (Figure 1.10, 
B).91 They screened a diverse compound library against UDP-galactopyranose mutase which 
uses UDP-sugar donors. Although, the ligand displacement assays are rapid to perform, 
Walker’s results indicated that a particular fluorescently labelled donor is required for each 
enzyme, even if the natural donor sugar is identical. This results in every GT requiring a 





Figure 1.10. Fluorescently labelled donor analogues used in ligand displacement assays for inhibitor 
screening against Murg by Walker’s group
89





Walker’s group also monitored O-linked glycosylation by a general protease-protection assay 
where the peptide substrate was labelled with FRET pair and subjected to glycosylation.56 
Protease was added to discriminate between glycosylated and non-glycosylated peptides. The 
protease cleaved the unglycosylated peptide chain that had a shorter fluorescence signal than 
the glycosylated peptide chain due to the FRET pair used. The fluorescence signal was, 
therefore, measured to determine the degree of peptide glycosylation. The assay was 
validated for HTS in order to identify inhibitors against GTs that catalyse O-linked glycosylation. 
 
In recent years, a new type of GT assay has been developed. Wongkongkatep and co-workers 
investigated binding affinities of an artificial chemosensor.92 They discovered that the 
chemosensor selectively bound to pyrophosphate monoesters leading to a significant increase 
in the fluorescence signal. Therefore, they successfully exploited this approach for the 
investigation of two galactosyltransferases that produce NDP during the catalytic reaction. This 
method is carried out in a continuous fashion without labelled substrates and it is applicable 
for HTS and for many NDP generating GTs. Chandrasekaran and co-workers used a very 
different approach in their label-free assay. They utilised glycan-modified microspheres as 
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acceptors for GTs.93 The glycosylation was monitored with specific fluorescent lectins or 
antibodies that recognise the newly formed glycoside bonds and an increase in fluorescence 
was then recorded with a flow cytometry. Although, the method is applicable for HTS, specific 





Glycosidases, also called glycoside hydrolases, play a diverse role in almost all living organisms, 
with the exception of some archaeans and some unicellular parasitic eukaryotes.94 
Glycosidases are currently classified into 132 families according to the CAZy database, based 
on their amino acid sequence similarities.17, 18 The families can be further combined into clans 
sharing common tertiary structures and evolutionary origin.95 About three quarters of the 
glycosidase families have structural information available, whereas, about one-third of the GT 
families have a known structure.96 Glycosidases are more stable enzymes than GTs and they 
are easily isolated from numerous natural sources such as micro-organisms and plants. 
Glycosidases catalyse the cleavage of the glycosidic bonds in glycosides and glycans.97 The 
hydrolysis of the glycosidic bond is achieved by glycosidases with overall inversion or retention 
of anomeric carbon configuration of the substrate. Glycosidases can be classified into endo- 
and exo-acting enzymes. Endo-acting glycosidases hydrolyse the glycosidic bond in the interior 
of the saccharide chain, whereas exo-acting glycosidases act at the nonreducing end, 
producing a monosaccharide as a leaving group.98 
 
 
Figure 1.11. Chromogenic substrates for the analysis of α-galactosidase. A) 4-methylumbelliferyl-α-D-




Numerous assays have been developed for monitoring glycosidase activity and for inhibitor 
screening.94 Glycosidase assay development is simpler than for GTs because the hydrolysis 
reaction occurs in a single substrate manner. Generally, natural glycosidase substrates are 
poly- or oligosaccharides and do not contain chromophores, therefore, chromogenic 
substrates have been developed for monitoring the activity of various glycosidases. The most 
recent fluorogenic substrate, resorufinyl-α-D-galactopyranoside (Figure 1.11, B), was used in a 
HTS assay in order to discover inhibitors or activators against α-galactosidase.99 The α-
galactosidase reaction with resorufinyl-α-D-galactopyranoside produces galactose and 
resorufin, which is strongly fluorescent with an excitation at 573 nm and an emission at 590 
nm.  Chromogenic assays that uses 4-methylumbelliferyl-α-D-galactopyranoside100 or p-
nitrophenyl-α-D-galactopyranoside101 as substrates (Figure 1.11, A and C) are available for 
monitoring activity of α-galactosidase. 
 
1.4. Project objectives 
 
GTs are potential drug targets as they are involved in essential biological processes, such as in 
cell adhesion and in bacterial cell wall biosynthesis. Currently, there are only a handful of 
effective GT inhibitors that could be used as tools for studying the mechanism of GTs and the 
biological function. In order to discover novel GT inhibitors, robust and operationally simple 
screening assays are required. Therefore, the key objective of this project was to develop GT 
assays for the discovery of novel inhibitors and for inhibitor characterisation. 
 
 Previous studies showed that a strongly fluorescent novel sugar nucleotide analogue (5-(5-
formyl-2-thiophene)-UDP-Gal, 5FTUDP-Gal, Figure 1.12) was a potential tool to investigate 
GTs. The preliminary investigations demonstrated that the UDP-Gal analogue bound to 
several galactosyltransferases, which resulted in a fluorescence intensity quenching and 
this read-out was used for the design of a novel ligand displacement assay (Figure 1.12).102  
Therefore, the aim was to optimise and validate this assay set up for inhibitor screening, 





Figure 1.12. Fluorescent UDP-Gal analogue (5-(5-formyl-2-thiophene)-UDP-Gal) and principle of the 
ligand displacement assay 
 
 The fluorescent UDP-Gal analogue was previously successfully used in the ligand 
displacement assay with α1,4-galactosyltransferase C from N. meningitidis (LgtC), α1,3-
GalT from Bos taurus (B. taurus) and from Homo sapiens (H. sapiens), α1,3-GalT mutant 
(AA(Gly)B).102 Therefore, the aim was to investigate the applicability of the fluorescent 
UDP-Gal analogue to other glycosyltransferases by using the ligand displacement assay 
(Chapter 2).  
 
 The aim was to develop a novel biochemical assay in order to investigate activities of GTs 
and for characterisation of potential GT inhibitors. (Chapter 3). The novel GT assay based 
on an unnatural fluorescent acceptor and coupling of the LgtC reaction to a glycosidase 
reaction. The aim was also to develop a HPLC-based method in order to investigate 
activities of GTs and to run the HPLC-based method in parallel during the novel assay 
development. The development of the novel GT assay was not achieved. Therefore, the 
aim was to optimise and validate an existing phosphatase coupled biochemical assay to 
monitor GT catalysed reaction and to characterise potential GT inhibitors. 
 
 In order to identify novel LgtC inhibitors, the aim was to use the optimised and validated 
ligand displacement assay for compound library screening (Chapter 4).  The aim was to 
screen two different compound libraries and screen the second library with the ligand 
displacement assay and with the phosphatase coupled assay in order to investigate 
differences of the assays by comparing the outcomes. The aim was also to characterise the 




2. Fluorescence-based ligand displacement assay 
2.1. Introduction 
 
Generally, glycosyltransferase (GT) assays that have previously been developed are not 
applicable for high-throughput screening (HTS). Radiochemical assays are sensitive and widely 
used for monitoring GT activity, however, the disadvantages are the availability of radiolabeled 
substrates, washing steps and removal of unreacted radiolabeled substrates from the labelled 
products which often requires chromatographic methods.66 In general, assay formats that 
include chromatographic separations are unsuitable for compound library screening due to 
their time-consuming and non-automated protocols. In addition, chromatographic methods 
such as HPLC and CE are commonly coupled with UV-detectors which limit monitoring of the 
primary product of GT reaction if substrates are not labelled with a chromophore.63 However, 
some GT assays that are suitable for HTS have been reported,63, 66 although some of these 
methods have some considerable limitations. For example, immunological assays103 require 
specific antibodies for each reaction product and in coupled enzyme assays,84 large quantities 
of different enzymes are utilised which makes the assay expensive. Many of the high-
throughput methods have been developed for monitoring activity,84 substrate specificity92 and 
saturated mutagenesis82 of GTs, but few of these assays have been applied for compound 
library screening.  
 
A novel fluorescent UDP-Gal analogue has been previously developed102 and preliminary 
studies demonstrated that this fluorophore binds to various retaining GalTs (LgtC, α1,3-GalT 
from B. Taurus and from H. Sapiens) in a similar orientation to the natural substrate. 
Fluorescence intensity quenched upon the fluorophore binding to the catalytic pocket and the 
fluorescence was restored in the presence of a high affinity binder.102 This combination was 
then used for the design of a novel ligand displacement assay (LDA). A small compound library 
was screened suggesting that the fluorophore could be used as a tool for the discovery of 
galactosyltransferase (GalT) inhibitors.104 
 
In principle, the assay format can be easily adapted for HTS and possibly applied to other 
sugar-nucleotide-dependent enzymes. Therefore, in order to use the novel LDA for inhibitor 
screening in HTS format, an optimisation process was required. The preliminary results 
indicated that the fluorophore could be used with several GTs, and this encouraged 
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investigating the use of a fluorescent UDP-Glc analogue with two glucosyltransferases. 
Therefore, two other bacterial GTs, TcdB from Clostridium difficile (C. difficile) and NGT from 
Actinobacillus pleuropneumoniae (A. pleuropneumoniae) were investigated.  A bacterial GalT, 
α1,4-galactosyltransferase C (LgtC) was used as a model enzyme for the LDA optimisation and 
validation studies because of the possibility to express large quantities of this enzyme and the 
preliminary studies demonstrated that the UDP-Gal analogue bind to LgtC. In addition, 
previous studies demonstrated that the UDP-Gal analogue binds to mammalian GT, β1,4-GalT 
and behaves as a substrate.102 The determined Km of UDP-Gal analogue was 74 µM whereas, 
Km of the natural substrate, UDP-Gal, was 46 µM. Therefore, β1,4-GalT was introduced to the 
studies as a positive control with LgtC. 
  
Prior to introducing the ligand displacement assay, and the assay optimisation process in more 
detail, the GTs utilised in this chapter (LgtC, TcdB, NGT and β1,4-GalT) will be introduced. The 
protein structure and function of the donor substrate binding of the studied GTs must be 





Lipopolysaccharide α1,4-galactosyltransferase C (LgtC) from N. meningitidis is a retaining 
galactosyltransferase and it belongs to the GT family 8.16 LgtC is involved in the biosynthesis of 
meningococcal LOS by transferring α-D-galactose from UDP-Gal to lactose of the terminal 
lactose moiety (Scheme 2.1).16 N. meningitidis is a Gram-negative pathogenic bacteria that is 
only found in humans and causes a life-threatening meningitis and meningococcemia 
worldwide.50 Bacterial meningitis is generally treated with antibiotics although drug-resistant 
bacteria are increasingly problematic, making widely used antibiotics ineffective.105 An 
effective vaccination exists for meningococcal serogroups A, C, Y and W135, and very recently 
a novel vaccine against serogroup B has been discovered.106 However, the protection against 
these infections is 73 to 87 % caused by the serogroup B, 107 therefore, new antibiotics to treat 





Scheme 2.1. LgtC catalysed reaction 
 
The high-resolution crystal structure of LgtC has been determined in complex with Mn2+ and 
UDP-2-deoxy-2-fluoro-galactose (UDP-2FGal), a sugar donor analogue, in the presence and in 
the absence of the acceptor sugar analogue, 4’-deoxylactose.16 The structure of LgtC is formed 
from nine β-sheets and fourteen α-helixes that are organised into two domains (Figure 2.1). 
The large N-terminal domain contains the active site that is surrounded by β-sheets. LgtC has 
four Asp-x-Asp (DXD, x is any amino acid) motifs and two of them are located at the active site. 
The C-terminal domain is smaller and has membrane associated functions.16 Upon donor 
substrate binding to LgtC, the enzyme undergoes significant structural changes and two 
flexible loops are proposed to become ordered, from open (inactive) to closed (active) 
conformation (Figure 2.1, flexible loops in green).16, 108 However, a substrate free crystal 
structure of LgtC is still unavailable and therefore, the position of the flexible loops is unclear 
in the apo stage. 
 
Figure 2.1. Crystal structure of LgtC complex with UDP-2FGal in yellow (ball- and- stick model) Flexible 




After the three-dimensional structure was published, mechanistic studies of LgtC have been 
carried out experimentally and computationally.27, 28, 108, 109 Kinetic analysis showed that LgtC 
follow an ordered bi-bi kinetic mechanism where UDP-Gal binds first to the active site, 
followed by the acceptor.109 Recent investigations proposed that LgtC uses a SNi-like reaction, 
where transfer occurs via a short lived oxocarbonium-phosphate ion pair intermediate or via 
an oxocarbenium ion-like transition state.28, 108  
 
LgtC has been found to be involved in the biosynthesis of the lipopolysaccharide (LPS) of 
human pathogen Haemophilus influenzae (H. influenzae).110 Phase-variable genes, including 
lgtC, express the galabiose motif (Gal-α1,4-Galβ) that is recognised by monoclonal antibody 
4C4111 and autotransporter protein Hap112 in H. influenzae. Inactivation of lgtC has been shown 
to lead to decreasing the virulence of H. influenzae in an infant rat model of invasive 
infection.110 The lack of Hap on the bacterial cell surface leads to a decreasing interaction with 
the host.112 H. influenzae R2866 strain (lgtC “on”), isolated from a meningitis patient and its 
derivative R3392 (lgtC “off”) strain have been used to study the role of lgtC in virulence of H. 
influenzae113-115 and the results strongly indicate that active lgtC increases virulence of H. 
Influenzae. Because LgtC has shown to play an important role in the biosynthesis of bacterial 
cell wall, it is of great interest for the future design of new type of inhibitors that could block 




Golgi resident type II membrane protein β1,4-Galactosyltransferase I (β1,4-GalT) is an 
extensively studied GT. To date, β1,4-GalT has been reported as involved in two different 
enzymatic activities. β1,4-GalT synthesises a disaccharide unit, Gal-β1,4-GlcNAc (N-
acetyllactosamine) by transferring galactose from UDP-Gal to GlcNAc and therefore continuing 
the oligosaccharide chain elongation on the cell surface.21 In the presence of mammary gland-
specific protein α-lactalbumin, β1,4-GalT forms a lactose synthase complex. Binding of α-
lactalbumin changes the acceptor specificity of β1,4-GalT and galactose is transferred to 
glucose, yielding lactose (Gal-β1,4-Glc), a milk sugar.21, 116-118 The diversity of β1,4-GalT was 
recently expanded when a poly-LacNAc moiety of the branched β1,6-GlcNAc was found 




Since the first crystal structure of β1,4-GalT was published its biochemical and kinetic 
mechanisms have been widely studied. The N-terminus of the active domain is a Rossmann-
like fold which recognises donor substrates while the C-terminal assists acceptor binding.120 
The catalytic pocket is located between the two domains and two flexible loops, a small 
(residues 313-316) and a long (residues 345-365) loop assists donor binding. During the 
catalytic cycle, the conformation of β1,4-GalT changes radically. Mn2+ binds first to the active 
site while the enzyme remains in an open conformation. During the sugar donor binding two 
flexible loops undergo significant conformational changes creating the acceptor binding site 
(Figure 2.2).117, 121 Tryptophan 314 (W314) plays a crucial role in donor binding and β1,4-GalT 
activity. During the closed conformation (active) the W314 residue is inside the catalytic 
pocket, interacting with both the UDP-Gal and the acceptor molecule.122 
 
 
Figure 2.2. A significant structural change in open (Green, conf. I) and closed (Magenta, conf. II) 
conformations of β1,4-GalT. The long loop (residues I345-H365) and the short loop containing W314 
(ball-and-stick model). W314 is facing in to the catalytic pocket in closed conformation (active 







β1,4-GalT is expressed in all mammalian tissues. On the eukaryotic cell surface it can function 
as a receptor molecule and participate in cellular interactions by binding to particular 
extracellular glycoside substrates. Therefore, β1,4-GalT has an important role in several 
cellular functions including neurite extension,123 sperm-egg interaction,124 cell adhesion and 
migration.125 β1,4-GalT producing gene knockout in mice resulted in decreased β1,4-GalT 
activity in most tissues124 and the mice fertility was decreased,126 differentiation of epithelial 
cells, and increased lethality and growth retardation.127 Recent studies have suggested that in 
humans, β1,4-GalT is involved in growth and adhesion of cancer cells128, 129 and may play a role 




Bacterial toxin (TcdB or Toxin B), released by C. difficile causes severe antibiotic-associated 
diarrhea and pseudomembranous colitis.131 TcdB targets GTPases, proteins that are involved in 
multiple eukaryotic cellular functions including signalling, cell cycle progression, actin 
cytoskeleton regulation, gene transcription and various enzyme activities. Rho, Rac and Cdc42 
belong to GTPases132, 133 and TcdB inactivates them by glucosylation using UDP-Glc as a donor 
substrate.134, 135 TcdB is a large clostridium toxin and it is formed from four domains that are 
related to cellular uptake and toxicity. The C-terminal binding domain identifies target cell 
surface proteins and assists in binding.133 The translocation domain uptakes the two remaining 
domains to the cytoplasm by forming a transmembrane pore.136, 137 The activity of the cysteine 
protease domain (CPD), the fourth domain, is responsible for the cleavage of 
glucosyltransferase domain that is responsible for the toxicity of C. difficile. Only the N-
terminal segment of the CPD is released to the cytosol where the GTPases can be glucosylated 
causing cell apoptosis.138, 139 
 
The crystal structure of the glucosyltransferase domain of TcdB has been reported in the 
presence of UDP-Glc and a manganese ion.134 The crystal structure model of the active domain 
contains 543 residues and encloses chiefly parallel β-sheets surrounded by sheet segments. 
This topology closely resembles the structure of LgtC and TcdB is assigned to GT type A fold.134 
The TcdB catalysed reaction retains the anomeric conformation and is dependent on Mn2+, in 





As the acceptors of TcdB are generally unavailable, the LDA could be an alternative method for 
the inhibitor discovery of this bacterial toxin because acceptors are not required in the assay 
format. In order to expand the LDA for glucosyltransferases, based on the structural 
similarities and the mechanism similarities with LgtC (both GT-A fold and retaining GT) it was 
assumed that the fluorescent UDP-Glc analogue binds to TcdB similarly to the fluorescent UDP-




N-glycosyltransferase (NGT) from A. pleuropneumoniae, a homologue of HMW1C from H. 
influenzae, was recently discovered. The NGT is an inverting GT and belongs to the GT-41 
family.140-142 NGT and HMW1C modify the asparagine residues of the HMW1 adhesion protein 
from H. influenzae by forming N-linkages with glucose or galactose and they are also able to 
create bonds between two hexoses.143 N-glycosylation of HMW1 protein leads to bacteria 
adhesion to the respiratory epithelial cells, therefore, glycosylation is a significant step in the 
pathogenesis of H. Influenzae.140 
 
Recently, the crystal structure of NGT has been reported in the presence and the absence of 
UDP-Glc and in the presence of a known glycopeptide.141 NGT consists of three domains, the 
N-terminus an all α-helical domain, and the GT-B fold which is divided into two domains, GT-1 
and GT-2 on the C-terminus. The core structures of GT-1 and GT-2 are similar and the UDP-
hexose binding site is positioned at their interface. Binding of UDP includes slight 
conformational changes in the NGT structure.141 The side chains and the three loops on the 
UDP-hexose’s binding site co-operate by placing the amino acid near UDP and assist the 
formation of the hydrogen bonds during sugar donor binding.141   
 
Similar to TcdB, the LDA was an attractive method for NGT because the acceptor proteins of 
NGT are not easily available. In addition, the LDA has been investigated only with retaining, GT-
A fold galactosyltransferases. Therefore, NGT which possesses a GT-B fold and which is an 




2.2. Fluorescence-based displacement assay 
 
A fluorescent UDP-Gal analogue (5-(5-formyl-2-thiophene)-UDP-Gal, 5FTUDP-Gal, Figure 2.3) 
was recently characterised102 and the results demonstrated a slow turnover when 5FTUDP-Gal 
was utilised as a substrate and therefore 5FTUDP-Gal was unsuitable for the development of 
biochemical assays.  The preliminary studies illustrated that the fluorescence intensity was 
quenched when the 5FTUDP-Gal was incubated in the presence of various GalTs including LgtC 
and α1,3-GalT, and the binding occurred in a similar orientation to the natural substrate UDP-
Gal.102 The protocol of the assay was of interest due to its simplicity and aptitude for HTS. 
Therefore, after sufficient assay optimisation, the aim was to apply the LDA to a compound 
library screen against GTs. Additionally, to enable more financially viable assay, the LDA 
adaptation to 384 well microplate format was investigated.  
 
 
Figure 2.3. Structure of the fluorophore used in the LDA, 5-(5-formyl-2-thiophene)-UDP-Gal 
 
The fluorescence based ligand displacement assay can be divided into two sets: ligand binding 
and ligand displacement. Before performing the ligand displacement experiments, the ligand 
must bind to the donor binding site of desired enzyme. The ligand binding can be examined by 
incubating the ligand (5FTUDP-Gal, fluorophore) in various enzyme (e.g. LgtC) concentrations. 
If the ligand binds to the enzyme, then the fluorescence quenches with increasing 
concentration of the enzyme (Figure 2.4 A). If fluorescence quenching is not observed, then 
the particular enzyme is unsuitable for ligand displacement experiments. Fluorescence can be 
restored by high affinity binders (e.g. natural substrates, UDP-Gal or UDP) that release the 
ligand from the catalytic pocket of the enzyme and the increase fluorescence intensity can be 





Figure 2.4. Principle of the ligand displacement assay. A) Fluorescence intensity quenches when the 
ligand (5FTUDP-Gal) is incubated with increasing concentration of a protein (e.g. LgtC).  B) Fluorescence 
intensity is restored with increasing concentration of a high affinity binder or inhibitor (e.g. UDP) 
 
The preliminary studies of the LDA were performed with bovine α1,3-GalT as a model 
enzyme.102 The control experiments included incubations in the absence and in the presence 
of MnCl2 and various concentrations of MnCl2, and in the absence and presence of α1,3-GalT. 
These observations indicated that the fluorescence quenching was due the fluorophore 
binding. The binding site of the fluorophore was investigated with the natural donor, UDP-Gal, 
which displaced the fluorophore from the active site of α1,3-GalT. Additionally, the control 
experiments included an incubation time and stability of the fluorophore. The LDA was 
inadequate for compound library screening and the assay required more control experiments 
regarding the functionality, the stability and the reproducibility. Therefore, the following 
investigations on the ligand binding affinity and the ligand displacement, using LgtC as a model 
enzyme were performed: 
 Reaction volume 
 Concentration of the fluorophore (5FTUDP-Gal) 
 Concentration of DMSO 
 Incubation time 
 Buffer and buffer pH 
 Concentration and activation of LgtC 
 Concentration of MnCl2 
 Non-specific binding 
 Reproducibility  




2.2.1. Investigating:  reaction volume, concentration of fluorophore and DMSO, 
buffer and incubation time 
 
The preliminary studies were performed in 50 mM Tris/HCl (tris (hydroxymethyl)-
aminomethane/hydrochloric acid) buffer including 10 mM MnCl2 at pH 7.0, reaction volume 
was 200 µL, fluorophore concentration 200 nM, incubation time 10 minutes and reaction 
temperature 30 °C.102 The lower reaction volume was investigated in order to keep the 
material consumption as low as possible during the assay optimisation. The impact of the 
reaction volume was investigated by performing a calibration curve of the fluorophore 
(5FTUDP-Gal) at 100 µL and 200 µL. Linearity was identical with increasing concentration of the 
fluorophore (Figure 2.5) and therefore, the reaction volume was reduced to 100 µL for all 
subsequent experiments. The previously used fluorophore concentration (200 nM) was in the 
linear range, therefore, it was unchanged.  
 
 
Figure 2.5. Linearity of fluorophore in the range of 39 nM to 2500 nM at total volume of 100 µL and 200 
µL  
 
Tris/HCL buffer (pKa 8.06 at 25 °C144) has poor buffering capacity below pH 7.5144, 145 and in 
order to ensure that the pH remained stable during enzymatic reactions, Tris/HCl buffer was 
compared with HEPES (N-(2-Hydroxyethyl)-piperazine -N’-ethanesulfonic acid) in various pH. 
HEPES has a lower pKa (pKa 7.48 at 25 °C
144) and its effective pH range is slightly lower: 6.8-8.2. 
In addition, HEPES has a low metal-binding constant. Therefore, it is particularly suited to 
investigate metal-dependent enzymes.146  
R² = 0.9998 






















































































































Figure 2.6. Ligand displacement assay with various UDP-Gal concentrations in Tris/ HCl (A) and in HEPES 
(B) buffers in various pH  
 
The LDA was adapted to investigate differences between Tris/HCl and HEPES buffer at various 
pH. The assay functioned over the entire pH range tested with Tris/HCl and HEPES buffers 
(Figure 2.6), indicating that fluorophore binds to LgtC and can be replaced with high affinity 
binder, UDP-Gal. The specified IC50 values (Table 2.1) suggested that the fluorophore binds 
more tightly to LgtC with HEPES buffer at pH 7.4 and above. Above pH 7.4 more UDP-Gal is 
required to replace the fluorophore. However, 13mM HEPES buffer at pH 7.0 was chosen for 
subsequent experiments, because pH 7.0 is widely used in various GT assays82, 84 and the LDA 
functions well at this pH. 
 
Table 2.1. IC50 for UDP-Gal in Tris/HCl and HEPES buffers at various pH 
pH (TRIS/ HCl) IC50, µM (TRIS/ HCl) pH (HEPES) IC50, µM (HEPES) 
7.4 22 ± 2 6.8 22 ± 8 
7.7 21 ± 10 7.0 30 ± 4 
8.0 40 ± 23 7.2 23 ± 3 
8.3 22 ± 2 7.4 39 ± 2 
  7.8 38 ± 2 
 
 
Pre-incubation and incubation times were investigated in the LDA. The fluorophore binding 
and displacement is assumed to occur rapidly, therefore, a long incubation time is not 
necessary. To support this hypothesis, a control experiment was performed with various pre-
incubations. The final reading was taken 20 minutes after the last component was added. 
 Incubation 1: Binder (UDP in this case) and fluorophore incubated for 10 minutes then 
LgtC added 
 Incubation 2: Binder and LgtC incubated for 10 minutes then fluorophore added 




The results indicated that displacement occurs similarly in all cases because the IC50 values did 
not change significantly (Table 2.2). For practical reasons, the fluorophore and the binder or an 
inhibitor of interest were incubated first and LgtC was added last (incubation 1). This was the 
chosen pipetting order for all subsequent experiments. 
 
Table 2.2. IC50 values in different incubation modes and in various final incubation times. Experiments 
performed at 30 °C 
Incubation 
modea 
IC50 (UDP), µM 
Incubation 
time, min 
IC50 (UDP-Gal), µM IC50 (UDP), µM 
1 24 ± 3 10 26 ± 2 35 ± 2 
2 18 ± 3 20 31 ± 2 36 ± 2 
3 26 ± 3 30 35 ± 2 34 ± 1 
  60 39 ± 3 39 ± 2 
a
Reaction mixtures incubated 20 minutes before final reading was taken 
 
The final incubation time, the incubation time after the final component (LgtC) addition, was 
studied by displacing the fluorophore with UDP-Gal or UDP. The fluorophore displacement can 
be monitored in real time. The results demonstrated that UDP and UDP-Gal displace the 
fluorophore rapidly as the incubation time did not have significant effect on the IC50 value 
(Figure 2.7 and Table 2.2). The fluorophore possibly photobleaches slightly during the 
incubation, therefore, increased IC50 values were observed with increasing incubation time. 20 
minutes incubation time was chosen for all future experiments because the balance of the 
displacement was reached and photobleaching of the fluorophore can be avoided. In addition, 
20 minutes incubation time provided a longer monitoring window in compound screening if 
potential inhibitors displace the fluorophore slowly. 
 
  
Figure 2.7. Displacement assay with UDP-Gal (A) and UDP (B) with various incubation times 
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Finally, it was important to ensure that the ligand displacement assay can tolerate DMSO. 
DMSO increases the solubility of organic compounds which are often poorly soluble in aqueous 
buffers. Therefore, DMSO is a necessary additive in assay buffer when the assay is designed for 
compound screening. The effect of DMSO on the LDA was investigated by varying the 
concentration from 0 % to 10 % (v/v). The results demonstrated that the ligand displacement 
assay tolerated DMSO up to 10 %. DMSO did not have a significant effect on the fluorescence 
intensity signal or the fluorophore displacement either with UDP-Gal or UDP (Figure 2.8). 
 
 
Figure 2.8. Effect of DMSO on the LDA with various concentrations of UDP-Gal (A) and UDP (B) 
 
The control experiments indicated that the LDA is not effected by the assay buffer, the type of 
incubation used or high DMSO concentration, which makes the LDA very robust. All the 
experiments above were performed at 30 °C by incubating the fluorophore with binder prior to 
the enzyme addition, total reaction volume of 100 µL, 200 nM of the fluorophore and all 
reactions were performed in 13 mM HEPES (pH 7.0) buffer. These conditions were kept in all 
subsequent experiments unless otherwise indicated. 
 
2.2.2. Influence of LgtC activation  
 
Kinetic studies have shown that LgtC requires activation with DTT (dithiothreitol) to reach full 
enzymatic activity.147 However, the crystal structure studies of LgtC suggested that there are 
no cysteine (Cys) residues that react in the donor substrate binding site.16 During the acceptor 
binding a conformational change occurs and Cys 246, located in the flexible loops, forms a 
hydrogen bond with one of the oxygen atoms of lactose. These findings suggest that LgtC 
activation affects only the acceptor binding and is not necessary if donor binding is monitored. 
[UDP-Gal] uM















































































However, there is no three-dimensional data available for LgtC in complex with the 
fluorophore and it is currently unknown if there is more than one fluorophore molecule bound 
to the donor binding site or if the fluorophore is bound partly to the acceptor binding site. 
Therefore, a control experiment was carried out in order to investigate whether the activation 
changes the required LgtC concentration to obtain a fluorophore binding curve by assuming 
that more fluorophore molecules are bound to the activated LgtC. Effect of activation was 
investigated by comparing activated and non-activated LgtC in the binding affinity assay.  
 
The degree of fluorescence quenching was identical when the binding curves of activated and 
non-activated LgtC were compared (Figure 2.9). The results suggested that activation did not 
affect the fluorophore binding and confirmed the hypothesis that the fluorophore probably 
does not bind to the acceptor binding site. Therefore, activation may only have an effect when 
the acceptor binds to the LgtC-donor complex leading to the formation of reaction products. In 
this assay mode, the acceptors are not utilised and binding of the fluorophore is monitored, 












































2.2.3. Influence of metal 
 
The manganese (II) ion is required for the activity of LgtC as it binds to the DXD motif and 
assists UDP-Gal binding to the active site.16 Therefore, it is possible that, as with the natural 
substrate, the fluorophore binding will occur only in the presence of Mn2+. The preliminary 
studies with α1,3-GalT demonstrated that fluorescence quenching was not observed in the 
absence of Mn2+ and significant quenching occurred only when Mn2+ was present.102 A control 
experiment was performed to examine the requirement of Mn2+ on the LDA with LgtC in the 
presence Mn2+ and without Mn2+ addition.  
 
Surprisingly, different results were obtained with LgtC, compared to α1,3-GalT. Fluorescence 
was quenched in both, in the presence and without addition of Mn2+ (Figure 2.10). The reason 
for the quenching was identified from the LgtC expression and purification protocol (Chapter 
2.7.1). The LgtC stock solution contains 5 mM of Mn2+ and this concentration was enough to 




Figure 2.10. Effect of manganese for fluorophore binding to LgtC. Fluorophore binding affinity 
monitored with increasing concentration of LgtC without Mn
2+









































The impact of the Mn2+ was studied with the LDA without addition of Mn2+ (10 µM of Mn2+ 
from LgtC stock) and in the excess104 (10 mM) of Mn2+. The results indicated that Mn2+ has a 
significant effect on IC50 values. IC50 increased from 32 µM to 213 µM with UDP-Gal and 30 µM 
to > 1000 µM with UDP (Figure 2.11) in the presence of 10 mM Mn2+. These results suggested 
that more fluorophore is bound to LgtC or the fluorophore binds very tightly to LgtC in high 
Mn2+ concentration. Recently Chan and co-workers studied conformational dynamics of LgtC 
and they showed that donor sugar analogue (UDP-2FGal) associated with LgtC only in the 
presence of a metal ion.108 Therefore, it was assumed that at high Mn2+ concentration 
interaction between the fluorophore and LgtC is increased and thus higher concentration of 
binder is required to displace the fluorophore. 
 
  
Figure 2.11. Effect of manganese ion (10 mM) in the ligand displacement assay with UDP-Gal (A) and 
UDP (B) 
 
The manganese (II) ion activates various metal-dependent GTs5, 26 and several GT biochemical 
assays are developed in the presence of excess of Mn2+ (mM range).74, 82, 84 The maximum 
catalytic activity of GTs is reached faster in the excess of Mn2+ and thus biochemical assays can 
be run in lower enzyme concentrations. However, the sensitivity of the LDA was lost in the 
presence of 10 mM Mn2+ because the fluorophore was not displaced at low concentrations of 
UDP and UDP-Gal. The aim was to develop a sensitive assay to identify inhibitors. Based on the 
obtained results, if Mn2+ is added to the assay buffer then higher concentration of 
binder/inhibitor is required to displace the fluorophore and this may increase a possibility of 
false negative hits in inhibitor screening. Furthermore, if Mn2+ is not added, the reaction 
conditions are closer to natural human tissue Mn2+ concentration (µM range).148  Because the 
sensitivity of the LDA was lost in the presence of Mn2+ all subsequent LDA experiments were 
performed without Mn2+ addition to the assay buffer. 
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2.2.4. Non-specific binding and influence of surfactant 
 
All the binding affinity experiments indicated that certain non-specific binding of the 
fluorophore was occurring because the fluorescence did not quench linearly with increasing 
concentration of LgtC. The fluorescence quenched in two steps at low LgtC concentrations.  
With increasing concentration of LgtC (Figure 2.12, blue curve): the fluorescence initially was 
quenched sharply, (step 1), then levelled off (2) and quenched again, reaching plateau (3). 
 
The fluorophore does not exert any specific binding to bovine serum albumin (BSA) and 
therefore, BSA was chosen for the investigation of non-specific binding. With increasing 
concentration of BSA the fluorescence initially quenched sharply and then completely levelled 
off at the same fluorescence intensity as the first plateau (step 2) was observed with LgtC 
(Figure 2.12). These results indicated that non-specific binding is not protein dependent and 




Figure 2.12. Investigation of non-specific binding with BSA as a control. Binding affinity of the 
fluorophore with increasing concentration of LgtC or BSA. Steps of quenching marked as 1-3 on the blue 
curve 
 
A possible explanation for the “two-step” fluorescence quenching is that the fluorophore is 
able to aggregate and the fluorescence quenching may be due to the aggregate’s non-specific 







































binding to the active site of LgtC causing a decrease in fluorescence. These binding modes are 
likely occurring at the same time causing the “two-step” binding curve with increasing 
concentration of LgtC. 
 
Triton X-100 (TX-100, polyoxyethylene octyl phenyl ether) is a non-ionic surfactant that can be 
used to protect proteins from binding to plastic surfaces (i.e. pipette tips or microplates) or 
dissolve molecular aggregators.149 A critical micelle concentration (CMC) of TX-100 is 0.2 mM 
(approximately 0.02 % v/v).150 The assay capability to tolerate TX-100 and how fluorophore 




Figure 2.13. Fluorophore binding to LgtC in the presence of various TX-100 concentrations 
 
The shape of the binding curves changed significantly in the presence of TX-100 (Figure 2.13). 
Now fluorescence initially remained stable, followed by fluorescence quenching and finally 
reaching a plateau. These results suggested that the first sharp quenching was due to non-
specific binding of the fluorophore.  This was then further investigated in the ligand 
displacement assay where the fluorescence was restored merely to sixty percent by addition of 
UDP. The sixty percent level was also observed from the binding affinity experiments (Figure 
2.13, blue curve), where the first plateau was reached with increasing concentration of LgtC 
and in the absence of TX-100. Therefore, in order to investigate the influence of the surfactant 












































0 10 ± 1 
0.001 12 ± 1 
0.01 11 ± 1 
 
Figure 2.14. Influence on TX-100 at 0, 0.001 and 0.01% for fluorophore displacement with UDP and IC50 
of UDP, respectively 
 
The results showed that the IC50 of UDP values were not affected by the TX-100 and as 
illustrated in Figure 2.14, the fluorescence was restored to 60 % in the absence of TX-100, 80 % 
at 0.001 % of TX-100 and completely restored at 0.01 % TX-100. These findings suggested that 
non-specific binding of the fluorophore is prevented in the presence of TX-100. The results also 
suggested that the fluorophore binds specifically to LgtC because the fluorescence can be 
completely restored with natural substrate which binds to the donor binding site. Thus, it was 
assumed that the fluorophore forms small particles which quench fluorescence due to 
unspecific binding. Therefore, fluorescence is impossible to restore completely with a natural 
donor which only displaces specifically bound fluorophore molecules. If the fluorophore forms 
small particles which TX-100 is able to dissolve then the completely restored fluorescence is 
observed. 
 
These results were important, because the assay window (the fluorescence difference 
between negative and positive controls) increased in the presence of TX-100. Therefore, 0.01 
% of TX-100 was added to the assay buffer in subsequent experiments. Furthermore, TX-100 
and its capability to prevent compound aggregation are introduced in more detail in Chapter 4 












































2.2.5. Influence of LgtC concentration 
 
An optimum concentration of LgtC was required for the LDA. LgtC concentration was chosen 
from the binding curve (normalised fluorescence intensity versus LgtC concentration) area 
where a maximum amount of fluorophore is bound to LgtC, approximately at 15 % normalised 
fluorescence intensity (Figure 2.13). At this LgtC concentration the maximum variation in 
fluorescence intensity can be observed in the fluorophore displacement experiments. It was 
assumed that a high LgtC concentration would increase and a low concentration would 
decrease IC50 values due to the availability of the number of donor binding sites. The LDA was 
performed in various LgtC concentrations in order to investigate how significantly IC50 changes. 
 
As assumed, the IC50 increased significantly with increasing concentration of LgtC (Figure 2.15). 
Three fold increase in LgtC concentration raised IC50 from 21 µM to 106 µM. Most of the 
fluorophore is bound at concentrations between 5 and 8 µM of LgtC and fluorescence remains 
at the same level as observed in Figure 2.13. However, excess of LgtC concentration should be 
avoided because more binder would be required to displace the fluorophore and the assay 








Figure 2.15. Fluorophore displacement with UDP at 1.0, 5.0 and 15 µM of LgtC, and IC50 of UDP 
respectively. The LDA performed without the addition of Mn
2+
 and in the presence of TX-100 (0.01 %) 
 
The optimum LgtC concentration for subsequent LDA experiments was suggested to be 
optimised individually for each LgtC batch because the IC50 values are significantly dependent 
on the LgtC concentration. The concentration optimisation can be performed by the binding 
affinity assay with increasing concentration of LgtC and in fixed concentration of the 
fluorophore. 
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2.2.6. Summary of ligand displacement assay optimisation and determination of 
assay reproducibility  
 
The LDA was developed for the discovery of novel inhibitors against GTs. LgtC was used for the 
assay optimisation and most of the assay parameters were changed from the original assay set 
up,102 including reaction volume, buffer, concentration of DMSO, the addition of Mn2+ was 
omitted and TX-100 was introduced (Table 2.3). Overall, during the optimisation the LDA 
proved to be a very robust technique that is not affected by the assay conditions, by pH of the 
assay buffer or by the concentration of DMSO. 
 
Table 2.3. Comparison of the “original” and the optimised LDA parameters 
Parameter “original” “optimised” 
Reaction volume 200 µL 100 µL 
Buffer 50 mM Tris/HCl, pH 7.0 13 mM HEPES, pH 7.0 
[Fluorophore]a 200 nM 200 nM 
Incubation time 10 minutes 20 minutes 
Incubation temperature 30 °C 30 °C 
[DMSO] 5 %b, c  10 %b 
[MnCl2] 10 mM - 
[LgtC] unknown Variable 






only in compound screening experiments 
 
The LDA (IC50 values) is sensitive to Mn
2+ concentration and LgtC concentration changes. IC50 
values increased significantly and the assay sensitivity was poorer when 10 mM MnCl2 was 
added to the reaction buffer (Chapter 2.2.3). Therefore, addition of MnCl2 was omitted in 
order to keep the assay more sensitive for compound screening. Variations in IC50 values from 
10 µM to 44 µM with UDP were observed between LgtC batch changes (Table 2.4). LgtC is 
prone to precipitate after purification, therefore, the determined protein concentrations may 
have a slight variation. The optimal concentration of LgtC was determined prior to the IC50 
experiments, by recording fluorescence intensity in various LgtC concentrations. The optimum 
concentration of LgtC was found when normalised fluorescence intensity quenched 
approximately to 15 %. Variable IC50 values hampered the comparison of the results, therefore, 







Table 2.4. Concentrations of various LgtC batches and determined IC50 values with the optimised LDA 
LgtC batch [LgtC] stock [LgtC] in assay IC50 (UDP) 
1 270 µM 13 µM 31 µM 
2 135 µM 10 µM 44 µM 
3 321 µM 4 µM 10 µM 
4 225 µM 5 µM 21 µM 
 
 
It is important to verify that the assay results are reproducible and the variability of the results 
of the assay is acceptably low. Assay parameters, including signal-to-background (S/B) ratio 
and Z’ factor determine the assay robustness and reproducibility during normal assay 
conditions.151 S/B ratio is the mean maximal signal and the mean minimum signal, describes 
the dynamic range of the assay without any data variation information and the Z’ factor 
describes the available signal window which is the total separation between negative and 
positive control minus the error associated with each control. The Z’ factor defined as the 
Equation 1, where stda is the standard deviation of positive control (the highest obtained FI), 
stdb is standard deviation of a negative control (the lowest obtained FI), a is the mean of the 
positive control and b is the mean of the negative control.151  
 
Equation 1.           
            )
    )
)  
 
In order to validate the LDA the reproducibility was examined by determining the S/B ratio and 
Z’ factor with the optimised LDA conditions (Table 2.3). Two 96 well microplates were 
prepared on different days in the absence and in the presence of TX-100. Each microplate 
contained 32 replicate negative controls (fluorophore + LgtC), replicate positive controls 
(fluorophore + LgtC + 5 mM UDP) and control wells at the highest fluorescence (fluorophore).  
 
Table 2.5. Z’ factor and S/B ratio of the optimised LDA 
Surfactant Z’ factor S/B 
0 % TX-100 0.54 5.9 







An acceptable Z’ factor is greater than 0.5 for HTS151 and the assay reached this criteria in the 
absence and in the presence of TX-100, Z’ factors 0.54 and 0.73 respectively (Table 2.5). TX-100 
has a capability to lower the surface tension of aqueous solutions and this feature possibly had 
a positive effect on reproducibility because the Z’ factor increased from 0.54 to 0.73 in the 
presence of TX-100. Additionally, as presented in the chapter 2.2.4, in the presence TX-100 the 
fluorescence intensity recovered completely which resulted in an increase to the S/B ratio 
from 5.9 to 7.7. High Z’- value (>0.5) and S/B ratio (>5) demonstrated that LDA was repeatable 
and robust for future HTS of compound libraries.  
 
2.3. Stability of LgtC 
 
Enzymes can lose their activity during storage due to conformational changes. The change in 
activity can be observed through activity assays where the substrate concentrations are 
constant, so the explanatory factor of the decrease is a reduction in the activity of enzyme. The 
stability and change in function of LgtC was investigated with four different methods after two 
and five months from the expression. Four different methods were chosen to ensure that the 
change in LgtC function is not caused by the standard deviation of the assay. LgtC was 
expressed and purified in house as previously reported.16 Detailed expression and purification 
of LgtC is described in experimental chapter 2.7.1. 
 Binding of the fluorophore was determined with the binding affinity assay 
 Fluorophore displacement was determined by the LDA (IC50 of UDP-Gal) 
 Specific activity was determined by NADH coupled assay directly after expression and 
after 5 months (see chapter 2.7.2) 
 Binding affinity of UDP-Gal (Km) and the catalyst rate constant (Kcat) were determined 
by phosphatase coupled assay (see chapter 3.4)   
 
The results suggested that the fluorophore binds to LgtC with lower affinity after 5 months 
from expression than after 2 months. A change in binding curves was observed particularly 
between 1-5 µM of LgtC (Figure 2.16 A).  Although the same concentration and batch of LgtC 
was utilised in the LDA, less UDP-Gal was required to displace the fluorophore (Figure 2.16 B) 
resulting decrease in the IC50 value from 32 µM to 13 µM. The results are comparable to the 
results in chapter 2.2.5, where various LgtC concentrations were examined and decreased IC50 













































































Figure 2.16. Change in binding affinity (A) and the fluorophore displacement (B) after 2 and 5 months 
expression of LgtC. IC50 of UDP-Gal decreased from 32 µM to 12 µM over the time 
 
The investigations performed by two different biochemical assays indicated that catalytic 
activity of LgtC decreases over the time. The specific activity of LgtC dropped from 4.2 U/mL to 
3.7 U/mL (12 %) in five months. In addition, Km and Kcat values changed significantly (Table 2.6). 
Km increased from 27 µM to 81 µM and LgtC capability to turn substrate molecules to product 
reduced from 0.12 to 0.05 per second.  
 
 
Table 2.6. Change in specific activity, Km, Kcat and IC50 of UDP-Gal determined with LgtC after 2 and 5 
months after the expression 
Storage time 






2 months 4.2 U/ mL 27 µM 0.12 s-1 32 µM 
5 months 3.7 U/ mL 81 µM 0.05 s-1 12 µM 
a
NADH coupled assay (Chapter 2.7.2), 
b
phosphatase coupled assay (Chapter 3.4), 
c
optimised LDA as 
described in Table 2.3 except in the absence of TX-100  
 
 
All the results indicated that function and catalytic activity of LgtC is reduced over the 
examined time, possibly by denaturation. As all three assays indicated lower binding affinity or 
lower activity actions of LgtC over time, the observed changes were most likely due to changes 
in LgtC, not the standard deviation of the assay used. The results suggested that a 
conformational shift of LgtC changes the binding affinity of the substrates over the time. LgtC 
preserves its function for less than five months, therefore, regular binding affinity and activity 
controls were suggested. If the IC50 values were compared then the binding affinity of the 
fluorophore experiment should be performed prior to the LDA to choose the optimal LgtC 
concentration. If the impact of an inhibitor to Km is investigated then the Km should be 
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determined in the absence of inhibitor on the same day as a control. These control 
experiments are important as the use of aged LgtC may suggest inhibition (false positive 
results), although the change in activity can be caused by an inactive or less active LgtC.   
 
2.4. Assay adaptation to 384 well microplates 
 
HTS approaches are commonly used in drug discovery and 384 well microplate formats are 
widely used.152, 153 Compared to 96 well formats, the 384 well formats allow the determination 
of numerous compounds simultaneously and a much smaller amount of valuable materials are 
used. These factors contribute to making large compound library screening more practically 
viable. All the assay optimisation and control experiments were performed in 96 well 
microplates. Therefore, the aim was to adapt the 96 well format to 384 well microplates. To 
start with, the reaction volume of two different 384 well microplates were evaluated and 
compared. The previously optimised assay parameters were then directly adapted to 384 
micro well format. 
 
2.4.1. Linearity of fluorophore and reaction volume 
 
Non-coated 384 well microplates from two different suppliers, Nunc and Greiner, were 
compared. Nunc 384 well microplates were made from polystyrene the same as the Nunc 96 
well microplates and Greiner microplates were made from polypropylene. The functionality of 
the microplates was evaluated by determining a concentration range of the fluorophore 
(5FTUDP-Gal) in which the concentration and the measurement signal has a linear 
dependence: linear regression (r2). The linear regression of the fluorophore was determined in 
various reaction volumes with Nunc and Greiner microplates to attain the optimum reaction 








Table 2.7.  Linearity of fluorophore in range of 12.5 to 1000 nM (10 measurement points) in various 
reaction volumes performed in the assay buffer (13 mM HEPES pH 7.0) 
Volume in well, µL r2 (Nunc) r2 (Greiner) 
10 0.998 1.000a 
20 0.996 0.999 
30 0.999 0.999 
40 0.999 0.998 
50 0.996 0.999 
a
Volume 15 µL in the well (the lowest recommended volume by the manufacturer) 
 
The linearity of the fluorophore was identical with both 384 well microplates (Table 2.7). 
Greiner micro plates were matte finished, practically easier to work with and less expensive 
than Nunc microplates. Therefore, Greiner microplates were chosen for subsequent 
experiments. Reaction volume did not impact the fluorescence of the fluorophore linearity and 
because the lowest possible reaction volume was desirable, 20 µL was selected. 
 
2.4.2. Fluorescence based ligand displacement assay 
 
Previously optimised LDA parameters (Chapter 2.2.6) were directly adapted to 384 well 
microplate format. The binding affinity of the fluorophore was identical when the binding 
curves obtained with the 96 and 384 well microplates were compared (Figure 2.17 A). 
Consequently, the same concentration and the batch of LgtC were used for the ligand 
displacement experiment (Figure 2.17 B) in 96 and 384 well microplates.  
 
[LgtC] uM









































































Figure 2.17. Comparison of 96 and 384 well microplates. Binding of fluorophore increasing 
concentration of LgtC (A) and ligand displacement with UDP (B) determined by the optimised assay 





The results indicated that the studied 384 well microplate functioned in a similar fashion to 
the 96 well microplate and further optimisation was not required. The 384 well microplate is 
practically useful when only a small amount of material (i.e. protein) is available or equally 
importantly, for compound library screening. 
 
2.4.3. Ligand displacement with other sugar nucleotides and nucleotides  
 
The suitability of the LDA for compound screening was investigated with various sugar 
nucleotides and nucleotides that have different binding affinity to LgtC. UDP-Gal is a natural 
donor substrate to LgtC16 and it displaces the fluorophore in competitive fashion. Also UDP, 
UMP and uridine are assumed to bind specifically to the donor binding site of LgtC and 
behave as competitive inhibitors, although with lower affinity than UDP-Gal.  
 
The ligand displacement experiment was performed in fixed concentrations of all assay 
components except the binders, UDP-Gal, UDP, UMP and uridine on the 384 well microplate 
format and with the optimised assay conditions (Chapter 2.2.6). The IC50 values were 
determined for each binders and then the obtained IC50 values were compared with the 
published results which were performed with the preliminary assay conditions.104  
 
 
Figure 2.18. Fluorophore displacement with UDP-Gal, UDP, UMP and uridine determined with the 
optimised LDA (DMSO (10 %), TX-100 (0.01 %) in 13 mM HEPES (pH 7.0) buffer) 
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Results indicated that UDP-Gal binds to LgtC with the highest affinity then UDP, UMP and 
finally uridine as expected (Figure 2.18). The same trend was observed with the published 
results (Table 2.8). A variation between the determined and the published IC50 values was 
observed. The main difference between the assays was the concentration of MnCl2 
(published results104), and the LDA was performed in the presence of DMSO and TX-100. As 
previously discussed in chapter 2.2.6, the IC50 values are mostly affected by the concentration 
of Mn2+ and LgtC, however, not the concentration of DMSO or TX-100 (chapters 2.2.1 and 
2.2.4, respectively). Slightly different IC50 values can be explained with LgtC concentration 
used in the assay. The LDA assay was performed at 8 µM of LgtC, however, the concentration 
was unknown in the reported assay. The most significant difference between the results is 
the lower IC50 values in the presence of Mn
2+. As demonstrated in the chapter 2.2.3, IC50 of 
UDP-Gal increased from 32 µM to 213 µM in the presence of 10 mM Mn2+. The possible 
explanation for different IC50 values in the presence of Mn
2 (26 µM vs. 213 µM for UDP-Gal) is 
the actual concentration of Mn2+ and it could be that the concentration of Mn2+ was lower 
than 10 mM in the assay of the published results.   
 
 
Table 2.8. IC50 values for various nucleotides determined the optimised LDA and the published results 




UDP-Gal 16 ± 1 26 ± 8 
UDP 26 ± 2 83 ± 49 
UMP < 1000 293 ± 91 
uridine < 1000 < 1000 
a
Optimised assay (10 % DMSO, 0.01 % TX-100 in 13 mM HEPES pH 7.0 buffer, 384 well microplate), 
b




Overall, the results showed that the compound screening assay can be performed in 384 well 
microplates and how low affinity binders would behave in the LDA. In addition, there is a 
difference in the IC50 values obtained with the optimised assay and the preliminary assay set 






2.5 Investigation of other glycosyltransferases 
 
The binding affinity experiments demonstrated that the fluorophore binds to LgtC. The 
specific binding was demonstrated with the natural donor substrate on the ligand 
displacement experiments. Previously, it has been shown that quenching is not limited to 
LgtC. The fluorophore specifically bound also to other GTs resulting fluorescence quenching: 
α1,3-GalT from B. Taurus (α1,3-GalT) and human blood group B enzyme (GTB) and AA(Gly)B 
(GTB mutant).104 The studied GTs belongs to the GT family 6, except LgtC, and all possess a 
retaining stereochemistry and a GT-A fold. Therefore, the possibility to expand the use of the 
fluorescent donor analogues (5FTUDP-Gal and 5FTUDP-Glc) and the LDA for other GTs was 
investigated. GTs with different characteristics were chosen, including different GT families, 
GT folds and stereochemistry (Table 2.9). The availability of UDP-Glc analogue, (5-(5-formyl-
2-thiophene)-UDP-Glc, (5FTUDP-Glc, Figure 2.19) allowed the investigation of two bacterial 
GlcTs, NGT and TcdB. Previous studies showed that the fluorophore (5FTUDP-Gal) behaved as 
a donor substrate for mammalian GT, β1,4-GalT, demonstrating the binding ability of the 
fluorophore to this GT.102 Therefore, β1,4-GalT was included to the binding affinity 
experiments as a control.  
 




GT family Organism Stereochemistry Fold 
LgtC Gal GT8 N.  meningitidis Retaining GT-A 
TcdB Glc GT44 C. difficile Retaining GT-A 
NGT Glc and Gala GT41 A. pleuropneumoniae Inverting GT-B 
β1.4-GalT  Gal GT7 B. taurus Inverting GT-A 
a
NGT transfers galactose with lower affinity  
 
 
Figure 2.19. Structure of fluorescent UDP-Glc analogue (5-(5-formyl-2-thiophene)-UDP-Glc, 5FTUDP-
Glc) used studying NGT and TcdB 
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The binding affinity of the fluorophores (5FTUDP-Gal/ Glc) to β1,4-Gal, NGT and TcdB was 
investigated and compared with the binding curve of LgtC. The experiments were performed 
using similar conditions as for LgtC. Buffer and pH were specifically adapted for each enzyme. 
For example, TcdB was found to be active in buffer containing 25 mM Tris, 150 mM NaCl, 150 
mM K2SO4, 5 mM MnCl2 and 5 mM MgCl2 at pH 7.5
85, therefore, this particular buffer was 
utilised in the binding affinity experiments. 
 
 
Figure 2.20. Fluorophore binding monitored with increasing concentrations of LgtC, TcdB, β1.4-GalT 
and NGT. The experiments performed in the presence of TX-100 and DMSO 
 
The results were unexpected because fluorescence quenching was not observed with other 
GTs: TcdB, β1.1-GalT or NGT (Figure 2.20). The previous enzyme kinetic studies strongly 
suggested that the 5FTUDP-Gal binds to the β1,4GalT102 however, the fluorescence remained 
high. Possible explanations for the observed results are that binding of the fluorophore does 
not occur, binding occurs but fluorescence intensity remains high or protein concentration is 
too low. 
 
Hypothetically, the fluorescence quenching could be explained by the coverage of the 
fluorophore. All examined GTs contain flexible loops that are located near the active site and 
during donor sugar binding the loops are suggested to become active participating in donor 
binding and product release.16, 120, 134, 141 In case of LgtC and TcdB the sugar moiety of the 
donor is bound to the bottom of the active site (Figure 2.21 A and D), under the phosphate 
groups.16, 154 In the case of LgtC, the loop area covers the sugar donor within the enzyme,16, 108 






































movements have been observed in NGT and β1,4-GalT.120, 141 UDP is almost completely 
buried in the cleft of NGT (Figure 2.21 D).141 This could promote fluorescence quenching 
however, the 5-substituted formyl-2-thiophene may prevent subtle conformational changes 
that further precludes 5FTUDP-Glc binding and fluorescence remains high. The active site of 
β1,4-GalT is large (Figure 2.21 B) and during the sugar donor binding the acceptor binding 




Figure 2.21. Molecular surface presentation of the active sites of A) LgtC (PDB: 1G9R), B) β1,4-GalT 
(PDB: 1FR8), C) NGT (PDB: 3Q3H), D) TcdB (PDB: 2BVL), and E) α1,3-GalT (PDB: 1K4V) in the presence 




The amino acids involved in binding of the sugar donor and with uracil are diverse. It is not 
clear which amino acids could interact with the 5-formyl-2-thiophene and cause the 
fluorescence quenching. Recently reported results demonstrated that fluorescence intensity 
was quenched when 5FTUDP-Gal was incubated with bovine α1,3-GalT.104 The amino acids 
interacting with the uracil portion of α1,3-GalT and LgtC are different, and it cannot be 
concluded which amino acids could promote fluorescence quenching. For example, valine 
136 interact with O2 and N3, water molecule interact with O4 of the uracil of α1,3-GalT155 
and aspartic acid 8 interact with O2 and N3, asparagine 10 interact with O4 of the uracil of 
LgtC.16 However, the donor substrate is buried within both GTs, LgtC and α1,3-GalT (Figure 
2.21, A and E, respectively) that could quench the fluorescence signal. Mutagenesis studies 
with α1,3-GalT suggested that binding of sugar donor induces conformational changes in 
both the ligand and in the enzyme. Studies indicated that UDP-Gal can bind to α1,3-GalT in a 
distorted conformation156 similarly than UDP-2FGal to LgtC wherein pyranose ring is bent 
under the phosphates and is nearly parallel to the plane of the pyrophosphate.16 
Hypothetically, this conformational change could occur in the fluorophore upon binding to 
LgtC however, not with β1,4-GalT. One possibility is that 5FTUDP-Gal is a so called “molecular 
rotor”. Molecular rotors are fluorescent molecules that undergo intramolecular twisting 
motion upon photon absorption.157 Non-planar (twisted) state has lower excited energy and 
higher ground stage energy, therefore, the corresponding lower relaxation energy. 
Dependent on the chemical structure, relaxation from the twisted state is associated either 
with longer emission wavelength or without photon emission (non-fluorescent).157 Therefore, 
possibly the planarity of the thiophene-uracil in bound 5FTUDP-Gal is disturbed due to 
binding which may lead to twisted intramolecular charge transfer and quenching in 
fluorescence.  
 
Alternatively, during the fluorophore binding to NGT and TcdB, the fluorophore may prevent 
conformational changes of the enzymes and the suggested loops remain inactive or the 
structure of the fluorophore is unfavourable and binding to the donor binding site does not 
occur. Alternatively, higher concentrations of NGT and TcdB may be required to obtain 
fluorescence quenching. However, this is unlikely if the fluorophore binds to other GTs 
similarly than to LgtC because, comparing the concentrations used in the binding affinity 
assay, at 150 µM/mL of LgtC fluorescence was significantly quenched however, quenching 




The results suggests that binding of the fluorophore can occur although the fluorescence 
quenching is not observed because the previous studies strongly indicated that the 5FTUDP-
Gal served as substrate of β1,4-GalT.102 Hypothetically, the fluorescence intensity is 
quenched when the whole fluorophore is buried within the enzyme or alternatively, the 
fluorophore molecule is twisted during favourable binding to active pocket of the enzyme. 
Currently, the fluorophore, 5FTUDP-Gal, can only be used in the investigation of LgtC, α1,3-
GalT and GTB.  
 
2.6 Summary and conclusions 
 
A robust and operationally simple assay for compound screening against glycosyltransferases 
was successfully optimised from a previously described fluorescence based ligand 
displacement set up104 by using LgtC as a model enzyme. The majority of the optimised assay 
conditions were changed from the preliminary method (Table 2.3).  
 
The most significant assay conditions that effect the assay results were MnCl2 and enzyme 
concentrations. At high MnCl2 concentration, a higher concentration of binder was required 
to displace the fluorophore (5FTUDP-Gal) and because the sensitivity of the assay reduced, 
MnCl2 was omitted. In high enzyme concentration availability of donor binding sites 
increased and more fluorophore was bound which required higher concentrations of binders 
to displace the fluorophore. The optimum enzyme concentration was found when 
normalised fluorescence intensity was quenched approximately to 15 %. In addition, the LDA 
(IC50 values) was demonstrated to be sensitive to the concentration of LgtC (chapter 2.2.6). 
Therefore, if the analysis of two sets of results were compared, then the same batch and 
concentration of LgtC was used in each experiment. The optimum concentration of LgtC is 
also required for the identification of potent inhibitors because too high concentration of 
enzyme could cause false negatives. The LDA uses a high concentration of LgtC compared to 
biochemical assays, where the required concentration is approximately 100 fold lower. The 
difference can possibly be explained by the assay mode. In the LDA, only binding of the 
fluorophore is monitored whereas in the biochemical assay, the formation of reaction 
product is monitored. In the biochemical assay one LgtC molecule produces numerous 
product molecules whereas in the LDA, the balance between the fluorophore and LgtC is 
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observed, therefore, a higher concentration of LgtC is required in order to obtain desired 
results.    
 
The surfactant, TX-100 had a positive impact on the LDA because in the presence of TX-100 
the characters of non-specific binding disappeared: the “two-step” binding curves and 
incomplete fluorescence recovery with specific binders. As fluorescence was completely 
restored in the presence of TX-100 the assay signal window improved (S/B ratio). The 
influence of TX-100 was also observed with increased Z’ factor that indicated improved 
reproducibility of the LDA. Hypothetically, the non-specific binding was caused by 
aggregation of the fluorophore which TX-100 dissolved.  
 
The stability and storage time was unknown for LgtC. The change in specific activity, IC50 and 
Km values was determined by NADH coupled assay (described in chapter 2.7.2), the LDA and 
the phosphatase coupled assay (described in chapter 3.4), respectively for the same LgtC 
batch 2 and 5 months after the expression. The results were important because the binding 
affinity of the fluorophore and the activity of LgtC changed over the examined time period. 
Therefore, a control that measures the function of LgtC was suggested to be included in the 
experiments. 
 
Other GTs were examined in order to expand the use of fluorophores (5FTUDP-Gal/Glc) and 
investigate the applicability of the LDA. Fluorescence quenching was not observed with NGT, 
TcdB or β1,4-GalT. The binding mechanisms of the fluorophore and which amino acids are 
involved in fluorescence quenching are currently unknown.  Previous experiments 
demonstrated that β1,4-GalT can use the fluorophore (5FTUDP-Gal) as a donor substrate,102 
suggesting that the binding of the fluorophore can occur without fluorescence quenching. 
Based on the coverage of the fluorophore within the catalytic pocket, the fluorescence 
intensity is quenched possibly when the whole fluorophore is buried within the enzyme. 
Alternatively, the planarity of the fluorophore is lost upon binding which results in 
fluorescence quenching.  Currently, there is no clear trend for fluorescence quenching based 
on GT-family and the binding of the fluorophore is observed with retaining and inverting GTs 
using other methods. In practise, the usage of the fluorescent UDP-Gal /Glc analogues and 





Table 2.10. Summary of all GTs investigated with the binding affinity experiments in the current and in 













LgtCa Gal GT-8 Retaining GT-A yes no 
TcdBa Glc GT-44 Retaining GT-A no no 
NGTa Glc GT-41 Inverting GT-B no no 
β1.4-GalTa, c Gal GT-7 Inverting GT-A no yes 
α1,3-GalTb, c Gal GT-6 Retaining GT-A yes yes 
GTBb Gal GT-6 Retaining GT-A yes no 
AA(Gly)B GTB 
mutantb 












Overall the LDA proved to be a very robust method during the assay optimisation. The 
determined IC50 values remained unchanged in the studied assay buffers and pHs, 
concentration of DMSO or incubation time. The Z’ factor (>0.5) that is generally used 
parameter for checking the quality of screening assays, illustrated a high reproducibility of 
the LDA. The LDA is practical to perform because the assay format does not include acceptors 
and the enzymatic reactions are carried out in a low reaction volume (100 µL) in 96 micro 
well plates that reduce the consumption of valuable reagents. Additionally, the LDA was 
adapted to 384 micro well plates which further reduce the consumption of the assay 
reagents and make the assay more suitable for large compound library screening. The simple 
assay protocol contains only three pipetting steps, and together with 384 well microplates, 
the assay can be simply adapted to HTS. The optimised assay was developed for inhibitor 
















2.7.1 Expression and purification of LgtC 
 
The expression and purification process of LgtC followed a protocol that was obtained in 
collaboration with M. Palcic. The Escherichia coli (E. coli) cells containing LgtC plasmid were 
grown in tryptone broth (TB) + M9 salts + supplements (1M MgCl2, 0.1M CaCl2, 10mg/ml 
vitamin B1, 20% w/w glucose, 20% w/w casamino acids and 100 mg/ml ampicillin) liquid 
media in a shaker at 30 °C and 200 rpm for 16 hours. The main culture was prepared by 
diluting the starting culture with TB + M9 media to an OD600 of 0.1-0.2 to ensure that the cells 
are fresh. The main culture was then grown to an OD600 of 0.6-1.0 and the expression was 
induced with isopropylthio-β-galactoside (IPTG) at a final concentration of 0.5 mM. After 
incubation of the main culture at 30 °C for 16 hours, the cells were harvested by 
centrifugation at 4k rpm for 10 minutes at 4 °C and the cell pellet was re-suspended in 
disruption buffer (20mM MOPS, 500mM NaCl, 5mM imidazole, 1 protease inhibitor tablet 
(without EDTA), pH 7.0 adjusted with 1M NaOH). A sonicator probe at 50% duty cycle and at 
power setting 7 was used to disrupt the cells at 5 °C and the cell debris was removed by 
centrifuging at 20 rpm for 90 minutes at 4 °C. The supernatant was collected and filtered 
through 0.2 µm filters. 
 
The supernatant solution was purified by IMAC on HisTap HP column with Ni2+. The manual 
mode of GradiFrac was used combined with UV and conductivity detector. All buffers and the 
column were kept in ice during the purification. The column was equilibrated in loading 
buffer (composition of the buffers on Table 2.11) and non-specifically bound proteins were 
washed in washing buffer. The fractions were eluted with eluting buffer and collected in 
MnCl2 solution to give final concentration of 5mM. 
 
Table 2.11. The compositions of loading, washing and eluting buffers used in LgtC purification 
Component Loading Washing Eluting 
MOPS 20 mM 20 mM 100 mM 
NaCl  500 mM 500 mM 500 mM 
Imidazole  5 mM 20 mM 500 mM 






The flow-through (fractions that were collected during loading the column), wash and 
protein fractions were analysed with SDS-PAGE. NuPAGE MOPS SDS buffer kit was utilised 
during the sample preparation. The samples were denaturated in NuPAGE LDS sample buffer 
in the presence of a reducing agent by heating the mixture to 70 °C for 10 minutes.  10 µL of 
the denaturated samples were loaded to the NuPAGE 4-12% Bis-Tris 10 well gels and the gels 
were placed into an electrophoresis chamber that was connected to PowerEase 500 Power 
Supply. The chamber was filled with MOPS running buffer and antioxidant solution was 
added to the middle chamber. The gels were run for 50 minutes at a voltage of 200 V and a 




Figure 2.22. SDS-PAGE analysis of collected fractions. Lane 1 is a protein ladder. Lanes 2-3 are flow-
through, lanes 4-6 are washes and 7-9 are collected LgtC fractions. Lane 7 is the first collected fraction 
(concentration not determined), lane 10 is LgtC from previous batch. Concentration of LgtC on lanes 8-
10 are 11.84, 5.6 and 19.55 mg/mL respectively.  
 
The fractions that contained a reasonable amount of pure LgtC were dialysed in 20 mM 







2.7.2 Concentration and activity of LgtC 
 
LgtC concentration of the stock solution was determined by a NanoDrop spectrophotometer. 
The activity of new LgtC batches were determined with a continuous assay where UDP is 
coupled to nicotinamide adenine dinucleotide (NADH) oxidation via pyruvate kinase (PK) and 
lactate hydrokinase (LDH).84 The NADH coupled assay was optimised for determination of 
LgtC activity in house.   
 
The activity assay was performed in clear 96 well microplates in total volume of 300 µL. All 
dilutions were made in 13 mM HEPES buffer at pH 7.0 including 50 mM KCl and 13 mM 
MnCl2. A serial dilutions of concentrations of LgtC were activated in 5 mM DTT at 30 °C for 30 
minutes. The reaction mixture contained PK (10 U/mL), LDH (15 U/mL), 
phosphoenolpyruvate (PEP) (700 µM), NADH (600 µM) and lactose (300 µM) (all final 
concentrations) was added to LgtC. The reaction was started by adding 300 µM of UDP-Gal to 
the reaction mixture and reduced absorbance at 340 nm was recorded. The assay contained 
positive control (UDP added instead of UDP-Gal), negative control (No UDP or UDP-Gal 
added) and blank (no NADH added). The rate of reaction in mAbs/min can be converted to 
mmol/min by using the standard curve of NADH concentration against absorbance. The unit 
activity (U/mL) and specific activity (U/mg) of the undiluted stock can be calculated by 
correlating with protein concentration. 
 
2.7.3 General settings 
 
All measurements were carried out in black NUNC F96 MicroWell polystyrene plates on a 
BMG labtech PolarStar microplate reader. The fluorescence intensity measurements were 
carried out at the excitation wavelength 350 ± 5 nm and an emission wavelength 430 ± 5 nm 
which were relevant to the fluorophores, 5FTUDP-Gal and 5FTUDP-Glc (λex 351 nm, λem 434). 
5FTUDP-Gal and 5FTUDP-Glc were synthesised and characterised in house by Dr Lauren 
Tedaldi. The flashes per well was set to 10 and gain was set to 90 % to the control 
(fluorophore only in assay buffer) well on the microplate. LgtC was expressed in house (see 
chapter 2.7.1) and molecular weight of 36000 Da18 was used for calculating molar 




50 mM Tris / HCl buffer and 13 mM HEPES buffers were prepared in ultrapure water and pH 
was adjusted with HCl or NaOH respectively. All buffers were filtered with nylon 0.2 µm 
membranes prior to use and stored in the refrigerator for maximum two weeks. 
 
All assay components were prepared in 13 mM HEPES buffer at pH 7.0, unless otherwise 
stated. Fluorophore concentration is fixed (0.2 µM) in all experiments. Binder (i.e. UDP) 
concentration varied in the ligand displacement experiments whilst the enzyme 
concentration remained fixed. The binding affinity experiments were performed in variable 
enzyme concentration (Table 2.12). The mixture of fluorophore and TX-100 (+ DMSO in 
binding affinity experiments) in 13 mM HEPES buffer was added to the microplates first, then 
binder (only in the ligand displacement assay) and finally the enzyme.  The final reaction 
volume was 100 µL. The samples were prepared at least in duplicate and incubated for 20 
minutes at 30 °C before taking the final reading. 
 
Table 2.12. Concentrations of the assay components in the binding affinity and ligand displacement 
assays 
Component [Stock] [Final] Volume of stock, µL 
Bindera Various [binder], x10 in 
100 %c DMSO 
Various [inhibitor] in 
10 %c DMSO 
10 
Fluorophore 1 µM 0.2 µM 20 
Enzymeb X5 X1 20 
HEPES buffer 13 mM 13 mM 40 
TX-100 0.1 %c 0.01 %c  10 
a
In the binding affinity experiments binder is replaced with 100 % DMSO. 
b
In the binding affinity assay 




The general microplate layout in the binding affinity and ligand displacement experiments 
are presented in Figure 2.23 and Figure 2.24 respectively. 
 
 1 2 3 4 5 6-12 
A M M M M M ... 
B M+E1 M+E1 M+E1 M+E8 M+E8 ... 
C M+E2 M+E2 M+E2 M+E9 M+E9 ... 
D M+E3 M+E3 M+E3 M+E10 M+E10 ... 
E M+E4 M+E4 M+E4 M+E11 M+E11 ... 
F M+E5 M+E5 M+E5 M+E12 M+E12 ... 
G M+E6 M+E6 M+E6 M+E13 M+E13 ... 
H M+E7 M+E7 M+E7 M+E14 M+E14 ... 
Figure 2.23. General microplate layout in the binding affinity experiments (96 well microplate). 
Enzyme (E) and mixture containing fluorophore, DMSO and TX-100 (M). All dilutions in 13 mM HEPES 
buffer (pH 7.0) 
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 1 2 3 4 5 6-12 
A M+E M+E M M ... ... 
B M+E+I1 M+E+I1 M+I1 M+I1 ... ... 
C M+E+I2 M+E+I2 M+I2 M+I2 ... ... 
D M+E+I3 M+E+I3 M+I3 M+I3 ... ... 
E M+E+I4 M+E+I4 M+I4 M+I4 ... ... 
F M+E+I5 M+E+I5 M+I5 M+I5 ... ... 
G M+E+I6 M+E+I6 M+I6 M+I6 ... ... 
H M+E+I7 M+E+I7 M+I7 M+I7 ... ... 
Figure 2.24. General microplate layout in the ligand displacement (IC50) experiments (96 well 
microplate). Enzyme (E), binder (I) and mixture containing fluorophore and TX-100 (M). All dilutions in 
13 mM HEPES buffer (pH 7.0) 
 
All experiments included controls. Controls in the binding affinity experiments included only 
fluorophore, no enzyme and thus fluorescence intensity remained high. Negative controls in 
the ligand displacement experiments included enzyme and fluorophore (low fluorescence 
intensity) and positive controls contained a fluorophore in each measured nucleotide sugar 
concentration in the absence of enzyme (high fluorescence intensity).  
 
All raw data is normalised as a percentage of the control which possess the highest 
fluorescence intensity on the examined microplate. The results of the binding affinity assay 
are presented in excel by plotting the normalised fluorescence intensity over the range of 
various enzyme concentrations. The IC50 values were calculated by plotting the normalised 
fluorescence intensity over the range of sugar nucleotide concentrations to GraFit 7.0.3. 
 
2.7.4 Assay parameters; reaction volume, concentration of fluorophore and 
DMSO, buffer and incubation time  
 
Linearity of the fluorophore was investigated in the range of 39 nM to 2500 nM at the total 
reaction volume of 100 µL and 200 µL. All dilutions were prepared in 13 mM HEPES pH 7.0 
buffer.  
 
Comparison of Tris/HCl and HEPES buffers were examined at pH 7.4 to 8.3 and 6.8 to 7.8 
respectively, the impact of the DMSO concentrations was examined at 0, 2, 5 and 10 % (v/v) 
and final incubation times of 10, 20, 30 and 60 minutes were examined. Three different pre-




 Incubation 1: UDP and fluorophore incubated for 10 minutes then LgtC added 
 Incubation 2: UDP and LgtC incubated for 10 min minutes then fluorophore added 
 Incubation 3: LgtC and fluorophore incubated for 10 minutes then UDP added  
 
The final reading was taken 20 minutes after the last component was added. All experiments 
were performed with the LDA with UDP, UDP-Gal, or both, in various concentrations (0.01 to 
10000 µM).  
 
2.7.5 Activation of LgtC 
 
Activation of LgtC was investigated by binding affinity assay. LgtC was activated in 5 mM of 
DTT in 13 mM HEPES buffer (pH 7.0) for 30 minutes at 37 °C, prior to use. The highest final 
LgtC concentration in the well was 32 µM and diluted by half, down to the lowest 
concentration of 0.004 µM. 
 
2.7.6 Influence of metal 
 
The experiment was performed in the absence and in the presence of 10 mM MnCl2. A MnCl2 
solution in 13 mM HEPES buffer (pH 7.0) was prepared daily, prior to experiments. Binding 
affinity experiments included the highest final LgtC concentration in the well of 27 µM, and 
diluted by half down to the lowest concentration of 0.42 µM. The influence of the metal was 
also investigated in two separate ligand displacement assays with UDP and UDP-Gal at 
concentrations from 0.01 to 10000 µM. 
 
2.7.7 Non-specific binding and influence of surfactant 
 
Non-specific binding was investigated by the binding affinity assay in the absence and in the 
presence of BSA (Mw 66 kDa), and in 0 %, 0.001 % and 0.01 % of TX-100 in the absence of 
BSA. The highest final BSA/LgtC concentration in the well was 8.2 µM and diluted by half, 
down to the lowest concentration of 0.002 µM. The experiment in the presence of various 
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concentrations of TX-100 was titrated with LgtC concentrations from 0.008 to 64 µM. UDP 
concentrations in the LDA were from 0.001 to and 10000 µM. 
 
2.7.8 Influence of LgtC concentration 
 
Various concentrations of LgtC were investigated by the LDA at concentrations of 1.0, 5.0 or 
15 µM in the presence of TX-100 (0.01 %) and DMSO (10 %) (v/v). UDP concentrations varied 
from 0.005 to 5000 µM. 
 
2.7.9 Reproducibility experiment 
 
Reproducibility was determined on the 96 well microplates and the experiment was 
performed on two different days. The negative control (low fluorescence intensity) included 
5 µM LgtC and 200 nM fluorophore, the positive control (high fluorescence intensity) 
included 5 µM LgtC, 200 nM fluorophore and 5.0 mM UDP. The control (high fluorescence 
intensity) included 200 nM fluorophore.  The experiment was performed in the absence and 
in the presence of TX-100 at 0.01 %. Each Z’-factor plate contained 32 replicate negative 
controls, 32 replicate positive controls and 32 control wells (Figure 2.25). On the second day 
column one was positive control (P), column 2 was control (C) and column 3 was negative 
control (N) etc. 
 
 1 2 3 4 5 6 7-12 
A N P C N P C Etc. 
B N P C N P C Etc. 
C N P C N P C Etc. 
D N P C N P C Etc. 
E N P C N P C Etc. 
F N P C N P C Etc. 
G N P C N P C Etc. 
H N P C N P C Etc. 
Figure 2.25. Microplate layout in the reproducibility experiment. Negative control (N), positive control 





2.7.10 Stability of LgtC 
 
The same LgtC stock (321 µM) was used in the stability experiments. The experiments were 
performed in identical conditions two and five months after expression. The specific activity 
was determined directly after and five months after the expression.  
 
The specific activity was determined by NADH coupled assay (conditions described in Chapter 
2.7.2). The turnover of the substrates to the products were monitored at 0.54, 5.4 and at 54 
µM of LgtC.  
 
The binding affinity was performed on the 96 well microplates, at fixed fluorophore 
concentration (200nM) and variable LgtC concentrations from 0.013 µM to 13 µM.  
 
The LDA was performed on the 96 well microplates, at fixed fluorophore and LgtC 
concentrations, 200nM and 4 µM respectively. UDP-Gal concentrations vary from 0.01 to 
10000 µM. 
 
The Km experiments were performed with phosphatase coupled assay (described in Chapter 
3.4 and the reaction conditions in chapter 3.6.3.1). The experiments were carried out in 
mixture of MnCl2 (5.0 mM), CEL (1.0 mg/ mL), CIP (10 U/mL) and lactose (2.0 mM) in 13 mM 
HEPES buffer (pH 7.0). LgtC was activated and the experiment were carried out at 20 nM and 
UDP-Gal (donor substrate) at 3.1, 6.3, 12.5, 25, 50, 100, 200 µM. The Km values were 
calculated by the initial velocity over the range of UDP-Gal concentrations to GraFit 7.0.3. 
 
2.7.11 Assay adaptation to 384 well microplates 
 
Nunc and Greiner non-coated 384 well microplates were compared by performing 
fluorophore calibration curve from 12.5 to 1000 nM (ten points) in various reaction volumes 
(10 µL for Nunc, 15 µL for Greiner, 20, 30 40 and 50 µL). Both, the binding affinity and the 
ligand displacement assays were performed at 20 µL in triplicate in the presence of TX-100 
(0.01 % (v/v)). The ligand displacement assay was performed with UDP-Gal, UDP, UMP and 




2.7.12 Investigation of other GTs 
 
NGT and TcdB were received from the collaborators. Dr Jon Cuccui and Professor Brendan 
Wren provided NGT, and Professor Klaus Aktories and Dr Thomas Jank provided TcdB. LgtC 
and β1,4-GalT were expressed and purified in house. The experiments were carried out in 
triplicate on 384 well microplates with increasing protein concentration, at 200 nM of 
fluorophore and at 0.01 % of TX-100 (v/v). Reaction conditions are listed in Table 2.13. 
 
Table 2.13. Conditions used in binding affinity assay for studied GTs 
Enzyme Buffer [Metal] pH Fluorophore 
LgtC 13 mM HEPES - 7.0 5FTUDP-Gal 
β1.4-GalT 13 mM HEPES + 50 mM KCl 5 mM MnCl2 7.0 5FTUDP-Gal 
TcdB 25 mM Tris, 150 mM NaCl, 
150 mM K2SO4 
5 mM MgCl2 and 
5 mM MnCl2 
7.5 5FTUDP-Glc 
NGT 300 mM NaCl + 250 mM 
imidazole 




NGT has a low binding affinity to UDP-Gal,141 therefore, the experiment was carried out also 
with 5FTUDP-Gal. However, the fluorescence quenching was not observed. The binding 
affinity experiment with NGT was also attempted in HEPES buffer. The fluorescence was 
quenched linearly with increasing concentration of the pure imidazole buffer (NGT storing 
buffer) in HEPES buffer, therefore, the assay was performed in the imidazole buffer to 














3 Biochemical assays 
 
In the previous chapter (Chapter 2), a ligand displacement assay (LDA) was developed for the 
identification of glycosyltransferase (GT) inhibitors. The LDA monitor only the displacement 
of the fluorescence donor analogue, whereas biochemical assays are designed for monitoring 
the enzymatic turnover. As the LDA is unsuitable for the determination of enzymatic activity 
the biochemical assay was required. The aim of this chapter was to develop a biochemical 
assay in order to determinate the kinetic parameters of LgtC and to evaluate inhibitors 
identified from compound screening (Chapter 4).  
 
3.1 Introduction  
 
A variety of biochemical assays have been developed for the characterisation of GTs.63, 66 
Ideally the enzymatic reaction is monitored in real time and monitoring the glycosylated 
product formation is favourable because small concentration changes in the product 
formation are easier to detect than the concentration changes in donor substrate 
concentrations. As the natural acceptors are poor light emitters, the development of 
biochemical assays based on monitoring the glycosylated product can be problematic. 
Radiochemical and mass spectrometry assays66, 80, 158 have been reported for monitoring the 
formation of glycosylated products however, these approaches have disadvantages (i.e. 
radiochemical waste and expensive equipment). Other techniques such as detecting the 
post-derivated product72, 74 and labelled acceptors73, 159 are reported. Natural GT reactions 
can be monitored by detecting the UV-active nucleobase of the donor substrate or the 
secondary product by UV-detection.63 The assays based on the chromatographic separation 
by HPLC (high-performance liquid chromatography) coupled with UV-detection70 are suitable 
for detection both the depletion of NDP-donor or formation of NDP-product simultaneously. 
In addition, the essential determination of the amount of enzymatic hydrolysis of the donor 
is possible under the assay conditions. Many other GT assays have been developed based on 
monitoring the secondary product with various detection methods such as fluorescent 




The aim of the chapter was to develop a biochemical assay in order determine enzyme 
kinetic parameters catalysed by LgtC and to evaluate inhibitors from the compound library 
screening (Chapter 4). Several biochemical assays were explored: 
 
 HPLC method was optimised for the separation of NDP donor and product of LgtC 
catalysed reaction, and the HPLC method was adapted for determination of the 
kinetic parameters of the LgtC catalysed reaction 
 A novel GT assay was introduced. The development progress was monitored 
alongside the HPLC-based method. During the assay development, unexpected 
features of LgtC were observed. LC-MS/MS method was then developed and utilised 
for further investigations 
 A phosphatase coupled assay was successfully optimised for the monitoring the LgtC 
catalysed reaction 
 
3.2 HPLC method 
 
HPLC is a generic analytical method for separation a mixture of compounds, compound 
identification and quantitative analysis. Several chromatographic techniques are reported for 
the analysis of nucleotides and sugar nucleotide simultaneously from complex biological 
matrices.162 Ion-exchange chromatography (IEC) and ion-pair chromatography (IPC) are the 
most popular techniques to separate polar and ionic molecules such as nucleotides and 
nucleotide sugars.163-167 IPC is a general technique to improve the retention of polar 
compounds in reversed phase chromatography (RP-LC). Ion-pair reagents that have a charge 
opposite to the molecule of interest are added to the mobile phase. The improvement of the 
retention can occur either by dynamic ion-exchange on the stationary phase or formation of 
neutral ion-pairs which are retained in non-polar stationary phase.168 
 
HPLC method can be easily adapted for the determination of kinetic parameters of enzymatic 
reactions. Saccharides are non- UV-active, therefore, monitoring the primary product 
(galactosyllactose) of LgtC catalysed reaction is impossible without derivatisation (Scheme 
3.1). The donor sugar (UDP-Gal) and the secondary reaction product (UDP) reaction are UV-
active and they are possible to quantify by HPLC coupled with UV-detector. In order to obtain 





Scheme 3.1. LgtC catalysed reaction can be monitored by HPLC/UV due to the UV-active catalytic base 
of UDP 
  
3.2.1 Method optimisation 
 
The intention of the HPLC method was to separate and quantify the depletion of UDP-Gal 
and formation of UDP in LgtC catalysed reaction. Formation of the side product (UMP) was 
expected by enzymatic or chemical hydrolysis of UDP-Gal, therefore, UMP was also included 
to the method development. Before the HPLC-based method was adapted for monitoring the 
LgtC catalysed reaction, the retention of the compounds and HPLC parameters were 
optimised using standard (UMP, UDP and UDP-Gal) solutions. 
 
Ion-pair chromatography has been proved to be an effective separation and quantification 
method for polar compounds such as nucleotides and nucleotide sugars, including UDP-Gal 
and UDP.70, 162, 169, 170 Kochanowski and co-workers developed a sensitive and reproducible IPC 
method for the identification and quantification of intracellular nucleotide and nucleotide 
sugar levels from Chinese hamster ovary cells.169 Because UDP-Gal, UDP and UMP were 
separated with this chromatographic method, the method was selected to optimise the 






Kochanowski separated 8 nucleotides and 5 sugar nucleotide by using a standard C18 column 
(3 µm particle size, 15 cm x 4.6 mm).169 The eluent system consisted of two buffers. Buffer A 
was 100 mM potassium phosphate buffer including 8 mM tetrabutylammonium hydrogen 
sulphate (TBAHS) as an ion-pair reagent and buffer B was 70% buffer A with 30% methanol 
(MeOH). The retention time of UDP-gal and UDP was less than 15 minutes and the total run 
time was 47 minutes, therefore, the gradient of the run was modified to obtain shorter 
analysis time: 0 to 77 % buffer B in 27 minutes was changed to 0 to 50 % buffer B in 15 
minutes (Table 3.1).  
 
 
Table 3.1. Gradient steps of HPLC method for analysis of UMP, UDP-Gal and UDP 
Time (min) Buffer A (%) Buffer B (%) 
5 100 0 
15 100-50 0-50 
2 50 50 
1 50-100 50-0 
5 100 0 
 
 
A mixture of UMP, UDP and UDP-Gal (25 µM each) was analysed by the optimised HPLC 
gradient at flow rate 1 mL/min and detected at 265 nm. The column temperature was set to 
30 °C and the injection volume was set to 50 µL.  
 
All compounds were retained on the column and the peaks were clearly separated with the 
increasing gradient of MeOH concentration (Figure 3.1). The peak shape and response of all 
components were satisfactory at the injection volume 50 µL. The peaks were identified by 
comparing the retention times of individual standards. UMP, UDP-Gal and UDP peaks 




Figure 3.1. UMP, UDP-Gal and UDP eluted at 5.8, 9.4 and 12.8 min, respectively. Separations were 
performed with the optimised gradient (Table 3.1), an RP column and the wavelength of UV detection 
was 265 nm  
 
3.2.2 System suitability 
 
The system suitability test was performed to ensure that the complete testing system 
including the instrument, the used reagents and the column were suitable for the intended 
application.171 The consistency of the system performance (precision of replicate injections) 
and the chromatographic suitability (e.g. tailing factor, column efficiency and resolution) are 
the main components of the system suitability. The intention of the HPLC method was to 
quantify the concentration of UDP-Gal and UDP during the enzymatic reaction. The following 
system suitability calculations were performed to ensure that the optimised HPLC method 
was adequate for particular analysis.  
 
Precision measurements define how reproducible the results are and assure that the 
autosampler is delivering the same volume each time. The precision is determined with 
measurements of multiple sampling of the same homogenous sample. The precision is 
expressed as the standard relative deviation (%RSD)171 calculated as in Equation 2, where St 
is standard deviation and M is mean. 
 






























The column efficiency (N) is a measure of the dispersion of a peak. The column efficiency 
depends on the retention time (RT) and peak width (W1/2) at half height of the peak. The 
higher the retention time and the narrower peaks, the greater the column efficiency and the 
more effective separation.171 The column efficiency was calculated as in Equation 3. 
 















N   
 
The resolution (R) illustrates how well two peaks are separated.  The resolution of the two 
peaks can be calculated using the retention times ((RT)A and (RT)B) and the peak width at the 
base (WA and WB). When the resolution is > 1.5 the valley between two peaks returns to the 
baseline.171 Resolution was calculated as in Equation 4. 
 
Equation 4  










   
 
The tailing factor (T) is a measure of the symmetry of a peak that can be calculated from the 
peak width at 5% height (W0.05) and the distance from peak front to apex point at 5% height 
(f). Tailing factor of a perfectly symmetrical peak corresponds to value 1.171 Tailing factor was 
calculated as in Equation 5. 







The precision of the retention time, peak area and height were determined for UMP, UDP-
Gal and UDP at 25 µM by performing six replicate injections, and calculating the %RSD. UDP-
Gal may be hydrolysed to UMP and inorganic phosphate via UDP, thus UMP was added to the 
precision measurements. Column efficiency and tailing factor of the peak were determined 
for UDP-Gal and UDP at 25 µM. In addition, the linearity of UDP-Gal and UDP was determined 
as it was important to obtain an accurate concentration of donor sugar and product of 
enzymatic reaction. The linearity of a method is defined as its ability to obtain test results 
that are directly proportional to the sample concentration within a given range.171 The 
linearity was studied in a concentration range from 1.0 µM to 200 µM of UDP-Gal and UDP, 
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and the linear regression (R2) was determined by plotting the peak area versus the 
concentration of measured sample. All the system suitability results are presented in Table 
3.2.  
 
















UMP 5.76 (0.1) 466542 (0.2) 50522 (1.2) - - - 
UDP-Gal 9.24 (0.1) 297493 (0.4) 33350 (0.5) 22667 1.1 0.997 
UDP 12.83 (0.04) 497848 (0.6) 41708 (0.5) 25667 0.9 0.996 
a
Determined at range of 1.0 µM to 200 µM 
 
UMP retained first then UDP-Gal and finally UDP, by the optimised HPLC method. All 
nucleotides and sugar nucleotides were visibly separated except a small apparent shoulder of 
UDP-Gal. Further investigations showed that the impurity was derived from UDP-Gal (97 % 
pure by the manufacturer). The resolution between UDP-Gal and the impurity peak was 1.6. 
Resolution higher than 1.5 is satisfactory for an accurate integration because the valley 
between two peaks touches to the baseline.171 Based on visual evaluation, the limit of 
quantification (LOQ) of UDP-Gal and UDP was approximately 1.0 µM. Below the 




Figure 3.2. Peak area increased linearly with increasing concentration of UDP-Gal and UDP in range of 
1.0 µM to 200 µM with optimised HPLC method 
 
R² = 0.9968 





























The recommended %RSD for precision is > 1 % by U.S. Food and Drug Administration 
(FDA).172 Based on the recommendations of FDA the reproducibility of retention time, height 
and peak area were excellent for all components except for UMP. %RSD of the peak height of 
UMP was slightly out of range (1.2 %). This can cause variable results if peak height of UMP is 
used for the determining the concentration of UMP. However, this result was not significant 
because the intention was to record peak area of UDP-Gal or UDP accurately. UDP and UDP-
Gal peaks were symmetrical and the peaks are clearly separated from the baseline. The 
tailing factor and the column efficiency were in the limits of FDA recommendations; ≤ 2.0 and 
> 2000 respectively. In addition, the linear regression (>0.996) indicated an excellent 
relationship between peak area and concentration of UDP-Gal and UDP in range of 1.0 µM to 
200 µM (Figure 3.2).  
 
3.2.3 Adaptation of the HPLC method for monitoring LgtC catalysed reaction 
 
The HPLC method was developed to quantify UDP-Gal and UDP, therefore, the HPLC method 
was adapted to follow the LgtC catalysed reaction by monitoring the depletion of UDP-Gal or 
formation of UDP. The suitability of the optimised HPLC-based method was evaluated by 
determining repeatability (%RSD) and Km of UDP-Gal of the LgtC catalysed reaction in order 
to use the assay for compound characterisation.  
 
The reaction conditions used by previous laboratory members were adapted to monitor the 
LgtC catalysed reaction.52 The reactions were carried out in 50 mM MOPS buffer, including 10 
mg/mL of BSA and 20 mM of MnCl2 at pH 7.0. The lactose concentration was at 2.0 mM, 
UDP-Gal was fixed or variable depending on the experiment, and reactions were initiated by 
adding LgtC. After 10 minutes incubation at 37 °C the reactions were stopped by placing the 
samples in dry ice. The samples were then thawed prior to the injection and the optimised 
HPLC method was used to quantify formation of UDP or depletion of UDP-Gal. 
 
Previous results (chapter 2.2.2) suggested that LgtC activation is not necessary when binding 
affinity is monitored. However, enzyme kinetic studies have suggested that activation with 
DTT increases catalytic activity of LgtC.147 Therefore, the effect of the activation on LgtC 
activity was studied by HPLC-based assay. UDP formation was monitored in various activated 
and non-activated LgtC concentrations (Figure 3.3). The results showed a 1.4-1.9 fold 
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increase in LgtC activity, supporting the hypothesis that the activation only effects the 
acceptor binding. The results suggested that activation creates a favourable conformational 
change for the acceptor binding and product release. Therefore, LgtC was activated prior to 
use for all future experiments.  
 
 
Figure 3.3. UDP formation of non-activated versus activated LgtC catalysed reaction followed by HPLC-
based method with detection wavelength 265 nm. Lactose and UDP-Gal concentrations 2.0 mM and 
200 µM, respectively 
 
Reproducibility of HPLC-based method was studied by performing LgtC catalysed reaction 
eight times in identical conditions over one day. The UDP-Gal concentration was fixed to 60 
µM and reactions were stopped after 10 minutes incubation by placing the samples in dry 
ice. Formation of UDP peak was monitored and the variability was 4.1 %RSD (Table 3.3). 
 
Table 3.3. Reproducibility of LgtC catalysed reaction by monitoring UDP peak area (n= 8)   




Experiment performed at 2.0 mM of lactose, 0.63 nM of activated LgtC and at 60 µM UDP-Gal  
 
The suitability of the optimised HPLC method for enzymatic kinetic studies was evaluated by 
determining the Km and Kcat of LgtC catalysed reaction (Table 3.4) by monitoring the 
formation of UDP. The initial reaction velocity was measured at various UDP-Gal 
concentrations ensuring the donor conversion to the product was 10 % or less. As 































sensitivity of HPLC-based assay was examined in the presence of 10 % (v/v) DMSO ensuring 
capability to characterise possible hits from the compound library screening (Chapter 4).  
 




UDP-Gal 4.9 ± 1.6 6.0 ± 1.0 
UDP-Gal (10 % DMSO) 2.2 ± 1.1 6.1 ± 3.0 
a
Experiment performed at 2.0 mM of lactose, 0.63 nM of activated LgtC and UDP-Gal concentrations 
of 1.6, 3.1, 6.3, 12.5, 25, 50, and 100 µM 
 
The kinetic parameters of LgtC were determined by HPLC-based method. Km was slightly 
lower than the literature values (13-29 µM16, 108, 173), however, the difference is probably from 
the conditions used in particular biochemical assay. The results indicated that DMSO did not 
have significant effect for the assay efficiency as Km and Kcat remained on the same range. 
Low Km value of UDP-Gal demonstrates a high binding affinity to LgtC which results that the 
used assay is required to detect accurately small substrate or product concentration changes. 
However, the accuracy of the obtained Km values are questionable because the 
measurements required detection of low UDP concentrations near LOQ, particularly at 1.6 
µM and 3.1 µM of UDP-Gal. Detection near the LOQ may cause inaccurate measurements 
which may significantly effect the initial velocity at the lowest UDP-Gal concentrations and 
can result in error on Michaelis-Menten curve. Thus, the slight difference between the Km 
values in the presence and in the absence DMSO may be due to the poor detection sensitivity 
not the effect of DMSO. 
 
Overall the HPLC-based method has disadvantages and advantages. A disadvantage is the 
sensitivity and high LOQ which complicate the accurate determination of small concentration 
changes of UDP and UDP-Gal in the enzymatic kinetic experiments. Therefore, the HPLC-
based method may produce inaccurate results if it is used for the characterisation of 
potential LgtC inhibitors at low UDP-Gal concentrations. However, the HPLC- based method 
can be used for less efficient enzymes (higher Km value) than LgtC. Additionally, a 
disadvantage of the HPLC-based method is the time consuming assay protocol which was 
seen during Km determination. The time consuming steps are the equipment set up, the 
samples must be thawed prior to each injection and only one sample can be analysed at 
once. An advantage of the HPLC-based method is that it can be used for the direct 
quantification of the depletion of the donor substrate or formation of the product and the 
results can be used for producing Michaelis-Menten curves without the need for labels or 
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additional derivations. In addition, the hydrolysis product, UMP, can be monitored 
simultaneously with UDP-Gal and UDP. The HPLC-based method is not practical to perform or 
sensitive enough for the determination of kinetic parameters of LgtC. However, the method 
may generate useful information if unforeseen results are discovered with 
spectrophotometric assays where usually only one substance can be monitored.  
 
3.3 Development of glycosidase coupled assay 
 
As described in the previous section, the HPLC-based assay was a time consuming assay 
protocol and the sensitivity was low (LOQ = 1.0 µM). Therefore, an alternative biochemical 
assay was required because the HPLC-based assay was impractical for the determination of 
enzyme kinetic values and for the evaluation of inhibitors identified from compound library 
screening.  
 
Several GTs have been shown to use unnatural substrates.174-177 For example, α1,3-GalT 
which naturally catalyses the transfer of galactose from UDP-Gal to disaccharides such as 
terminal lactose and N-acetyllactosamine containing glycoconjugates can use p-nitrophenyl-
β-galactoside (pNPβGal) as an acceptor.13 When pNPβGal was used as an acceptor, only 
α(1,3)-linked disaccharide derivative was formed, whereas in the reaction with free galactose 
as an acceptor, a mixture of regioisomers were formed.13 In addition, Jamaluddin and co-
workers supported the theory of acceptor substrate promiscuity of α1,3-GalT by performing 
a crystal structure of pNPβGal complex with α1,3-GalT and demonstrating that pNPβGal 
binds similarly to the natural acceptor substrate, N-acetyllactosamine.178 Recent substrate 
engineering studies have shown that LgtC is able to use both, unnatural donor and acceptor 
substrates. LgtC has been shown to use α-galactosyl fluoride174 and 2,4-dinitrophenyl-β-D-
galactoside13 as donor substrates in the presence of natural nucleotide, UDP. Systematic 
substrate engineering studies demonstrated an acceptor diversity of LgtC. LgtC was able to 
process variable unnatural substrates and depending on the alkyl or aryl substituent of the 
acceptor sugar, galactose was transferred via α(1-2), α(1-3) or α(1-4) linkages at synthetically 





The substrate flexibility can be beneficial for the designing of biochemical assays of GTs 
because the GT substrates which are generally poor light emitters could be replaced with 
fluorescent, unnatural substrates. The sugar moiety of the acceptor molecule is important for 
biological activity and recent studies suggested that LgtC could utilise variable acceptor 
molecules with the requirement for the presence of sugar. Therefore, a novel fluorescence 
based biochemical assay was designed with LgtC. An advantage of this novel fluorescence 
assay is that it is sensitive and it can be performed on 96 well microplates.  
 
3.3.1 Principle of the glycosidase coupled assay 
 
The aim was to develop a novel fluorescence-based biochemical assay by monitoring the LgtC 
catalysed reaction by using an unnatural fluorogenic acceptor coupled with a glycosidase that 
cleaves the sugar from the aglycone causing a change in fluorescence. Hypothetically, 
glycosylation might protect adjacent cleavage site from hydrolysis. The new assay was then 
designed by coupling the glycosidase and GT reaction. In this approach, a fluorogenic 
acceptor is subjected to glycosylation and then treated with a glycosidase that discriminates 
between the glycosylated and non-glycosylated fluorogenic acceptor molecules (Scheme 
3.2).  The resulting fluorescence signal is measured to determinate the amount of hydrolysis 
which is related to the degree of glycosylation. For example, in the presence of a high affinity 
inhibitor, the non-glycosylated fluorogenic substrate is hydrolysed by the glycosidase, leading 
in the increase of the fluorescence signal.   
 
 
Scheme 3.2. General principle of the glycosidase coupled assay. LgtC catalyses the transfer of 
galactose from UDP-Gal to the fluorogenic acceptor producing glycosylated product which cannot be 
hydrolysed by specific glycosidase and fluorescence remains low. The unreacted acceptor is then 




The requirements of this glycosidase coupled assay were (1) identify a 
fluorogenic/glycosidase pair, (2) fluorogenic substrate must be a good acceptor for LgtC and 
(3) there must be a large difference in fluorescence intensity signal between the glycosylated 
and non-glycosylated products. Exo-acting glycosidases179 cleave a sugar at the non-reducing 
end of the chain and β-mode exo-acting glycosidases were the option with most potential for 
the coupling with LgtC catalysed reaction because they are unable to recognise α-linked 
sugars. Thus, the α1,4-linked galactose of the glycosylated product by LgtC is protected.  
 
Resorufin modified sugars were of interest as fluorogenic acceptors because they have a long 
fluorescence emission wavelength that is less prone to interfere with fluorescent compounds 
in the characterisation of potential inhibitors, and additionally, the hydrolysed product 
(resorufin) is strongly fluorescent compared to the resorufin-sugars.180 Modified resorufin 
molecules have been used for studying glycosidases such as cellulose,181 mannosidase,182 
glucosidase180, 183 and galactosidase99 activities in various assay modes, including HTS.184 A 
substrate of β-galactosidase, resorufin-β-galactopyranoside (Rgal)185, 186 was a potential 
fluorogenic acceptor substrate for LgtC as it could mimic the natural acceptor (lactose).   
 
 
Scheme 3.3. Resorufin-β-galactopyranoside (Rgal) hydrolysed by β-galactosidase results strongly in 
fluorescent resorufin (λem =590 nm, λex =570 nm) 
  
Rgal and β-galactoside “pair” was selected for the development of a coupled assay together 
with LgtC. The aim was to establish reaction conditions to detect resorufin which was 
comparable to the amount of unreacted Rgal. The designed assay consists of two separate 
reactions: β-galactosidase catalysed reaction and LgtC catalysed reaction.  This coupled assay 
development contained the following studies: 
 Linearity and stability of resorufin  
 Optimisation of concentration of β-galactosidase   
 Functionality of Rgal as an acceptor for LgtC by HPLC  
 Optimisation of concentrations of LgtC and Rgal 
 Positive and negative control investigation 
 Optimisation of incubation time 
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3.3.2 Optimising β-galactosidase catalysed reaction 
 
The functionality of the β-galactosidase catalysed reaction was investigated. β-galactosidase 
has been reported to function in 50 mM HEPES pH 7.3 buffer including 1.0 mM MgCl2.
187 This 
buffer with 1.0 mM MnCl2 was chosen for the preliminary experiments because of its 
similarity with the LgtC assay buffer that was used in the HPLC-based method (chapter 3.2.3). 
The aim was to find an optimal β-galactosidase concentration that hydrolyses galactose from 
Rgal rapidly. The hydrolysis of Rgal was investigated in real time with various β-galactosidase 
concentrations (Figure 3.4, A). At the highest β-galactosidase concentration (8.2 U/mL) all 
Rgal was hydrolysed very rapidly and to reach the same level of hydrolysis at 0.13 U/mL of β-
galactosidase, 20 minutes incubation was required. 0.5 U/mL of β-galactosidase was selected 
for future experiments because at this concentration 10 minutes incubation time was 
optimum to hydrolyse all Rgal and the consumption of large amounts of material was 
prevented. 
 
The fluorescence linearity of resorufin, the hydrolysis product of Rgal, was investigated in 
various concentrations of Rgal in order to discover a suitable acceptor concentration. The 
linearity of fluorescence of resorufin decreased at concentrations over 20 µM. The linear 
range of detected resorufin was between 0.08-10 µM (Figure 3.4, B) and the acceptor, Rgal, 
had to be used in this concentration range. 
 
In addition, the stability of resorufin was investigated by monitoring the fluorescence of 
standard solutions of resorufin in various concentrations. Photobleaching of resorufin was 
not observed during one hour incubation at 37 °C (Figure 3.4, C). Therefore, the high stability 







Figure 3.4. Hydrolysis of Rgal (20 µM) with various β-galactosidase concentrations (A). Fluorescence 
linearity of resorufin by hydrolysis of 0.8 to 50 µM Rgal by 0.5 U/mL of β-galactosidase (B). Stability of 






























































































3.3.3 Coupling LgtC reaction and β-galactosidase reactions 
 
Preliminary tests were performed with the HPLC-based assay (Chapter 3.2.3) to evaluate Rgal 
functionality as an acceptor with LgtC. The LgtC catalysed reaction was performed by using 
Rgal as an acceptor instead of lactose. The results showed that the UDP-Gal peak decreased 
and UDP increased with increasing concentration of LgtC (Figure 3.5). This indicated that LgtC 
used Rgal as an acceptor. 
 
 
Figure 3.5. Reaction process of LgtC catalysed reaction monitored by optimised HPLC method (Chapter 
3.2.1). The reaction monitored at 0.005 U/mL and at 0.05 U/mL of LgtC, and compared to the peak 
area of UDP-Gal in the negative control where LgtC was not added. Rgal at 100 µM was used as an 
acceptor and UDP-Gal at 60 µM as a donor. 
 
The LgtC reaction and β-galactosidase reactions were then coupled in order to monitor the 
glycosylation by fluorescence detection. At the start, positive and negative controls were 
investigated. A positive control, when LgtC is active, results in a weak fluorescence signal as 
Rgal is galactosylated and protected from the β-galactosidase. The positive control was then 
performed without adding β-galactosidase to the reaction mixture. A negative control would 
result in a high fluorescence signal and would be observed in the absence of glycosylation 
(i.e. LgtC is non-active). The negative control was investigated in two ways: in the absence of 






























The fluorescence intensity was assumed to be the same for both negative controls. Initially 
the control experiments were performed with activated LgtC, resulting in stronger 
fluorescence intensity for the negative control in the absence of LgtC compared to the 
negative control in the absence of UDP-Gal (Figure 3.6). The experiment was repeated with 
non-activated LgtC and the fluorescence intensity of both negative controls reached the 
same level. These results indicated that possibly DTT quenches the fluorescence intensity of 
resorufin, therefore, subsequent experiments were performed without LgtC activation and 
the negative control was then performed in the absence of UDP-Gal. The control experiments 
showed a low fluorescence signal on the positive control, therefore, the positive control was 




Figure 3.6. Negative and positive control investigations by coupling LgtC and β-galactosidase reactions. 
The experiment was performed at fixed concentrations of UDP-Gal (50 µM), Rgal (6.3 µM), LgtC (0.1 
U/mL) and β-galactosidase (0.5 U/mL). Fluorescence monitored at λem =590 nm and λex =544 nm 
 
The reaction progress of the LgtC catalysed reaction was then investigated with various UDP-
Gal concentrations and various incubation times, at fixed Rgal concentration. The assumption 
was that if the reaction is completed then almost all Rgal is glycosylated and a low 
fluorescence signal would be observed, similar to the fluorescence intensity level as the 
positive control. As illustrated in the Figure 3.7, the reaction progressed slowly with 
increasing incubation time at various UDP-Gal concentrations, more rapidly in higher 
concentration than lower concentrations.  The fluorescence intensity remained high, 

























LgtC activation with DTT
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incubation time. Therefore, these results indicated that the glycosylation was not completed 
in the reaction conditions. The utilised LgtC concentration was doubled in the experiment 
compared to the preliminary test with HPLC-based method (Figure 3.5). The HPLC 
experiment showed that nearly all UDP-Gal was consumed in the reaction, therefore, the 
utilised LgtC concentration was assumed to be sufficient to complete the glycosylation. 
However, these results suggest that at least 60 % of Rgal was free in the reaction mixture in 




Figure 3.7. Glycosidase coupled reaction in various UDP-Gal concentrations and various incubation 
times. Reactions were carried out at 6.3 µM of Rgal, 0.1 U/mL LgtC and 0.5 U/mL β-galactosidase. 
Fluorescence monitored at λem =590 nm and λex =544 nm 
 
There are three possible explanations for the observed results: Rgal is a low affinity acceptor 
for LgtC, UDP-Gal is rapidly hydrolysed or LgtC transfers more than one galactose to the Rgal. 
The glycosidase coupled assay was developed to detect the unreacted Rgal without providing 
information about the reaction products or consumed UDP-Gal. To investigate further 
whether UDP-Gal was hydrolysed or Rgal was polygalactosylated, a method which could 
monitor both the consumption of the substrates and the formation of the products was 
required.   
 
The HPLC based-method was appropriate for monitoring the reaction because all 
components were UV-active. The LgtC catalysed reaction was then adapted to a HPLC-based 






































monitored at 30, 45 and 60 minutes incubation time. One new peak was observed on the 
HPLC trace when the product peaks of the LgtC catalysed reaction was analysed (Figure 3.8, 
A). The peak eluted at 15.2 minutes, after UDP and before Rgal, suggested the peak is 
glycosylated Rgal. A small UMP peak was observed but the peak size remained the same 
during the incubation time. As illustrated on the Figure 3.8 (B), after 60 minutes incubation, 
all UDP-Gal was consumed thus approximately 70 % of Rgal was unreacted. This indicated 





Figure 3.8. LgtC catalysed reaction stopped after 30 minutes incubation (blue trace) overlaid with the 
control, in the absence of LgtC (red trace) (A). LgtC catalysed reaction progress monitored by HPLC-
based method (B). The reaction was carried out at 200 µM of UDP-Gal and Rgal, 0.02 U/mL of LgtC in 



























































The Rgal was the limiting factor of the reaction rate because the concentration used was 
lower than the UDP-Gal concentration. However, the results obtained by the fluorescence 
based glycosidase coupled assay and the HPLC-based method, demonstrated that Rgal 
remained non-glycosylated at high UDP-Gal concentrations suggesting that UDP-Gal was not 
consumed in a one to one relationship to Rgal in the LgtC catalysed reaction. Therefore, 
additional investigations were required in order to identify the reaction product. 
 
3.3.4 LCMS method development for the identification of the unknown product 
 
Mass spectrometry (MS), which is a sensitive technique for the determination of molecular 
weight of molecules, was selected for the identification of the unknown product of the LgtC 
catalysed reaction when Rgal was used as an acceptor. MS is a widely used detection method 
and, combined with a separation method such as liquid chromatography (LC) allows an 
analysis of complex samples.188 Connection of the two is not trivial, since the mass 
spectrometry requires that the analyte must be ionised in the gas phase. Ionisation methods 
such as electrospray ionisation (ESI),189 allow for the transfer of large molecules from the 
liquid phase to the gas phase without breaking and if needed, also ionise them. Previously, 
the HPLC-based method was successfully adapted to monitor the donor and product of the 
LgtC catalysed reaction (Chapter 3.2.1). However, this HPLC method was unsuitable with the 
ESI/MS detection because a non-volatile ion-pair reagent was used. Therefore, an alternative 
chromatographic method was required for the separation of all reaction components.  
 
Hydrophilic interaction liquid chromatography (HILIC) is an alternative technique for 
separating ionic and strongly hydrophilic compounds without non-volatile ion-pair reagents, 
thus it is compatible with ESI/MS detection. The separation mode is similar to the normal-
phase liquid chromatography (NP-LC) because a polar stationary phase is used but the strong 
organic mobile phase (typically acetonitrile, ACN) is replaced with an aqueous–organic 
mixture containing at least 5 % water.190  The stronger solvent in the mobile phase is water, 
which promotes hydrophilic interactions between the analyte and a water-enriched 
hydrophilic stationary phase. The retention mechanism of HILIC is primarily described as a 
hydrophilic partition mechanism, in practice this "pure HILIC" mechanism is rare, as most of 
the HILIC separations are multimodal. In addition to the pure hydrophilic partition 
mechanism, the analytes interact with the stationary phase by ion-ion and hydrogen bonding 
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interactions.191 Thus, retention can be influenced by the choice of the stationary phase. The 
same polar stationary phases as in the NP-LC are applicable in HILIC, such as bare silica and 
chemically bonded amino-, cyano-, diol-, amide- and switterionic- etc. phases.190, 191 
 
The HILIC technique has many advantages compared to NP-LC and reversed-phase liquid 
chromatography (RP-LC), mostly due to the organic mobile phase. In contrast to NP-LC, the 
mobile phase includes water, but less than in the RP-LC. The elution order is reversed in the 
HILIC compared with RP-LC and the retention of polar compounds is better and non-polar 
compounds are retained poorly. MS response is better in HILIC compared with RP-LC because 
surface tension is smaller, therefore, the mobile phase is more volatile in ionisation.189 High 
organic solvent proportions are used in HILIC mobile phases and volatile buffers lower 
surface tension, which increases ionisation efficiency in ESI.189 Buffer salts such as ammonium 
formate or acetate192 are commonly used to improve peak shape or retention in the HILIC 
separations, however, only low concentrations are suitable in ESI, high concentrations 
hamper the ionisation.189 A current is proportional to flow rate in the ESI process. When 
current is increased by high flow rate, ion intensity decreases as larger droplets are formed 
which are less efficient for forming ions in the gas phase. Therefore a low flow rate is 
required.189 The HILIC methods are generally coupled with ESI/MS detection for the analysis 
of highly polar and ionic compounds192 such as nucleosides, nucleotides, carbohydrates, 
amino acids, peptides and proteins191 including nucleotide phosphates193 and nucleotide 
sugars.194 For example, Preinerstorfer194 and co-workers separated numerous hydrophilic 
intracellular metabolites including UMP, UDP and UDP-Gal with zwitterionic HILIC column 
and the metabolites were detected by LC-ESI tandem mass spectrometry (MS/MS). 
 
 
Scheme 3.4. LgtC catalysed reaction when Rgal used as an acceptor 
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The aim was to develop HILIC method for the separation all reaction components of the LgtC 
catalysed reaction (Scheme 3.4), strongly hydrophilic UDP and UDP-Gal, less polar Rgal and 
the unknown product in single chromatographic run which is compatible with ESI/MS. Similar 
hydrophobicity (LogP) of UDP and UDP-Gal (Table 3.5) can make the separation of these 
compounds challenging. Additionally, more hydrophobic Rgal retains with a non-polar 
conditions compared to polar UDP and UDP-Gal.  
 
Table 3.5. cLogP values of the analytes. Determined by ACD/3D Viewer Freeware 12.01 
Analyte Rgal Rgal-gala UMP UDP UDP-Gal 
LogP -1.31 -2.41 -1.58 -4.27 -4.51 
aExpected glycosylated product 
 
The development of the chromatographic method was performed with a HPLC coupled with 
diode array detector (DAD). After the suitable separation was achieved, the HPLC method 
was transferred to HPLC coupled with ESI-MS/MS which was used for the analysis of the 
unknown product. The LCMS method development contained following steps: 
 Investigation of the best chromatographic method for the separation of UDP-Gal, 
UDP and Rgal with bare silica, zwitterionic and amide modified silica HILIC columns 
by HPLC/UV  
 Optimisation of the LgtC catalysed reaction conditions for the LC-MS run by HPLC/UV   
 Optimisation of the LC-MS method for the analysis on the unknown reaction product 
 Analysis of the reaction products by LC-MS/MS 
 
3.3.4.1 Underivatised HILIC Silica bonded column 
 
Bare silica or underivatised silica is the most popular packing material and originally used in 
NP-LC.195 The surface of the silica is covered with hydrophobic siloxane (Si-O-Si) and different 
silanol groups (Figure 3.9) that can have different reaction and absorption activities.195 Polar 
silanols interact with water molecules by hydrogen bonding from the mobile phase which 
leads to the formation of aqueous layer on the surface of the sorbent. The retention process 
is mostly hydrophilic interactions between the analytes and the silica stationary phase but 
different retention modes such as ion-exchange and some hydrophobic retention by the 





Figure 3.9. Different types of silanol groups on the silica surface: A) single,  B) geminal and C) vicinal 
 
Volatile mobile phases increase ionisation of analytes, therefore, silica packed columns are 
suitable in LC-MS systems.196 Additionally, column bleeding is possible with derivatised silica 
packed columns191 when functional groups can be released from the surface causing 
increased background noise on MS-based detectors but this cannot happen on bare silica 
columns. A disadvantage of bare silica columns is their stability to basic conditions, above pH 
8, dissolution of silica skeleton can cause loss of column efficiency.197  Bare silica HILIC 
columns are mostly used for the separation of various small polar compounds such as 
nucleosides and nucleic acid bases.191, 196 Although, even there was a lack of applications for 
separation nucleotide sugars or nucleotide phosphates, bare silica bonded column was 
examined for the separation of UDP, UDP-Gal and Rgal.  
 
The compatibility of Waters Atlantis HILIC silica column (3 μm particle size, 50 x 2.1 mm) was 
investigated by analysing a mixture of UDP-Gal, UDP and Rgal. The most hydrophobic Rgal 
was expected to elute first and then more hydrophilic UDP and UDP-Gal. Possibility to change 
composition of water during the run, initially the lowest water concentration was chosen. 
The detection of the components was started at 100 % of ACN:5 mM ammonium acetate 
(95:5) at pH 5.0.  
 
The retention order was unexpected because in the HILIC systems, the retention order of 
polar analytes are usually opposite than in RP-LC separations.192 UDP and UDP-Gal eluted as 
one peak in the column-void volume, approximately at one minute before Rgal at 2.5 min 
(Figure 3.10). The underivatised silica stationary phase is categorised as a weak hydrophilic 
phase,198 therefore, strong adsorption or partition interactions between the hydrophilic UDP-
Gal and UDP are prevented. Hydrophobic interactions between Rgal and the stationary 





Figure 3.10. Separation of mixture of UDP, UDP-Gal and Rgal (100 µg/mL each) with bare silica column. 
UDP-Gal and UDP was detected at 265 nm (blue trace), and Rgal at 470 nm (red trace)  
 
The retention was poor for all analytes even in the weakest mobile phase (least water). 
Therefore, the unmodified silica column was inappropriate for the analysis of the substances 
of the LgtC catalysed reaction. Based on the results, more hydrophilic stationary phase was 
required for the separation of the polar analytes.  
 
3.3.4.2 ZIC-pHILIC column 
 
Zwitterionic columns, commercially called ZIC-HILIC (silica gel support) and ZIC-pHILIC 
(polymer support) have been specifically developed for HILIC. A covalently attached 
sulfoalkylbetaine functional groups (Figure 3.11) on the column surface have a strong 
capability to adsorb water, thus this stationary phase is attractive for HILIC applications. The 
sulfoalkylbetaine ligand contains a negatively charged sulfonic acid group and a positively 
charged quaternary ammonium group, and the net charge is zero. Although, due to the large 
distance of sulfonic group from the surface of the silica than the ammonium group there is a 
low negative surface charge which is little affected by the pH value of the mobile phase. 
Therefore, ion-exchange is lower and electrostatic interactions are stronger compared to 
amide- and bare silica phases. ZIC-HILIC columns have been used to separate sugar 
phosphates,199 nucleotide triphosphates193 and nucleotide sugars,194 therefore, the 





























Figure 3.11. Sulfoalkylbetaine zwitterionic stationary phase 
 
Polymeric-based SeQuant ZIC-pHILIC column (5μm particle size, 150 x 2.1mm) which is more 
hydrophilic than bare silica columns was examined. Two mobile phases were used: buffer A 
consisted of ACN and 10mM NH4Ac (pH 4) (95:5, v/v) and buffer B consisted of ACN and 
10mM NH4Ac (pH 4) (50:50). The mixture of UDP, UDP-Gal and Rgal were run on the gradient 




Figure 3.12. Mixture of UDP, UDP-Gal and Rgal (50 µg/mL each) analysed with ZIC-pHILIC column at 30 
°C (blue trace) and 60 °C (red trace), detection wavelength 265 nm 
 
Initially, the experiment was run at a column temperature of 30 °C and all the analytes were 
well retained, Rgal at 4 minutes and UDP/UDP-Gal at 9.3 minutes (Figure 3.12). Based on 
similar hydrophilicity of UDP-Gal and UDP (cLogP -4.51 and -4.27, respectively), it was 
assumed that the retention time was identical. Johnsen and co-workers discovered that the 




























they proposed the effect was due the dissociation of analyte/water clusters.193 Physical 
properties of UDP are similar to the nucleotide triphosphates (i.e. UTP, nucleotide 
triphosphate) that were used in the Johnsen study.  Therefore, it was assumed that by 
increasing column temperature the retention of UDP and UDP-Gal could change. Higher 
column temperature (60 °C) was examined and the results showed that the retention time of 
the peak at 9.3 minutes increased and the peak was split (Figure 3.12). In addition, the 
retention time of less hydrophilic Rgal reduced from 4 minutes to 3.6 minutes. The tall peak 
splitting at 60 °C demonstrated that UDP and UDP-Gal retained at 30 °C as one peak. The 
separation mechanism of UDP and UDP-Gal at elevated temperature is unclear. UDP-Gal is 
slightly more hydrophilic than UDP, however, UDP-Gal retained before UDP. Possibly ionic 
UDP can form hydrogen bonds with the aqueous layer and thus elute later. Or based on 
Johnsen’s research, UDP/water clusters could be formed in higher affinity compared to UDP-
Gal/water clusters and UDP is shielded from the mobile phase.193  
 
 
Table 3.6. Measured parameters of UDP, UDP-Gal and Rgal (50 µg/mL each) analysed with various 












1 1.16 0.81 0.46 4.53 20.73 21.20 
2 0.87 0.82 0.45 4.55 20.18 20.62 
3 0.54 0.69 poor 2.04 11.71 12.21 
4b 0.98 0.83 0.49 4.51 19.67 20.06 
5b, c 0.71 0.77 0.34 5.39 19.43 19.76 
a




column temperature 30˚C 
 
The separation of UDP and UDP-Gal was examined by running various gradient runs 
(presented in experimental chapter 3.6.2.3). More hydrophobic Rgal was retained in low 
aqueous content compared to hydrophilic UDP and UDP-Gal, therefore, gradients were set 
up by starting an isocratic 100 % buffer A for the first 5 minutes (gradient 4 & 5 in Table 3.6) 
or, the first 10 minutes (gradient 1). The retention time of Rgal with 100 % buffer A was 4.5 
minutes and remained the same when water content was slowly increased (gradient 2). 
When the water content in the mobile phase was increased rapidly (gradient 3), all analytes 
had a shorter retention times. However, different aqueous content did not significantly 
improve the resolution between UDP and UDP-Gal (Table 3.6). The best resolution was 
achieved with high aqueous content at 25 % buffer A (Table 3.6, gradient 1 & 4). The back 
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pressure significantly limited the aqueous content on the gradient run and the maximum 
buffer B used was 75 %. Therefore, the ZIC-pHILIC column did not meet the satisfactory 
resolution (R >1.5) between UDP and UDP-Gal. 
 
3.3.4.3 Amide bonded HILIC column 
 
The ZIC-pHILIC column was unsuitable for the separation of UDP and UDP-Gal because of too 
high back pressure in high water content, therefore, the last option was to investigate an 
amide modified silica HILIC column. Amide HILIC columns have been mainly utilised for 
analysis of peptides and monosaccharides,191 although also nucleotides200 and nucleotide 
sugars201, 202 have been successfully separated. The stationary phase contains a covalently 
bonded amide (e.g. carbamoyl) groups via short aliphatic linkage to the silica backbone 
(Figure 3.13). Compared to amino silica columns, the amide groups are less reactive and the 
retention of the ionic analytes is less prone for ion interactions.203  
 
 
Figure 3.13. Amide modified silica stationary phase 
 
Waters ACQUITY BEH Amide column (particle size 1.7µm, 150 x 2.1 mm) which is designed 
for ultra-performance liquid chromatography was examined. Mixture of UDP, UDP-Gal and 
Rgal was prepared in water:ACN (20:80) and analysed on a gradient run of increasing water 
content. Buffer A consisted of ACN: 10mM NH4Ac (pH 9) (95:5) and buffer B consisted of 
ACN: 10mM NH4Ac (pH 9) (50:50). Two sharp peaks at 3.4 and 17.8 minutes were observed 
(Figure 3.14 A). ZIC-pHILIC and amide column columns have similar retention behaviour,203 
therefore, the retention order of UDP and UDP-Gal was expected to be identical, and the 





Figure 3.14. A) Mixture of Rgal, UDP-Gal and UDP (green trace), 50 µg/mL each B) UDP (red trace) and 
UDP-Gal (blue trace), 100 µg/mL each examined with two separate HPLC runs. Detection wavelength 
265 nm 
 
The broad peak was identified as UDP (Figure 3.14 B) by analysing UDP and UDP-Gal (100 
µg/mL each) at identical conditions as the mixture with two separate chromatographic runs. 
Peak broadening can be caused by a stronger sample solvent than the mobile phase solvent.204 
In this case, the stronger solvent was water and UDP was diluted in water:ACN (20:80). The 
aqueous content was approximately 55 % at the retention time of UDP. The aqueous content 
of buffer B was then increased from 50 % to 70 % to investigate the influence of stronger 
solvent on peak shape.  
 
The peak shape of UDP improved significantly and the response of both UDP and UDP-Gal 
peaks increased (Figure 3.15, A & B) with higher aqueous content in the mobile phase. The 
retention time decreased with increasing polarity from 17.8 to 16.3 minutes, and from 18.7 to 
16.7 minutes for UDP-Gal and UDP, respectively. The peak shape and sensitivity of Rgal was 
maintained in higher aqueous content and surprisingly, the retention time increased from 3.5 
to 6.1 minutes (Figure 3.15, B & C). The retention of Rgal is reversed-phase-like, as elution was 
shorter in a more hydrophobic environment.  The peak in front of UDP-Gal was UMP, the 
hydrolysis product of UDP-Gal. Retention and separation of Rgal, UDP-Gal and UDP were 
satisfactory and the retention time of the product of the LgtC catalysed reaction was unknown 
at this stage. The retention time of the product was expected to be between Rgal and UDP-Gal 
based on the hydrophilicity. Therefore, the gradient was extended from 15 to 20 minutes 
(Figure 3.15, C) and as a result UMP, UDP-Gal and UDP retained later, at 18.2, 18.7 and 19.2 


















































Figure 3.15. Separation of the mixture of Rgal, UDP and UDP-Gal (50 µg/mL each). Overlay of HPLC runs 
in A) gradient 0-100 % of 10 mM NH4Ac:ACN (50:50) over 15 minutes against buffer A (10 mM 
NH4Ac:ACN (5:95)) B) gradient 0-100 % of 10 mM NH4Ac:ACN (70:30) over 15 minutes against buffer A 
and C) the same as trace B but gradient over 20 minutes. Detection wavelength 265 nm 
 
It has been shown that sample diluent has a significant influence on peak shape. Ruta and co-
workers studied peak shape in various sample diluents systematically with HILIC mode and 
they recommended to dilute samples in the lowest aqueous content possible to maintain 
suitable peak shape.204 The peak shape of UDP was tailing and Rgal was slightly split, thus 
various water contents in the sample diluents were studied to improve the peak shape. 
Mixtures of Rgal, UDP and UDP-Gal were prepared in 10 %, 20 % and 30 % water in ACN.  
 
The most symmetrical Rgal peak shape was obtained at 10 % of water and peak symmetry was 
lost with increasing water content (Figure 3.16 A) resulting in a split peak at 30 % water. Rgal 
retained at approximately 20 % of aqueous content in the mobile phase. The poor peak shape 
was possibly affected by the difference in the solvent strength between the mobile phase and 
the sample solvent. The opposite was observed with UDP-Gal and UDP (Figure 3.16 B). The 
response increased with increasing water content but remained the same at 20 % and 30 %. 
The recommendation of Ruta’s research “the lowest water content in dissolution solvent 
maintain suitable peak shapes“ 204  was not suitable for the analysis of strongly polar UDP-Gal 
and UDP. The possible explanation is the difference between the low water proportion in the 



























retention time of UDP-Gal and UDP. The aqueous layer of the stationary phase may be 
disturbed by the water content in the dissolution solvent which have ability to form hydrogen 
bonds and ionic UDP may be affected. Subsequent experiments were decided to be performed 
at 20% water because the response and the peak shapes of all analytes were agreeable.     
 
 
Figure 3.16. Influence of various water content in the sample solvent, 10 %, 20 % and 30 % of water in 
green, red and blue traces, respectively. A) with Rgal, detected at 470 nm and B) with UMP, UDP-Gal 
and UDP (respectively, in elution order) were detected at 265 nm  
 
In order to identify the unknown product of the LgtC catalysed reaction when Rgal was used 
as an acceptor from the HPLC trace, a test of the precision of peak retention of Rgal, UMP, 
UDP-Gal and UDP was performed. In addition, resolution between UMP and UDP-Gal, and 
between UDP-Gal and UDP were investigated. Six replicate injections from homogenic 
sample with fixed HPLC conditions were performed.  
 
Table 3.7. Reproducibility of retention time (RT) and resolution (R) for Rgal, UMP, UDP-Gal and UDP 
(50 µg/mL each), (n=6). Experiment performed with HPLC gradient: 0-100 % of buffer B (10 mM 
NH4Ac:ACN (70:30)) over 20 minutes against buffer A (10 mM NH4Ac:ACN (5:95)) 













Average 6.20 16.71 17.42 17.86 2.34 2.40 
RSD% 1.88 2.99 0.29 0.26 0.99 2.04 
 
 
The reproducibility of retention time was satisfactory for UDP-Gal and UDP (Table 3.7), 
however, the precision was not as repeatable for Rgal and UMP. The resolution between 






















































3.3.5 Optimisation of LgtC catalysed reaction conditions for LC-MS 
 
The HPLC method with the amide modified silica HILIC column was developed for the analysis 
of Rgal, UDP-Gal and UDP. The unknown product of the LgtC catalysed reaction when Rgal 
was used as an acceptor, was eluted between UDP and Rgal with the IPC method (Figure 3.8). 
Based on the polarity of the product, it was assumed that the retention time would be 
between Rgal and UMP with the HILIC method. Before coupling the HPLC method with the 
LC-MS instrument it was essential to determine the retention time of the product and 
optimise the reaction conditions to ensure that an appropriate amount of the product was 
formed.  
 
The reaction conditions were directly adapted from the glycosidase coupled assay (Chapter 
3.3.3) and the reaction products were separated and analysed with the amide HILIC method. 
The total volume of the reaction was 200 µL and the reaction was stopped by adding 800 µL 
ACN, thus, the aqueous proportion of the sample was 20 %. The control was prepared in the 
absence of donor (UDP-Gal) and treated as the normal reaction mixture. 
 
 
Figure 3.17. HPLC chromatogram of LgtC catalysed reaction, Rgal as an acceptor. A new peak appeared 
at 13 minutes (blue trace), blank and control traces in green and red, respectively. Compounds 































Rgal peak was decreased in the reaction compared with the control (no UDP-Gal) and a new 
peak retained at 13 minutes (Figure 3.17). Based on the retention time, the new peak is likely 
to be the glycosylated Rgal as the expected product is more hydrophilic than Rgal. The 
hydrolysis product of UDP-Gal, UMP was formed during the reaction and the UMP peak was 
observed before UDP-Gal. The baseline was noisy from 13.3 to 14.5 minutes, however, the 
irregularity was caused by the gradient because the same was observed in the blank. 
However, the retention time does not reveal how many galactose moieties are transferred 
and the product peak required identification. Therefore, these HPLC and reaction conditions 
were adapted to the LC-MS system. 
 
3.3.6 Analysis of the reaction product by LC-ESI-MS/MS 
 
The developed HILIC method was directly suitable for ESI because the volatile mobile phase 
and a low flow rate were used. The amide modified silica HILIC column was installed to HPLC-
ESI-MS/MS instrument which can perform two stage mass analysis to examine selectively the 
fragmentation of particular ions from the mixture.205 The LC-MS ionisation conditions were 
optimised prior to the analysis of the reaction product of the LgtC catalysed reaction.  
 
Fraction patterns of the standard solutions of UMP, UDP, UDP-Gal and Rgal were examined 
and the optimum product ion was chosen for each analytes to give the strongest signal by 
varying the collision energy (CEn). UMP, UDP and UDP-Gal were ionised with the negative 
mode and Rgal with the positive mode. UMP was determined by detecting the cleavage of 
the nucleotide base, UDP detected by the cleavage of single phosphate group, UDP-Gal 
detected by the cleavage of sugar phosphate and Rgal by the sugar cleavage (Table 3.8). 
Standards were not available for the expected glycosylated product, however the product 
was assumed to be ionised in positive ionisation mode, the same as for Rgal. 
 
Table 3.8. Optimised LC-ESI-MS/MS parameters, fraction patterns, molecular weight (Mw), collision 
energy (CEn) and retention times (RT) of the standard solution of the analytes 




Rgal 375.3 375.8 214.1 Pos 25 4.26 
UMP 324.2 323.3 211.1 Neg 28 12.27 
UDP-Gal 566.3 565.2 323.0 Neg 25 12.61 




LC-MS run of the standards did not show clear peaks on the total-ion spectrum because MS 
detection was not optimised. However, MS/MS analysis of the standards illustrated clearly 
visible peaks (Figure 3.18). The retention order of the standards was the same as with the 
standard HPLC time, however, the retention times were reduced which was possibly caused 
by the different LC instrument used (pump, tubing etc.). 
 
 
Figure 3.18. LC-ESI-MS/MS analysis of the standards of UMP, UDP, UDP-Gal and Rgal. The m/z 
fragmentation of the analysed peaks presented on next to the peak for each standard 
 
The aim was then to identify the molecular weight of the product of the LgtC catalysed 
reaction with LC-MS/MS. All the substances of the reaction were separated with the 
previously described method (Chapter 3.3.5). The retention time of the unknown product 
was assumed to be between Rgal and UMP. Based on the similar physical properties of the 
expected unknown product (Rgal-gal) and the acceptor Rgal, the ionisation was assumed to 
occur in positive mode. The product peak was identified by entering the molecular weight of 
the expected product manually. 
 
Initially it was investigated if the unknown product may be Rgal-gal. Based on a molecular 
weight of Rgal-gal, a peak eluted at 8.1 min (Table 3.9 and Figure 3.19) which was ionised 
with the positive mode. The observed m/z of 538.3 was assumed to be the parent ion and a 
corresponding product ion was formed by cleavage of digalactose, m/z of 215.2. The 
experiment was repeated and by comparing m/z with the controls: UDP-Gal and Rgal in the 
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absence of LgtC and UDP-Gal or Rgal in the presence of LgtC. The results confirmed that the 
observed peak at 8.1 minutes was not an artifact because the m/z was not found in the 
controls. However, because the expected product was Rgal-gal, the results did not explain 
the high consumption of UDP-Gal in the reaction. It was suggested that Rgal-gal could serve 
as an acceptor for LgtC and form multiple products by elongating the galactose chain. Thus, 
all possible glycosylated products up to four transferred galactose to Rgal with corresponding 
masses were examined with LC-MS/MS. One new peak at lower intensity was retained at 
10.2 minutes, and the parent and the product ions, 700.0 and 214.8, respectively, suggested 
that the peak is Rgal-gal-gal (Table 3.9 and Figure 3.19).  
 
 
Figure 3.19. Glycosylated products of LgtC catalysed reaction: Rgal-gal (8.5 minutes) and Rgal-gal-gal 
(10.2 minutes), and the corresponding masses below, respectively 
 
The LC-ESI-MS/MS results suggested that two products were formed in the LgtC catalysed 
reaction when Rgal was used as an acceptor. The mass of the products corresponded to Rgal-
gal and Rgal-gal-gal. In addition, the products retained with increasing hydrophilicity order 
which confirms the observed results and Rgal-gal-gal was detected with a lower intensity 
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than Rgal-gal-gal. The MS/MS is more sensitive than the UV-detection, and thus only one 
product peak was observed during HPLC analysis.  
 
Table 3.9. Identified products of the glycosylated product of the LgtC catalysed reaction when Rgal 
was used as an acceptor  
Compound Mw Parent ion Product ion Mode RT 
Rgal-gal 537.5 538.3 215.2 Pos 8.1 
Rgal-gal-gal 699.6 700.0 214.8 Pos 10.2 
 
 
The observed results suggested that LgtC utilises both, Rgal and Rgal-gal as acceptors and 
two galactosylated products were detected by LC-MS/MS. Antoine and co-workers found 
multiple side products during the enzymatic synthesis of globotetraose (GalNAc-β1,3-Gal-
α1,4-Gal-β1,4-Glc).206 The findings suggested that LgtC used globotriose (Gal-α1,4-Gal-β1,4-
Glc) as an acceptor after complete exhaustion of lactose resulting in polygalactosylated 
compounds. Tetra, penta and hexa-hexose derivatives of globotetraose were identified.206 
The glycosidase coupled assay was performed in the absence of lactose, therefore, Antoine’s 
results suggested that Rgal-gal could serve as an acceptor for LgtC. Multiple 
polygalactosylated products were possibly formed causing a rapid exhaustion of UDP-Gal, 
therefore, the reaction completion was not observed with the glycosidase coupled assay or 
HPLC-based assay when Rgal served as an acceptor. In addition, during the optimising the 
LgtC reaction conditions for the LC-MS experiments, UMP, the hydrolysis product of UDP-Gal 
was formed in the assay conditions (Figure 3.17). The glycosidase coupled assay based on the 
detection of the non-glycosylated acceptor and in the assay format, there was no method for 
detecting the hydrolysis of the donor substrate, UDP-Gal, which could have subtracted from 
the fluorescence signal. Therefore, the hydrolysis of UDP-Gal which has an impact on the 
depletion of UDP-Gal is impossible to quantify. Due to these difficulties, the development of 








3.4 Phosphatase coupled biochemical assay 
 
After the complexities encountered in the development of glycosidase coupled assay, an 
alternative biochemical assay was still required for the investigation of potential GT 
inhibitors. During the course of this project, a novel phosphatase coupled assay was 
described and this assay was optimised in house with β1,4-GalT and LgtC. 
 
3.4.1 Principle of the assay 
 
Wu and co-workers developed an universal phosphatase coupled assay (PCA) that was 
applied to several GTs including β1,4-GalT.85 The assay is based on specific phosphatase that 
releases an inorganic phosphate from the leaving groups of GT reactions and the released 
phosphate group is quantitatively detected by colorimetric malachite reagents (Scheme 3.5). 
Malachite green is a widely used colorimetric reagent that allows detection of inorganic 
phosphate due to the formation of a phosphomolybdate malachite green complex with 






Scheme 3.5. Phosphatase coupled GT assay can be applied to any GT reaction where the leaving group 




In this discontinuous assay, the enzymatic reactions are stopped after desired time by adding 
highly acidic malachite reagents which denature the protein. The PCA is suitable for Leloir 
GTs that generate nucleotides as the leaving groups such as UDP,5 therefore, the assay is 
adaptable for LgtC. The assay is an alternative choice for compound characterisation after 
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HPLC because the PCA protocol is rapid, simple to perform and the assay can be performed 
on 96 well microplate that allows determination of multiple compounds simultaneously.  
 
The PCA optimisation with β1,4-GalT was performed by Dr Evitt (the assay optimisation is 
described in appendix 1). Dr Evitt discovered an optimal phosphatase that hydrolysed 
inorganic phosphate specifically from UDP, and a carrier protein that improved 
reproducibility of the assay performance. The phosphatase coupled assay was suitable for 
detecting the secondary product (UDP) of LgtC catalysed reaction and no suitable assay 
existed to study activities of LgtC.  Therefore, the aim was to apply the improved PCA to LgtC 
for the first time. The following parameters were investigated to make the PCA suitable for 
the investigation of enzymatic kinetic parameters and for inhibitor characterisation with 
LgtC: 
 The acceptor needed to be changed 
 Influence of protein carrier and Mn2+ 
 Influence of DMSO,  Mn2+ and TX-100 on enzymatic kinetic parameters 
 
3.4.2 Optimising the assay conditions with LgtC 
 
The original phosphate assay was performed in the absence of a carrier protein.85 During the 
assay optimisation a carrier protein (hen egg-cell lysozyme, CEL) was discovered which 
significantly improved the assay performance with β1,4-GalT (appendix 1). The assay 
optimisation with LgtC was initiated by an experiment with increasing concentrations of LgtC 
in the presence and in the absence of the carried protein to study if LgtC was dependent on 
the carrier protein. In addition, the acceptor of β1,4-GalT, GlcNAc, was changed to lactose at 
the same concentration that was used in the HPLC-based method.  
 
The results indicated that the activity of LgtC improved significantly in the presence of CEL 
(Figure 3.20). The observed results indicated that the carrier protein possibly protected LgtC 
from attaching to plastic surfaces of the microplate and the pipette tips. Therefore, 






Figure 3.20. LgtC catalysed reaction in the presence and in the absence of CEL 
 
The background hydrolysis of UDP-Gal and ~7 % impurity was found during the PCA 
development was subtracted from the main signal in the assay set up with β1,4-GalT 
(appendix 1). The background control included UDP-Gal and β1,4-GalT in desired 
concentrations in the absence of acceptor. However, lactose, the acceptor of LgtC contained 
inorganic phosphate as an impurity and the background control was unsuitable to perform in 
the absence of the acceptor because the signal of the control decreased significantly. 
Therefore, whether the background control could be performed in the absence of LgtC the 
hydrolysis of UDP-Gal was investigated in the presence and in the absence of LgtC (Figure 
3.21).  
 
The results indicated that hydrolysis of UDP-Gal remained the same in the absence and in the 
presence of LgtC during the incubation time of 20 minutes. Because LgtC was incapable of 
hydrolysing UDP-Gal the background hydrolysis was performed in the absence of LgtC 
instead. The results also indicated that DTT in LgtC solution did not prevent the colour 
development at this concentration range because the absorbance signal obtained was similar 



























Figure 3.21. UDP-Gal hydrolysis in the presence and in the absence of LgtC at 20 nM and 50 nM 
 
The influence of manganese concentration on the background hydrolysis and activity of LgtC 
was investigated. All assay parameters were fixed, except manganese concentration. As 
demonstrated in the Figure 3.22, the background hydrolysis was independent of manganese 
concentration and activity of LgtC was dependent on manganese concentration.  The 
maximum activity of LgtC increased significantly in the presence of MnCl2 and maximum 
activity was observed at 5 mM of MnCl2. Moreover, the results showed LgtC is still active 




Figure 3.22. Formation of phosphate with increasing MnCl2 concentration and at fixed concentrations 











































The PCA was designed for use in the inhibitor characterisation experiments. Many small 
molecular compounds are prone to inhibit enzymatic activity by sequestering proteins which 
can cause false positive results. Therefore, influence of TX-100, which has been proved to 
prevent compound aggregation,209 was investigated with the PCA. The colour development 
of malachite reagents was examined at various UDP and TX-100 concentrations (Figure 3.23). 
The results illustrated that TX-100 did not affect the colour development in the measured 




Figure 3.23. Colour development of the malachite reagents at fixed phosphatase concentration and in 
various TX-100 and UDP concentrations  
 
In addition, influence of TX-100, DMSO and without addition of MnCl2 to the enzyme kinetic 
parameters such as Km, Vmax and Kcat were investigated. The concentration of LgtC was 
selected where the UDP-Gal conversion to the product was 10 % or less. In the standard 
assay conditions Km was 11.8 µM, that is comparable with the literature value, 18 µM.
16 The 
effect of DMSO to Km value was determined at 10 % (v/v) and the Km value decreased from 
11.8 µM to 3.5 µM indicating that DMSO activates LgtC. This effect may due to favourable 
conformation changes on the donor binding site in the presence of DMSO.210 The Km value 
remained the same in the absence and in the presence of 0.01 % (v/v) TX-100. Additionally, 
Km was in the absence of MnCl2 addition to evaluate if the PCA could be performed with 
similar conditions than the LDA (chapter 2). The result demonstrated that it was possible to 





























higher LgtC concentration was required to obtain the optimum turnover which increased the 
Km value. 
 
Table 3.10. Enzyme kinetic values of UDP-Gal in various assay conditions (n=3) 
Conditions Km (µM) Vmax (µM/min) Kcat (s
-1) 
Standarda 11.8 ± 2.7 0.43 ± 0.03 0.36 ± 0.02 
+ DMSO 3.5 ± 1.9 0.38 ± 0.05 0.32 ± 0.05 
+ DMSO, No Mn2+ 27.4 ± 4.1 0.34 ± 0.01 0.11 ± 0.01 
+DMSO +TX-100 3.5 ± 1.7 0.45 ± 0.04 0.30 ± 0.11 
a
Standard assay conditions, reaction mixture in 13 mM HEPES, pH 7.0: Lactose (2 mM), phosphatase 
(10 U/mL), CEL (1.0 mg/mL), MnCl2 (5.0 mM), UDP-Gal (0.79-200 µM) and desired LgtC concentration. 
DMSO concentration 10 % (v/v) and TX-100 concentration 0.01 % (v/v) 
 
The optimisation experiments demonstrated that the PCA can be used for the 
characterisation of LgtC activities with similar conditions to those with β1,4-GalT. The PCA is 
simple to perform and due to the tolerance for DMSO and TX-100, it is suitable for 
compounds characterisation against LgtC. The PCA can be performed with the similar assay 
conditions to the LDA, including the same DMSO, TX-100 and MnCl2 concentrations. An 
advantage of the PCA is the simple and rapid assay protocol. In addition, the background 
hydrolysis of UDP-Gal can be determined, and this is advantageous. However, a minor 
disadvantage of the assay is that the microplate holds many controls. In addition to 
background hydrolysis controls and phosphatase controls, the wells on the outer edge are 
left empty because the reaction velocity was lower, possibly due to different temperature.  
 
3.5 Summary and conclusions 
 
Three different assays have been investigated for the development of a biochemical assay for 
LgtC. After investigating the HPLC-based method and the novel glycosidase couple assay, the 
phosphatase couple assay was the option with the most potential to study activities of LgtC.    
 
The HPLC-based method was successfully developed for the separation of UMP, UDP-Gal and 
UDP in a single chromatographic run with total analysis time of 22 minutes. The system 
suitability tests demonstrated a satisfactory system performance. The disadvantages 
appeared when the HPLC method was applied to monitor the LgtC catalysed reaction.  The 
enzymatic reactions were stopped by placing the samples in dry ice and the most time 
consuming step was the sample thawing before each HPLC injection. The kinetic parameters, 
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such as Km, require numerous data points, therefore, the step must be performed multiple 
times which leads to a long analysis time. Stopping the enzymatic reaction chemically in 
order to achieve more automated assay protocol was investigated. The reaction stopping 
study was carried out with ethylenediaminetetraacetic acid (EDTA) and with HCl to inactivate 
LgtC by chelating available Mn2+ or by denaturation, respectively. In both cases LgtC 
remained active. Another option for stopping the enzymatic reactions is by diluting the 
samples, however, this manner would further increase LOQ. The LOQ could be decreased by 
increasing the injection volume, however, this could have a negative impact on the peak 
shape. Therefore, the reactions were stopped by freezing. 
 
The advantage of the HPLC-based method is that the enzymatic reactions can be monitored 
without additional derivations and the hydrolysis of UDP-Gal can be monitored 
simultaneously with the donor substrate and the reaction product. The usefulness of the 
HPLC-based method was proved during the development of the novel glycosidase coupled 
assay. The HPLC-based method provided useful information about the consumption of UDP-
Gal, whereas the glycosidase coupled assay detected only the amount of unreacted acceptor.  
 
The goal to develop a novel GT assay based on an unnatural fluorescent acceptor and 
coupling of the GT reaction to a glycosidase reaction was not achieved. During the assay 
development, unforeseen enzymological features of LgtC were discovered. LC-MS/MS was 
utilised for the investigations of unknown products and the results suggested that LgtC 
transfers one and two galactose moieties to the unnatural acceptor forming Rgal-gal and 
Rgal-gal-gal. Antoine and co-workers discovered similar behaviour with LgtC during the 
enzymatic synthesis of globotetraose.206 They observed polygalactosylated compounds which 
suggested that globotriose serves as an acceptor of LgtC after complete exhaustion of 
lactose. Previous studies had also shown that D-galactose serves as an acceptor with much 
lower efficiency compared to lactose.174 The glycosidase coupled assay was performed in the 
absence of lactose which suggests that α-linked galactose could serve as an acceptor for LgtC 
in the assay conditions. Additionally, resorufin-β-galactopyranoside (Rgal) is probably a less 
efficient acceptor than galactosylated product, therefore, Rgal remains unreacted. These 
results suggested that the assay design for LgtC is essentially performed in the presence of 
excess lactose that prevents the α1,4-linked galactose serving as an acceptor. To date, 
polygalactosylation has not been investigated systematically with LgtC. However, during the 
development of the glycosidase coupled assay, an assay based on the same principle was 
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reported. LgtC activities were examined by using an unnatural fluorescent acceptor,  4-
nitrophenyl-β-D-galactopyranoside.211  Questionably, a high Km value of UDP-Gal (5.85 mM at 
25 µM of acceptor and 5-100 µM of UDP-Gal) was reported which suggests that 
galactosylated 4-nitrophenyl-β-D-galactopyranoside may have served as an acceptor. 
However, the reaction products of LgtC were not further analysed in the report and it is 
unclear whether polygalactosylation was observed. 
 
Three HILIC columns were examined for the separation of UDP, UDP-Gal and Rgal.  
Satisfactory separation was obtained with the amide-bonded column which was then utilised 
for monitoring the LgtC catalysed reaction on the LC-MS experiments. The amide column is 
an alternative for IPC methods, the nucleotide sugars and nucleotides  were retained without 
ion-pair reagents and high buffer concentrations were not required. The IPC method was 
performed in high phosphate buffer concentration and, compared with the amide HILIC 
column, the separation of the nucleotide sugars can be performed in lower buffer 
concentration. This can increase the column lifetime, and additionally, possible buffer 
precipitation in the HPLC system can be minimised.  
 
The novel phosphatase coupled assay was developed by Wu and co-workers85 and after the 
assay was optimised with β1,4-GalT in house, it was applied to LgtC. The reaction monitoring 
based on a phosphatase that releases inorganic phosphate from UDP during GT reaction and 
the generated phosphate group is detected by phosphate detecting reagents. The assay 
conditions such as CIP, CEL, MnCl2, DMSO concentrations, incubation time and incubation 
temperature, remained the same with LgtC as used with β1,4-Gal. The enzyme kinetic studies 
of LgtC were carried out on multiwell microplates and the results demonstrated that the PCA 
was robust and sensitive technique. Additionally, the assay protocol is simple to perform and 
it is significantly less time-consuming than the HPLC-based method. For example, Km with 
LgtC can be performed with eight concentrations of UDP-Gal in triplicate samples in two 
hours, whereas, with the HPLC-based method, the same experiment would take 
approximately 22 hours.  
 
A disadvantage is that the PCA is a discontinuous assay, the reactions are stopped by adding 
malachite reagents. However, when the PCA is compared to another potential continuous 
assay, where UDP is coupled to NADH oxidation via pyruvate kinase and lactate 
dehydrogenase,84 less valuable materials are used. In addition, if the PCA is used for the 
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inhibitor characterisation, then the amount of false positive results is reduced due to fewer 
enzymes used and a longer detection wavelength (430 nm vs. 620 nm). The long detection 
wavelength is advantageous in inhibitor screening and characterisation as well as tolerance 
for DMSO and TX-100. Phosphate impurities and unspecific phosphatase inhibition can cause 
false positives in compound characterisation. However, the false positives can be avoided 
when the first screen is performed with another detection method (i.e. HPLC or LDA) or the 
assay is performed without coupling with to GT reaction. If the assay signal increases with 
increasing compound concentration then the compound likely contains inorganic phosphate 
and if the assay signal degreases with increasing compound concentration then the 
compound likely inhibits phosphatase or it is a real inhibitor. The feasibility of the 
phosphatase coupled assay for the HTS will be implemented in parallel with the ligand 




























The HPLC experiments were carried out using a Perkin Elmer series 200 HPLC system with a 
series 200 EP with DAD. The analytes were separated with Alltech Alltima C18 column (3 µm 
particle size, 15 cm x 4.6 mm) in combination with a guard column (3 μ particle size, 
7.5 × 4.6 mm, Alltech) and detected at 265 nm. The injection volume was 50 µL, the flow rate 
was 1.0 mL/min and the column oven was set to 30 °C. The data was acquired using Total 
Chrom Workstation version 6.2.0. All reagents used in this chapter are listed in App. 2. 
 
The mobile phase A (buffer A) was consisted of 100 mM potassium phosphate and 8 mM 
TBAHS. The pH was set to 6.5 by mixing 0.064 mol of acidic and 0.036 mol of basic potassium 
phosphate (KH2PO4 and K2HPO4, respectively). The buffer B was a mixture of 70 % of buffer A 
and 30 % of MeOH (v/v). The mobile phases were filtered with 0.2 µm nylon filter and 
degassed in the vacuum prior the use. 
 
The mixture of standard solutions of UMP, UDP and UDP-Gal at 25 µM each were prepared in 
water and used in the system suitability tests. The system suitability tests were performed 
with the gradient method (Table 3.11) and the Total Chrom Workstation performed the 
required calculations. The linearity of the method was performed by measuring the peak 
area of UDP and UDP-Gal at concentrations 1.0, 3.5, 10, 20, 25, 30, 50, 100 and 200 µM. 
 
Table 3.11. The gradient of the optimised HPLC method used in the system suitability and Km 
experiments 
Time (min) Buffer A (%) Buffer B (%) 
5 100 0 
15 100-50 0-50 
2 50 50 
1 50-100 50-0 
5 100 0 
 
 
The LgtC catalysed reactions were carried out in 1.5 mL eppendorf tubes, in 50 mM MOPS 
buffer (pH 7.1), including of MnCl2 (20 mM), BSA (1.0 mg/mL) and lactose (2.0 mM). UDP-Gal 
concentration varied depending on the experiment performed. LgtC was activated in 5.0 mM 
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DTT in MOPS buffer for 30 minutes at 37 °C, prior to use. The reactions were initiated by 
adding 0.63 nM of LgtC and incubated for 10 minutes at 37 °C. Total volume of the reaction 
was 100 µL. The reactions were stopped by placing the samples in dry ice and thawed prior 
to injection to the HPLC. The concentration of LgtC was chosen where the donor conversion 
to the product was 10 % or less by performing a calibration curve in various concentrations of 
LgtC. 
 
All the following experiments were performed as described above. 
 The influence of LgtC activation experiment was performed with activated and non-
activated LgtC at UDP-Gal concentration of 200 µM.  
 The reproducibility of the LgtC reaction was examined at fixed concentrations of all 
assay components at UDP-Gal concentration of 60 µM.  
 The Km experiment was performed at UDP-Gal concentrations of 1.6, 3.1, 6.3, 12.5, 
25, 50, 100 µM. Controls were included at each UDP-Gal concentration in the 
absence of acceptor. UDP calibration curve at 1.0, 3.5 and 10 µM was included to 
each experiment. The Km values were calculated by plotting the initial velocity over 
the range of UDP-Gal concentrations to GraFit 7.0.3. 
 
3.6.2 Glycosidase coupled assay 
 
A BMG Labtech PolarStar microplate reader with a fluorescence intensity detection mode 
was utilised for the development of the fluorescence based coupled assay. The experiments 
were carried out in black NUNC F96 MicroWell polystyrene plates. The fluorescence intensity 
was measured at 590 nm with excitation at 544 nm (resorufin λex 573 and λem 590) and the 
flashes per well was set to 10.The gain was performed on the well with the highest 
concentration of resorufin (hydrolysed by β-galactosidase) on the linearity experiments and 
on the LgtC, and galactosidase coupled experiments, on the negative control well (no UDP-
Gal, high fluorescence). The gain was set to 85 % on each experiment. All reagent used in this 






The HPLC experiments were carried out with the HP Agilent 1050 series HPLC with DAD and 
the data analysis was performed with ChemStation software. Alltech Alltima C18 column 
(3 µm particle size, 15 cm x 4.6 mm) in combination with a guard column (3 μ particle size, 
7.5 × 4.6 mm, Alltech) was used for the separation of the components of the LgtC catalysed 
reaction when Rgal was utilised as an acceptor.  
 
Resorufin and Rgal stock solutions (50 mM) were prepared in DMSO. In this experimental 
chapter all dilutions and reactions were carried out in 50 mM HEPES pH 7.3 buffer, including 
1.0 mM MnCl2 and 1.0 mM MgCl2, the total volume of the reactions was 200 µL and 
incubations were performed at 37 °C unless otherwise stated. In addition, the assay buffer 
was added to the controls instead of LgtC or UDP-Gal to keep the final volume at 200 µL. 
 
3.6.2.1 Optimising the β-galactosidase concentration, calibration curve and 
stability of resorufin   
 
The optimal β-galactosidase concentration was investigated at 20 µM of Rgal and β-
galactosidase concentration from 0.01 U/mL to 8.2 U/mL (6 data points). The linearity of 
fluorescence of resorufin was investigated by hydrolysing Rgal. Concentrations of Rgal 50 µM 
were diluted by half, down to 0.8 µM (7 data points) and hydrolysed by 0.5 U/mL of β-
galactosidase. The fluorescence intensity reading was taken after 10 minutes incubation and 
was utilised plotting the calibration curve. The stability of resorufin was investigated on the 
range from 0.8 to 50 µM (8 data points) by using standard resorufin solutions. Stability of 
resorufin was monitored for 60 minutes. 
 
3.6.2.2 Coupling LgtC and β-galactosidase reactions 
 
The investigations of whether Rgal was performing as an acceptor for LgtC, were carried out 
in the same HPLC setting and LgtC reaction conditions as those used as in chapter 3.6.1. 
Except Rgal was used as an acceptor at 100 µM and UDP-Gal concentration was 60 µM. The 





The investigations of the negative and positive controls on the fluorescence-based 
glycosidase coupled assay were performed at fixed concentrations of LgtC, β-galactosidase, 
UDP-Gal and Rgal at 0.1 U/mL, 0.5 U/mL, 50 µM and 6.3 µM, respectively. The influence of 
DTT was investigated by comparing negative controls that were performed with activated 
and non-activated LgtC. The negative control was carried out without LgtC or UDP-Gal and 
the positive control in the absence of β-galactosidase. LgtC initiated the reaction and the 
reaction mixture was incubated for 30 minutes and stopped by adding β-galactosidase. The 
gain was performed on the control well that contained Rgal and β-galactosidase (high 
fluorescence signal). Fluorescence intensity reading was monitored for 10 minutes after 
adding β-galactosidase. 
 
The investigation of the progress of LgtC catalysed reaction on the glycosidase coupled assay 
was carried out at fixed concentrations of LgtC, Rgal and β-galactosidase at 0.1 U/mL, 6.3 µM 
and 0.5 U/mL, respectively. The UDP-Gal concentration was 5.0, 100 or 500 µM. The negative 
control was carried out without UDP-Gal and the positive control in the absence of β-
galactosidase. The reactions were initiated by adding LgtC and stopped after 30, 45 or 60 
minutes incubation by adding β-galactosidase. The fluorescence intensity reading was taken 
after 10 minutes incubation. 
 
HPLC method for the analysis of the reaction progress of LgtC catalysed reaction when Rgal 
was used as an acceptor was modified from the previously developed method (Chapter 3.6.1) 
by increasing the content of MeOH (Table 3.12). The reaction progress was monitored in 
various incubation times by this modified HPLC method. The LgtC catalysed reactions were 
carried out in 50 mM HEPES buffer, including 1.0 mM of MnCl2 at pH 7.1 and the 
concentration of UDP-Gal and Rgal was 200 µM. The reactions were initiated by adding 0.02 
U/mL of activated LgtC (buffer for control) and stopped by placing the samples in dry ice after 
30, 45 and 60 minutes incubations at 37 °C.  
 
Table 3.12. Optimised HPLC gradient for the separation of UDP-Gal, UDP, Rgal and unknown product 
form LgtC catalysed reaction 
Time (min) Buffer A (%) Buffer B (%) MeOH (%) 
2 98 2 0 
5 98-60 2-40 0 
1 60-75 40-0 0-25 
12 75 0 25 
1 75-98 0-2 25-0 
5 98 2 0 
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3.6.2.3 LCMS method development 
 
The method development for the separation of UDP, UDP-Gal, Rgal and the product of the 
LgtC catalysed reaction was performed with HP Agilent 1050 series HPLC with DAD and the 
data analysis was performed with ChemStation software. UDP and UDP-Gal were detected at 
265 nm, and Rgal and the unknown product at 265 nm and 470 nm. The analytes were 
diluted in water:ACN (20:80) unless otherwise stated. Based on the requirement of the ESI in 
order to achieve optimal ionisation, the flow rate was set to 0.2 mL/min and ammonium 
acetate (NH4Ac) was used as an additive. Additionally, the concentration of the additive was 
kept the same during the chromatographic run and the polarity of the mobile phase was 
varied.  
 
Mobile phases were prepared by making NH4Ac stock solution (100 mM) in ultrapure water 
at desired pH and diluted to the desired concentration with ultra-pure water and/or ACN. 
The mobile phases were filtered with 0.2 µm nylon filter and degassed in the vacuum prior 
the use. 
 
Waters Atlantis HILIC silica column (3 μm particle size, 50 x 2.1 mm) was used for the analysis 
of mixture of UDP-Gal, UDP and Rgal (100 µg/µL each). 20 µL of the mixture was injected and 
the separation was started with isocratic run with 100 % of ACN:5 mM NH4Ac (95:5) at pH 
5.0. The column temperature was set to 30 °C.  
 
Polymeric-based SeQuant ZIC-pHILIC column (5μm particle size, 150 x 2.1mm) was used for 
the analysis of mixture of UDP-Gal, UDP and Rgal (50 µg/mL each). 5 µL of the mixture was 
injected and the column temperature was set to 30 °C. Two mobile phases were used: buffer 
A consisted of ACN: 10mM NH4Ac (pH 4) (95:5) and buffer B consisted of ACN: 10mM NH4Ac 
(pH 4) (50:50) (v/v) and the separation was started with increasing content of buffer B. 
Various gradients at higher column temperature (at 60 °C) were examined to improve the 








Table 3.13. Gradients examined with the ZIC-pHILIC column at 60 °C  
Gradient Time (min) Buffer A (%) Buffer B (%) 
1 10 100 0 
 1 100-27 0-75 
 14 25 75 
 1 25-100 75-0 
 10 100 0 
2 10 100-50 0-50 
 1 50-30 50-70 
 14 30 70 
 1 30-100 70-0 
 10 100 0 
3 5 50 50 
 3 50-35 50-65 
 18 35 65 
 1 35-50 65-50 
 10 50 50 
4 and 5a 5 100 0 
 5 100-25 0-75 
 15 25 75 
 1 25-100 75-0 
 10 100 0 
a30 °C 
 
Waters ACQUITY BEH Amide column (particle size 1.7µm, 150 x 2.1 mm) was used for the 
separation of mixture of UDP, UDP-Gal and Rgal (50 µg/mL). Injection volume was 5 µL. The 
separation was investigated with various gradients with increasing water content (Table 
3.14). Two mobile phases were used: buffer A consisted of ACN:10mM NH4Ac (pH 9) (95:5) 
and buffer B consisted of ACN:10mM NH4Ac (pH 9) (50:50) or (30:70) (v/v). The gradient a3 
was used for the investigation of the peak shape in 10 %, 20 % and 30 % water in ACN, and 
on the reproducibility studies where the injection of mixture of UMP, UDP, UDP-Gal and Rgal 












Table 3.14. Gradients examined with the amide column at 30 °C 
Gradient Time (min) Buffer A (%) Buffer B (%) 
a1a 15 100-0 0-100 
 2 0 100 
 1 0-100 100-0 
10 100 0 
a2b 15 100-0 0-100 
 2 0 100 
 1 0-100 100-0 
 10 100 0 
a3b 20 100-0 0-100 
 2 0 100 
1 0-100 100-0 
10 100 0 
a
Buffer B as ACN: 10mM NH4Ac (50:50), 
b
 Buffer B as ACN: 10mM NH4Ac (30:70) 
 
Adaptation of the LgtC catalysed reaction to the amide HPLC method was carried out with 
the gradient a3 (Table 3.14). The reactions were carried out in 1.5 mL eppendorf tubes in 50 
mM HEPES buffer, including 1.0 mM of MnCl2 at pH 7.1 and the concentration of UDP-Gal 
and Rgal was 200 µM. The reactions were initiated by adding 0.02 U/mL of activated LgtC and 
after 30 minutes incubation a 37 °C reactions were stopped by adding 800 µL ACN (total final 
volume 1.0 mL).  
 
LC-ESI-MS/MS analysis was performed on a Thermo Scientific Accela LC system coupled to a 
Thermo TSQ Quantum Access MS/MS with an ESI source. Data acquisition was achieved using 
Thermo Finnigan Xcalibur software, version 4.1. Fraction patterns of the standard solutions 
of UMP, UDP, UDP-Gal and Rgal (10 µg/mL in mobile phase B, ACN: 10mM NH4Ac (30:70)) 
were performed prior to the analysis of the product of the LgtC catalysed reaction. The 











3.6.3 Phosphatase coupled assay 
 
A multi-mode BMG Labtech PolarStar microplate reader with absorbance detection mode 
was utilised for the assay optimisation. The phosphatase coupled assay experiments were 
carried out in clear NUNC F96 MicroWell polystyrene microplates and absorbance was 
recorded at 620 nm. The Km values were calculated by the initial velocity over the range of 
UDP-Gal concentrations to GraFit 7.0.3. All reagents used in this chapter are listed in App. 2. 
 
All glassware used in the reagent preparation was washed with 1 M H2SO4 to ensure removal 
of phosphate and rinsed with ultrapure water. The malachite reagent A was prepared by 
diluting 6.3 N of sulphuric acid into ultrapure water, after cooling, 1.75 % w/v of ammonium 
molybdate tetrahydrate was added and then filled up to the required volume. The malachite 
reagent B was prepared by adding 0.35 % (w/v) of polyvinyl alcohol (PVA) to ultrapure water 
and dissolved by microwave heating. After cooling, 0.035 % of malachite green oxalate was 
added and filled up to the desired volume. 
 
3.6.3.1 Optimisation with LgtC 
 
All the assay components of LgtC reactions were diluted in 13 mM HEPES (pH 7.0) buffer and 
the reactions were carried out in mixture containing MnCl2 (5.0 mM), CEL (1 mg/ml), CIP (10 
U/ml), lactose (2.0 mM). DMSO (10 %, v/v) and TX-100 (0.01 %, v/v), if required. The 
reactions were initiated by adding UDP-Gal or UDP to the calibration curve/phosphatase 
control (Table 3.15).The reactions were incubated for 20 minutes at 30 °C and stopped by 
adding malachite reagent A and mixed thoroughly, and then malachite reagent B was added 
and again mixed thoroughly. The colour development was monitored for 30 minutes and the 
final reading was taken when the colour development was levelled out, approximately after 
20 minutes. UDP calibration curve, which also served as a phosphatase control was carried 
out at 0, 0.78, 1.56, 3.13, 6.25 and 12.5 µM in all experiments. LgtC was activated with DTT 
prior to the experiments and the concentration of LgtC was selected where the UDP-Gal 






Table 3.15. Phosphatase coupled biochemical assay set up with LgtC 
Assay step Component [Stock] [reaction] Volume of stock, 
µL 
1 Lactose 10 mM 2 mM 30 
CIP  100 U/ mL 10 U/ mL 15 
MnCl2 50 mM 5.0 mM 15 
CEL 10 mg/ mL 1.0 mg/ mL 15 
 Buffer 5x 1x 15 
2 LgtC/ buffera 5x 1x 30 
3 UDP-Gal/ UDPb 5x 1x 30 
4 20 min incubation at 30 °C    
5 Malachite reagent A 5x 1x 30 
6 Malachite reagent B 5x 1x 30 
7 colour development monitored at 620 nm for 30 minutes 
a
buffer added to the background hydrolysis and UDP calibration/phosphatase control wells, 
b
UDP-Gal 
was added to all wells to initiate reaction and UDP was added to the UDP calibration/phosphatase 
control wells 
 
The first experiment with LgtC was performed as presented in Table 3.15, in the absence and 
in the presence of CEL. The turnover of UDP-Gal was carried out at 20 µM and various LgtC 
concentrations (0, 0.32, 32 and 320 µM). 
 
Enzymatic hydrolysis of UDP-Gal was performed in the absence of lactose at 0, 20 and 50 nM 
of activated LgtC and at 0, 3.13, 6.25, 12.5, 25, 50, 100 and 200 µM of UDP-Gal. 
 
The influence of MnCl2 concentration was investigated at 0, 1.0, 2.5, 5.0, 10, 16, 20 and 25 
mM of MnCl2. LgtC and UDP-Gal concentrations were fixed at 20 nM and 13 µM, respectively. 
 
The influence of TX-100 for the colour development was investigated by performing UDP 
calibration curve at 0, 0.001 and 0.01 % (v/v) of TX-100. UDP calibration curve was carried 
out at 0, 0.78, 1.56, 3.13, 6.25 and 12.5 µM. 
 
Km was determined in various assay conditions: standard conditions (Table 3.15), in the 
presence of DMSO, in the presence of DMSO without MnCl2 and in the presence of DMSO 
and TX-100. The experiments were carried out at 0, 3.13, 6.25, 12.5, 25, 50, 100 and 200 µM 
of UDP-Gal. The layout of the microplate of the ordinary Km experiment is presented in Figure 






 1 2 3 4 5 6 7 8-12 
A         
B  M M M+E M+G1+E M+G2+E M+G3+E → 
C  M+U1 M+U1 M+E M+G1+E M+G2+E M+G3+E → 
D  M+U2 M+U2 M+E M+G1+E M+G2+E M+G3+E → 
E  M+U3 M+U3 M M+G1 M+G2 M+G3 → 
F  M+U4 M+U4 M M+G1 M+G2 M+G3 → 
G  M+U5 M+U5 M M+G1 M+G2 M+G3 → 
H         
Figure 3.24. Layout of the micro plate in Km experiments. Columns 2-3: UDP calibration (phosphatase 
control), rows B-D from column 4: various UDP-Gal in the presence of LgtC, rows E-G from column 4: 
background at each UDP-Gal concentration in the absence of LgtC. Master mixture (M) contain 
lactose, MnCl2, CEL and CIP, UDP at concentrations of 0, 0.78, 1.56, 3.13, 6.25 and 12.5 µM (U1-U5), 























4 Compound library screening and compound characterisation 
4.1 Introduction 
 
High throughput screening (HTS) is a popular method in drug discovery that allows the 
screening of thousands of compounds against selected targets simultaneously. Compound 
libraries are collections of structurally diverse small compounds with undefined properties 
and biological activities212 or focused subset of compounds that have proven biological 
activity to certain molecular targets.213 Structurally diverse compound libraries have a broad 
range of biological activities and therefore, the possibility of discovering novel inhibitors is 
increased.214 Focused compound libraries are designed often based on a certain protein 
family and the structures of the compounds are generally built on combinations of one 
scaffold and two or three side chains.213 For example, Winans and co-workers synthesised 
over 1000 compounds based on the substrate of human UDP-GlcNAc 4-epimerase and from 




Scheme 4.1.  Schematic presentation of design of focused compound libraries. Uridine analogues (1-3) 
with alternative linkers mimic the structure of natural donor. Various functional groups (R) replace the 





Drug-likeness of the compounds is important in the early stage of the drug discovery process 
and a number of compound collections have been produced by focusing the small molecule 
synthesis to drug-like compounds.216, 217 The Lipinski rule of five is a general guideline to 
determine the drug-likeness and it evaluates solubility and cell permeability of the 
compounds to be an oral drug. Based on the Lipinski’s rule, the drug-likeness of the 
molecules increases if the molecular weight is less than 500 Daltons, LogP (describes 
lipophilicity) is less than 5 and the molecule contains hydrogen bond donors and acceptors 
less than 5 and 10 respectively.218 Recently, Bickerton and co-workers refined the Lipinski’s 
rule of five and they called it quantitative estimate of drug-likeness (QED). Addition to the 
Lipinski’s rule, QED included polar surface area of molecule, number of aromatic rings, 
rotatable bonds and groups causing toxicity.219 The lipophilicity of the drug candidate 
molecule is the most important factor as the influence on absorption, metabolism, 
distribution and toxicity.220  
 
Compound dependent assay interference can cause false positive and negative readouts in 
the HTS of small molecule libraries. Spectral properties of the small molecules can cause false 
results due to their fluorescence, quenching and inner filter absorbance effects.221 The 
compound libraries generally contain a greater number of heterogeneous compounds that 
are fluorescent in the blue-green range and therefore, the assays that detect the 
fluorescence intensity in this range, are more prone to false positives.222, 223 Compound’s 
interference with the target enzyme is difficult to identify if the interference is concentration 
dependent and reproducible.224, 225 Various small compounds are able to form 50-1000 nm 
particles (aggregates) that non-specially inactivate the target enzymes by sequestering the 
surface.149 The compound aggregation is dependent on the assay conditions, properties of 
the compound and the target enzyme.223, 226 However, the aggregation is reversible in the 
presence of a non-ionic surfactant such as TX-100.149 In addition, the false positives can be 
caused by presence of reactive compounds that form covalent bonds with the target 
enzyme,227, 228 redox cycling compounds such as strong reducing reagents (i.e. DTT) can 
reduce cysteine residues of the target enzyme and effect their activity and impurities can 
either interfere with the assay signal or with the target enzyme.221, 228-230   
 
Generally, the HTS process involves more than two screens to eliminate the false positives 
and characterise the active compounds.152 For example, Helm and co-workers performed two 
screens to eliminate false positives and a third assay was utilised in the hit characterisation. 
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Initially they screened nearly 50000 compounds against MurG, a GT that catalyses the 
transfer of GlcNAc from UDP-GlcNAc to Lipid I.89 The HTS assay based on the fluorescence 
polarisation change upon the displacement of the fluorescence substrate. The primary screen 
was performed in a single compound concentration and 0.6 % of the compounds reached 
positive hit criteria. From the hits, 44 compounds with different structure scaffolds were 
selected and further analysed in the secondary screen. The secondary screen was based on 
monitoring a radiolabeled product and therefore, the different detection method eliminated 
possible false positives. 11 of the 44 compounds met the positive hit criteria and one of the 
compounds was characterised by a fluorescence based NADH coupled assay.89 
 
In this chapter, two compound libraries were screened against LgtC by the ligand 
displacement assay (LDA) which was developed in chapter 2 and the hits were characterised 
by the phosphate coupled biochemical assay (PCA) which was optimised in chapter 3. LgtC 
has been found to be involved in the biosynthesis of meningococcal LOS43 which is a 
requirement for the survival of bacterial cells and increasing virulence of H. influenzae113 
makes LgtC a potential antibiotic target. A diverse compound library and a target-focused 
library with proven bioactivity against other carbohydrate active enzymes were screened in 
order to identify novel inhibitors and leads (compounds that have biological activity152). The 
leads could be further modified to improve their activity. The compound libraries are 
introduced in more details in chapters 4.2 and 4.3. 
 
4.1.1 Compound library screening protocol 
 
The aim was to use the LDA for a large compound library screening for the first time. Like 
many HTS assays, the LDA is based on a fluorescently labelled ligand (5FTUDP-Gal). The 
emission wavelengths of the fluorophore is short (430 nm) which increases interference with 
the screened compounds that emit with similar wavelength. The LDA was developed and 
optimised with non-fluorescent compounds such as UDP (chapter 2) and behaviour of 
screened compounds whether they quench or increase the fluorescence intensity of the 
fluorophore at desired wavelength was not investigated before. Therefore, a test experiment 
was performed before carrying out the compound library screening to evaluate the possible 
outcome from the actual screening. 
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Thiazolidinone compounds have been synthesised and characterised in house.102 They have 
been reported to inhibit carbohydrate active enzymes such as UDP-galactopyranose mutase 
and dolichophosphate mannose synthase.104, 231, 232 Pesnot and co-workers reported that one 
thiazolidinone bound to three GalTs (GTB, LgtC and α1,3-GalT) with similar affinity104 which 
may indicate that the interaction between studied thiazolidinone and protein may not be 
specific. In addition, a systematic study of five-membered multiheterocycles, including 
thiazolidinones, suggested that the exocyclic sulphur atom offers interaction sites for polar 
interactions and hydrogen bonds which make them prone to bind to a large number of 
protein targets.233  However, thiazolidinones were a good test case for the investigation of 
possible outcome of the coloured compounds from the library screening due to their 
aromatic systems and similar emission wavelengths as the fluorophore.102  
 
Table 4.1. Structures of examined thiazolidinones 
 
Compound R1 R2 R3 R4 
T1 - - - -O-CH3-Ph 
T2 -Ph - -O-CH3-Ph -O-CH3-Ph 
T3 -CH2-COOH -CH3 - - 
T4 -CH2-COOH - -O-CH3-Ph -O-CH3-Ph 
 
Four thiazolidinones with various functional groups were selected for the test experiment 
(Table 4.1). The interference of fluorescence of the test compounds was examined in the 
presence of the fluorophore and compared to the pure fluorophore fluorescence signal. The 
results illustrated that with increasing concentration of the test compounds, T1 and T2 
elevated and T3 and T4 quenched the fluorescence signal (Figure 4.1). At 100 µM of T1 the 
fluorescence signal of the fluorophore was significantly increased and significantly quenched 
at 100 µM of T3 and T4. The quenching can be caused by a high concentration of the 
compound and the light is unable to pass through the sample to cause absorption, or T3 and 
T4 may deactivate the excited fluorophore upon contact and heat is released instead of 
emitted photon (collisional quenching).87 UDP was utilised as a positive control at 5.0 mM 
and the results also demonstrated that UDP did not have an influence on the fluorescence 




Figure 4.1. Tested thiazolidinones at 20 µM and 100 µM in the presence of the fluorophore. The 
control is pure fluorophore and UDP at 5.0 mM in the presence of the fluorophore. Fluorescence 
intensity was measured at λex= 350 nm and λem= 430 nm which are relevant to the fluorophore, 
5FTUDP-Gal 
 
The quenching and the fluorescent properties of the tested compounds on the LDA had to be 
considered. Therefore, the ligand displacement was investigated with two compounds that 
increase and quench the fluorescence signal of the fluorophore. T1 and T3 were selected and 
tested against LgtC at 100 µM. The maximum fluorescence intensity was obtained at 5 mM of 
UDP (positive control) and the lowest fluorescence intensity in the absence of UDP (negative 
control). The fluorescence intensity change between the negative and the positive control 
(Figure 4.2, ∆1) is the assay window (a maximum fluorescence change) which corresponds to 
complete fluorophore displacement (i.e. 100 % of the fluorophore is displaced in the 
presence of UDP (5.0 mM)).  
 
The fluorophore displacement of the tested compounds was unsuitable to determine in a 
similar way performed with UDP because the fluorescence intensity of the pure fluorophore 
was significantly changed in the presence of T1 or T3. For example, because the fluorescence 
intensity was significantly quenched in the presence of T3, the sample signal (T3 + 
fluorophore + LgtC) was lower than the negative control signal. Therefore, the same negative 
control was unsuitable for determining the percentage displacement. Consequently, the 
percentage change in the fluorescence intensity compared to the pure fluorophore (F) signal 
was used to calculate a negative control for both compounds by correcting the negative 

























25 % in the presence of T1 and quenched 38 % in the presence of T3 at (Figure 4.2, ∆2 and 
∆4, respectively). The negative control was then corrected for both test compounds 
depending on the percentage fluorescence increasing or quenching intensity assuming the 
change in fluorescence intensity is linear and remains the same during the screening 
experiment. The change in fluorescence intensity of the tested compounds was calculated 
between the corrected negative control and the sample signal (Figure 4.2, ∆3 and ∆5 for T1 
and T3 respectively) which is related to the assay window achieved with UDP. 
 
 
Figure 4.2. Fluorescence intensity (FI) comparison between the controls and T1 and T3 at 100 µM in 
the absence and in the presence of LgtC. I is binder: T1, T3 or UDP, E is LgtC and F is the fluorophore 
(5FTUDP-Gal). ∆1 is the assay window: the maximum FI change between negative and positive control 
(UDP 5.0 mM), ∆2 and ∆4 is the difference in FI caused by the tested compounds compared to the 
control (F only), ∆3 and ∆5 is the difference in FI between the corrected negative control (corrected 
neg) and the FI signal of the test compounds in the presence of F 
 
The percentage fluorophore displacement was calculated (Equation 6) by normalising the 
change in the fluorescence intensity between the measured sample (Fc) and the corrected 
negative signal (Fcorr) to the maximum FI change between the negative control (Fmin) and the 
positive control (Fmax). 
 
Equation 6  %Displacement       
         )






These results demonstrated how tested compounds may possibly behave and how to 
consider the fluorescence properties of the tested compounds in calculations. The negative 
control was corrected for each compound individually. The fluorescence intensity of the 
compounds was taken into account at this stage, therefore, the false negatives can be 
minimised. UDP behaves like a competitive inhibitor and it is non-fluorescent, therefore, it 
was utilised as a control in the compound screenings. UDP was introduced as a positive 
control at 5.0 mM and at concentration where 50 % of the fluorophore was displaced (IC50) 
by UDP was set as a limit for positive hits. 
 
The compound libraries, a diverse compound library and a target-focused library were first 
screened in a single compound concentration aiming to identify compounds that inhibit LgtC 
with the LDA. The second screen was performed in various compound concentrations (IC50) 
also with the LDA to remove the potential false positives. Because the LDA measures only 
binding and does not provide information about the catalytic activity of the enzyme, the final 
screen was performed with a biochemical assay using a different detection mode. The 
phosphatase coupled assay, was then utilised to confirm and characterise the hit compounds 
and determine the kinetic parameters against LgtC (i.e. the inhibition constant, Ki).  
 
4.2 Diverse compound library screening 
 
A diversity-oriented synthesis (DOS) library was received from Dr David Spring. The 
compound library included several scaffolds and numerous building blocks of the final 
molecules. Some of these structures are illustrated in Figure 4.3, Figure 4.4 and Table 4.2. 
The diverse library ensures that a wide range of structural diversity is represented in the 
sample set. The library consisted of a structural diversity of compounds that did not have 









The compound screening demonstrated that the LDA is a rapid method as, in total 393 
compounds were successfully screened in duplicate against LgtC in one day. Screening such a 
large number of compounds in one day is a great advantage. If the compound library was 
screened with the HPLC-based assay or the PCA then the screening would take approximately 
40 or 5 days respectively. The Z’-factor of the average of 9 measured micro plates was 0.74. 
The compounds were tested at 100 µM and the hit rate was high, 8.1 % of the compounds 
displaced more than 50 % of the fluorophore. Typically the hit rate in the compound library 
screening is 0.01-0.1 %224 and therefore, the high hit rate raised questions about false 
positives. Over 50 % of the hit compounds shared a bicyclic nitrogen heterocyclic scaffold 
(Figure 4.4 and Table 4.2). The hydroxyl group of the phenol ring of the compounds could 
possibly form chelates with manganese ion and cause high hit rate by inactivating LgtC. In 
addition, LgtC could be inhibited non-specifically by compound aggregation because the 
screening was performed in the absence of surfactants. The fluorescence of the compounds 
was unlikely to cause false negatives because the fluorescence of the compounds was taken 
in to account in the calculation (Equation 6).   
 
 
Figure 4.4. The general scaffold of the positive hits from the primary screen of the DOS library 
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4.2.1 Characterisation of the hits from the diverse compound library 
 
The top 13 compounds that displaced the fluorophore more than 50 % were selected for 
subsequent investigations for the discovery of potential false positives. Firstly, the IC50 was 
determined with the LDA to ensure that the hits were real. The compounds were clearly 
insoluble in the assay buffer above 100 µM, therefore, the highest concentration of the 
compounds in the IC50 experiment was limited to 100 µM.  The displacement of the 
fluorophore was dependent on the concentration of the compounds (Figure 4.5). However, 
accurate IC50 values were not achieved because a plateau was not reached in the 
concentration range used. 
 
 
Figure 4.5. Fluorophore displacement with one of the hit compounds from the primary screen (P2_27) 
in various concentrations against LgtC. Experiment carried out in the presence of 10 % DMSO and 
fluorophore displacement monitored at λex= 350 nm and λem= 430 nm 
 
The HPLC-based method (Chapter 3.2.3) was a valid alternative method for investigating the 
activity of the compounds and to exclude the possibility of chelation because the turnover is 
monitored in the excess of manganese ion by the HPLC-based method. In addition, a 
different detection method could exclude false positives if the positive hits are caused by the 
fluorescence of the compounds. The percentage inhibition was determined at 50 µM by the 
HPLC method and the percentage inhibition was then compared with the fluorophore 































Table 4.2. Structures of the hit compounds and percentage inhibition at 50 µM against LgtC by HPLC 








R1 R2 R3 R4 R5 R6 
P2_9  36 91 - - - - - - 
P2_14  33 64 - - - - - p-Cl 
P2_27  38 67 m-Cl, 
m-Cl 
=O - - - - 
P2_28  27 85 m-Cl, 
m-Cl 
-Ta -CO2Et - - - 




P2_72  0 95 - - - - - - 
P2_83  29 69 - - - - - - 
P2_89  49 95 - - - - m-Cl, 
p-CH3 
- 
P2_92 25 115 m-Br =O - - - - 
P2_93 32 98 - - - - m-Cl, 
m-Cl 
- 
P4_28 0 89 - - - - - - 
P4_29 20 49 - - - - - - 




ralated to control (no compound added, 100 % activity), 
c
related to 100 % fluorophore 
diplacement with excess of UDP 
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The observed percentage inhibition varied between 20 % and 49 % by the HPLC-based assay 
and the compounds P2_72, P4_28 and P4_41 did not show any activity against LgtC (Table 
4.2). The chemical structures of P2_72, P4_28, P4_41 and also P2_29 are relatively different 
than the remaining hits. The percentage inhibition and percentage fluorophore displacement 
results cannot be directly compared because the HPLC-based assay monitor the turnover of 
the LgtC catalysed reaction and the LDA only the fluorophore displacement. Therefore, the 
observed activity of P2_72, P4_28 and P4_41 was possibly due to the ligand displacement 
assay conditions. The percentage fluorophore displacement varied between 49 % and 115%. 
Hypothetically, false positives can be observed if the compounds form chelates with Mn2+. 
Mn2+ would then be unavailable and the fluorophore unable to bind to the donor binding 
site, resulting in a high fluorescence intensity signal on the LDA. This was an option because 
the LDA was performed without Mn2+ addition. However, the results obtained with the HPLC-
based assay which was performed in the excess of Mn2+ (20 mM), indicated that the 
compounds inhibited the activity of LgtC. If the compounds inhibit LgtC by chelation then the 
activity of the compounds should not be observed in high Mn2+ concentration. Therefore, the 
activity of the compounds against LgtC was a real inhibition or the observed activity was due 
to non-specific binding, or due to reactivity of the compounds.  
 
4.2.1.1 Synthesis of pyrimidopyrimidine compounds  
 
Most of the hit compounds shared a bicyclic nitrogen heterocyclic scaffold (Table 4.2). This 
scaffold had the most potential as a target structure based on the high activity against LgtC in 
the LDA and in addition, the HPLC-based method indicated activity. More material was 
needed for enzymological studies to complete the hit compound characterisation and to 
explore the structure-activity relationship. Therefore, a small library was designed and 
synthesised based on the activity against LgtC and availability of commercial reagents. 
 
The synthesis route of these pyrimidopyrimidine (PP) compounds was simple and all the 
reagents were commercially available to synthesise the selected compounds. A small library 
of 10 compounds (Table 4.3) contained six compounds that were included in the primary 
screening (1a, 1b, 1c (same as P2_27), 2a, 2b and 2c) and the positive results also 
encouraged synthesise of four novel PP analogues (1d, 1e, 1f and 1g).The benzoyl group 
attached to aminopyrimidine of the designed compounds remained unmodified and the 
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modifications were focused on the phenol ring on the other side of the heterocyclic scaffold 
by increasing the size with methane, chloride or bromide groups.  
 
 
Scheme 4.2. Synthesis of PP analogues 1b to 1g via Biginelli-type reaction. The functional roups (R1 
and R2) and yields are presented in Table 4.3 
 
The synthetic route to the PP compounds was followed as previously published.217, 234 The 
intermediate 1a (Scheme 4.2) was prepared via a three-component Biginelli-type reaction235 
where β-keto ester (ethyl benzoylacetate), aldehyde (isovaleraldehyde) in the presence of 
guanidine generates a dihydropyrimidine in dimethylformamide (DMF). Whereas the 
reaction with β-keto ester and guanidine in EtOH generates amino pyrimidinone, the 
intermediate 1a (Scheme 4.3). The final compounds were synthesised by modifying the 
intermediates 1a or 2a with an appropriate 3-formylchromone to form bicyclic nitrogen 
heterocyclic systems, 1b-1g and 2b-2c.  
 
Scheme 4.3. Synthesis of PP analogues 2b to 2c. The functional roups (R1 and R2) and yields are 
presented in Table 4.3 
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The final compunds were purified by washing with hot EtOH or/and MeOH until pure 
compounds were observed in proton nuclear magnetic resonance spectroscopy (1H-NMR). 
1H-NMR, 13C-NMR and MS were utilised for the characterisation (Chapter 4.5.4) and the 
purity of the compounds was determined by HPLC ensuring that possible impurities did not 
interfere the assay performance: the ligand displacement assay or the phosphatase coupled 
assay on the enzymological studies. The absorption spectrum of the synthesised compounds 
was measured to determine λmax prior to the purity determination (Chapter 4.5.5).   
 
Table 4.3. The functional groups (R1 and R2, see the positions from the Scheme 4.2 and Scheme 4.3), 
yields and purities of the synthesised PP analogues 
Compound R1 R2 Yield (%) Purity
c (%) λmax (nm) 
1a - - 49 - - 
1b -Br - 46 96 420 
1ca  -Cl -Cl 39 95 420 
1db -Cl - 55 99 380 
1eb  -Me -Me 51 96 380 
1fb  -Br -Br 43 41 380 
1gb, d  -OMe - - - - 
2a  - - 36 100 310 
2b  -Br - 2 - - 
2c  -Cl -Cl 26 24 310 
a




purity determined by HPLC, 
d
product synthesis not 
achieved 
 
Both intermediates (1a and 2a) and six final products (1b, 1c, 1d, 1e, 1f and 2c) were 
successfully synthesised up to 55 % yield (Table 4.3). Impurities of the final compounds were 
poorly soluble in used solvents (EtOH and MeOH) which hampered the purification step. The 
final compounds (1b-1g and 2b-2c) were not soluble in hot EtOH or/and MeOH and washing 
was carried out in these solvents. Pure compounds were achieved by repeating this washing 
step, except with 1f and 2c. The reaction product (1g) was not formed during the reflux 
(precipitation was not formed), and a mixture of compounds was observed by thin layer 
chromatography (TLC). 2b was successfully synthesised and pure compound was observed by 
NMR, however, most of the product was lost in the purification step and sufficient amount of 
the compound was not achieved for further analysis. The intermediate 1a was not UV-active 
and the purity determination was impossible with HPLC, however, the 1H-NMR analysis 
indicated a high purity product. The pure synthesised compounds: 1a, 1b, 1c, 2a and the 
novel compounds: 1d and 1e were chosen for the completion of hit compounds 
characterisation by the ligand displacement and the biochemical assays. 
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4.2.1.2 Determination of IC50 by ligand displacement assay 
 
The preliminary results indicated that the inhibition by the hit compounds was concentration 
dependent (IC50 experiment) and the results in the chapter 4.2.1 indicated that the inhibition 
of LgtC was not due to the compounds ability to form chelates with the manganese ion. A 
potential explanation for concentration dependent inhibition was an aggregation-based 
inhibition. The aggregation-based inhibition is caused by molecules that can form small 
particles which inhibit proteins by sequestering LgtC at micromolar concentrations in 
aqueous solutions236 and is dependent on a microenvironment, such as buffer concentration 
and pH, concentration of DMSO and surfactant.237-240 Shoichet’s group has investigated non-
specific inhibition by molecular aggregators and they have reported that the aggregation-
based inhibition can be reversed or prevented by adding a surfactant to assay buffer.236 
Therefore, the possibility that the hit compounds formed small particles which non-
specifically inhibited LgtC was a potential explanation because the compound screening was 
performed in the absence of a surfactant. 
 
Firstly, in order to investigate possible compound aggregation, the IC50 experiment was 
carried out in the presence and in the absence of TX-100 with the LDA. In theory, IC50 value of 
an aggregate-based inhibitor increases in the presence of surfactant and will have no effect 
for a real competitive inhibitor.209 As mentioned earlier, the PP analogues were poorly 
soluble in the assay buffer above 100 µM, therefore, the highest concentration of the 






Figure 4.6. Determination of IC50 for 1c in the presence and in the absence of TX-100 by the LDA 
 
 
The plateau of the curve was not achieved in the concentration range used and the IC50 value 
was not determined, however, a significant effect of surfactant was observed (Figure 4.6). 
The fluorophore displacement at 3 µM and above of 1c was four fold reduced in the presence 
of TX-100 indicating that the observed compound activity is possibly aggregation-based.209 
Additionally, the fluorophore displacement rose rapidly with the concentration in the 
absence of surfactant. The steep dose-response curves are reported to be an indication of 
aggregation-based inhibition. Shoichet has reported that the aggregation-based inhibitors 
can increase inhibition from 10 to 90 % less than 10-fold concentration range whereas a 
single-site inhibitor can do the same over an 81-fold concentration range.241  
 
4.2.1.3 Determination of Ki by phosphatase coupled assay and investigation of 
aggregation-based inhibition 
 
The determination of critical IC50 values which could have been used for comparing and 
characterising PP analogues was not yet achieved. Therefore, the phosphatase coupled 
biochemical assay (chapter 3.4.1) was introduced as an alternative method for the 
determination of Ki and aggregation-based inhibition of the compounds. The PCA is based on 
































turnover of the enzymatic reaction, providing information about the activity of LgtC in the 
presence of the tested compounds. Based on the same principle as the IC50 experiment, the 
Ki of an aggregate-based inhibitor increases in the presence of surfactant. Moreover, if the PP 
analogues are molecular aggregators, the inhibition is expected to be non-selective and they 
should be active against other enzymes.242 
 
In order to investigate whether the inhibition was aggregation-based, the Ki was determined 
in various TX-100 concentrations against LgtC and β1,4-GalT. Additionally, the influence of 
Mn2+ was examined. The Ki experiments were carried out with all synthesised PP analogues 
(1b-1g), including the intermediates (1a and 2a), the first scaffold of the PP structure which 
includes a phenyl attached to aminopyrimidine or aminopyrimidone (phenyl pyrimidine). In 
addition, the second scaffold which includes a benzoyl group attached to aminopyrimidine 
(benzoyl pyrimidine, BP, Figure 4.7) and one active compound from the compound screening 
(P2_93, from the batch received and not synthesised) were included for investigations of the 
structure-activity relationships and compound aggregation.  
 
 
Figure 4.7. Structure of benzoyl pyrimidine, BP 
 
Prior to the Ki determination the function of the PCA required investigation. A phosphatase 
catalysed reaction (Chapter 3.4.1) of the PCA is critical for the formation of inorganic 
phosphate that is proportional to the reaction product, UDP. Therefore, a control test was 
carried out to ensure that the phosphatase was not inhibited by the compounds of interest. 
The control experiment was investigated by titrating various concentrations of the PP 
analogues at fixed concentration of UDP and phosphatase. The results indicated that the 
same amount of inorganic phosphate/UDP was formed in the presence of the PP 
compounds. Because the phosphatase was unaffected by the PP analogues (Figure 4.8) and 





Figure 4.8. Phosphatase control by the PCA. The functionality of the phosphatase was not affected by 
UDP formation in various concentrations of 1c or P2_93. Experiment was carried out at fixed 
concentrations of UDP (6.25 µM) and phosphatase (10 U/mL)  
 
All the experiments were performed without addition of Mn2+ aiming to keep the same assay 
conditions such as in the LDA. The influence of Mn2+ was examined by determining Ki in the 
presence (5 mM) and in the absence Mn2+ for P2_93 and 1c. The Ki was 8.2 µM and 7.5 µM in 
the presence and 12 µM and 4.5 µM in the absence of Mn2+ for P2_93 and 1c respectively 
(Table 4.4). The unchanged Ki values indicated that the activity of LgtC was not influenced by 
the Mn2+ concentration. In addition, the results supported the hypothesis that the PP 
analogues were not chelating agents. 
 
The Ki values of the PP analogues increased with increasing TX-100 concentration (Table 4.4). 
For example 10-fold increase in the Ki value of 1b was observed when TX-100 increased from 
0 % to 0.01 % with LgtC. In addition, the PP analogues inhibited β1,4-GalT with the similar 
concentration range than LgtC. The intermediates (1a and 2a) and the second scaffold in the 



































Ki (0.001 % 
TX-100) 





P2_93  126 
12 
(8.2)b 
- - 6.6 - 
1b  56 3.8 4.9 39 7.7 108 
1c  108 4.5 (7.5)b 14 55 7.7 194 
1d  - 1.9 13 57 19 122 
1e  - 10 6.8 110 5.5 75 
1a  - 116 >200 >200 >200 - 
2a  - >200 >200 >200 >200 - 
BP - >200 - - >200 - 
a
Determined by the LDA at 100 µM, 
b
Determined in the presentence of 5.0 mM MnCl2  
 
The results indicated that the PP analogues were surfactant sensitive and they were active 
against both, LgtC and β1,4-GalT suggesting that the inhibition is not selective. Both enzymes 
are possibly inhibited non-specifically by molecular aggregators that can physically sequester 
the surface of the protein and can cause protein unfolding.236 A diverse range of compounds 
have been reported to aggregate and the prediction of the compound aggregation based on 
the structure is theoretically impossible.223, 242 However, conjugated, lipophilic, poorly soluble 
in aqueous solutions and phenol group containing compounds are common features for 
reported aggregation-based inhibitors.227 BP, which represents the second scaffold in the PP 
structure, has a phenol group which could be prone to aggregation, was used as a control to 
examine the aggregation and if a real inhibitor was hidden in the PP structure. However, no 
inhibition of LgtC or β1,4-GalT was observed by BP or the intermediates which are less 
aggregator-like compounds than the PP analogues. The results indicated that individually the 
two different scaffolds (BP, 1a or 2a) do not form aggregates, however, when these two 
scaffolds are combined, the PP analogues, aggregates are formed. 
 
Overall, the results strongly suggested that PP analogues (P2_93, 1b, 1c, 1d and 1e) are 
aggregate-based inhibitors based on the surfactant sensitivity and activity against two 
different GTs. Additionally, all the PP analogues are highly conjugated and hydrophobic 




4.2.1.4 Determination of particle size by DLS  
 
The results in the previous chapter indicated that the PP analogues were molecular 
aggregators due to their surfactant (TX-100) sensitivity and non-specific inhibition behaviour. 
To further investigate the aggregation behaviour of the PP analogues an alternative 
technique for detection of the particle size was required. Transmission electron microscopy 
and dynamic light scattering (DLS) methods have been used to determine a particle sizes in 
solution.238, 243, 244 McCovern and co-workers investigated aggregation-based inhibition and 
they visualised that the aggregates formed by promiscuous compounds sequester enzyme by 
transmission electron microscopy.149 DLS is a widely used technique for the investigation of 
particle size of aggregates and recently DLS has been coupled with plate readers allowing a 
particle size analysis parallel with high throughput screens.243, 245  
 
DLS measures the intensity fluctuations of the scattered light arising from the Brownian 
motion of spherical particles in solution.246 The Brownian motion is related to the particle 
size: larger particles move slowly and small particles quickly. The diffusion constant of the 
particles is measured and the size of the particles is calculated according to the Stokes-
Einstein relation246 (         , where k is Boltzmann’s constant, T is absolute 
temperature, η is viscosity and r is radius of the spherical particle). The Brownian motion is 
dependent on temperature, viscosity and concentration of the solution.246 In addition 
refractive index of the molecule of interest must be different than the diluents. 
 
The particle size of the synthesised PP analogues (1a, 2a, 1b, 1c, 1d and 1e) was determined 
by DLS. Sample diluent was copied from the LDA and the PCA, thus the compounds were 
dissolved in 13 mM HEPES pH 7.0 in final 10 % DMSO (v/v). The refractive indexes of PP 
analogues were between 1.58 and 1.67 (experimental chapter 4.5.6) and dissenting from the 
diluent (1.346247). Initially, the optimum concentration of the PP analogues for the particle 
size analysis was investigated. The particle size of 1b was measure at 10 µM, 50 µM and 100 
µM covering the concentration range used in the LDA and the PCA experiments. The particle 
size remained the same between 10 µM and 50 µM, and at 100 µM the particle size 
decreased significantly (Figure 4.9). DLS measures a single scattering events and possible 
multiple chattering events occurred at high sample concentration causing decrease in 
particle size. During the measurements of PP analogues, solubility problems were observed 




Figure 4.9. Particle size of 1b at 10 µM, 50 µM and 100 µM. Optimum concentration for DLS 
experiments was found between 10 µ and 50 µM of 1b 
 
The relationship of the compound concentration and the aggregate formation has been 
investigated240, 244 and the researchers demonstrated that each aggregating compound has a 
critical aggregating concentration and above the concentration more aggregates are formed, 
however, the particle size remains the same. Based on these investigations, the optimum 
concentration for the particle size experiments was chosen at 25 µM where particle size of 
1b was assumed as remaining the same. 
 
Table 4.5. Average particle size of PP analogues (n=3) in 13 mM HEPES buffer (pH 7.0) including DMSO 
(10 % (v/v)) 
Compound Size, nm PDIa Intensity kcpsb 
1a 217 ± 3 0.231 ± 0.027 214 ± 1 
2a 84 ± 2 0.183 ± 0.022 87 ± 6 
1b 1801 ± 123 0.712 ± 0.033 164 ± 2 
1c 178 ± 6 0.354 ± 0.022 237 ± 2 
1d 171 ± 4 0.339 ± 0.013 204 ± 2 




Kilocounts per second  
 
The results indicated that small particles were formed at 25 µM of each compound (Table 
4.5). The average particle size was approximately 200 nm, which indicate that the particles 
may be aggregates. The reported particle size of aggregates is between 100 and 1000 nm.238, 
242 The particle size of 1b was larger than the other tested compounds. The structure of 1b 























position on phenol ring. The high polydispersity index indicated that the solution contains a 
variable size of particles, therefore, an alternative explanation is that a non-uniform solution 
of 1b contains more large than small particles. Scattered light intensity remained high for all 
compounds, indicating a high number of molecules in solution. The intermediates (1a and 2a) 
did not inhibit LgtC or β1,4-GalT (Table 4.4) by the PCA and they were not expected to form 
particles. However, the particle size of 1a was in the same range as the final compounds (1c-
e) and 2a, which is smaller and more polar than 1a, formed particles, but they were smaller 
than 1a (Table 4.5). Possibly, the shape of the particles is unfavourable to sequester LgtC and 
β1,4-GalT compared to the final compounds (1c-e) that inhibited both enzymes.  
 
The results suggested that the compounds (1b-e) form aggregates which can non-selectively 
inhibit the activity of LgtC and β1,4-GalT. The results also indicated that the compounds were 
not completely soluble in the assay buffer at 25 µM. Therefore, the non-soluble particles may 
disturb the measurements. In addition, the precipitation of the compounds together with 
molecular aggregators may cause the false positive results in the compound screening and 
the biochemical assays. 
 
4.3 Target-focused library screening 
 
In recent years, target-focused libraries have been designed for improving the hit rates in 
HTS. The compound libraries have been designed based on the protein families248 and the 
three-dimensional structure of the target protein.249 Pyrazolones have been identified as 
novel GT inhibitors by virtual screening of 5 million commercially available compounds by 
targeting the acceptor binding site of heptosyltransferase (WaaC).250 The enzymological 
studies demonstrated that pyrazolones were competitive inhibitors against WaaC250 and the 
catalysis of the transfer of heptose to KDO (3-Deoxy-D-manno-oct-2-ulosonic acid) residue on 
the LPS of E. coli251 was inhibited in the micromolar range. Pyrazolone derivatives have also 
been identified as kinase252, 253 and HIV-1 integrase254 inhibitors and potential antibacterial 
agents.255, 256 A pyrazolone scaffold was chosen as a target structure for the discovery of 
inhibitors against LgtC, based on the pyrazolones activity against WaaC and the biological 





 A small pyrazolone library was available in house and a set of 21 pyrazolone analogues 
(Table 4.6) was screened by the LDA and the PCA. The outcome of the compound screenings 
was used for the investigation of correlation between percentage inhibition and the 
percentage fluorophore displacement which was related to the maximum fluorophore 
displacement with UDP (see Chapter 4.1.1). Further characterisation of the positive hits 
identified from the screening were characterised by the PCA. TX-100 (0.01 %, v/v) was 
introduced to both assays to prevent possible false positives due to compound aggregation. 
The compounds were tested in duplicate at 25 µM and the screen was divided into two days. 
Z’ factor average of two microplates was 0.91 with the LDA.  
 
 





p3 -CO2H - 
p4 - m-OH, p-OH 
p5 -CO2H p-OBn 
p6 -CO2H m-Br, p-OCH3 
p7 -CO2H p-N(CH3)2 
p8 - m-OBn, p-OBn 
p9 - o-OH, p-OH 
p10 -CO2H m-Br, p-F 
p11 - m-Br, p-F 
p12 - m-OCH3, m’-OCH3, p-OH 
p13 - p-Cl 
p14 - p-CN 
p15 - m-Br, p-OCH3 
p16 - - 
p17 - m-CF3 
p18 - o-CF3 
p19 - p-CF3 
p20 - p-Ph 




The results from the compound screening showed that the percentage fluorophore 
displacement was significantly lower for several compounds by the LDA than the percentage 
inhibition by the PCA (Figure 4.10). The maximum percentage fluorophore displacement 
observed by the LDA was 27 % whereas 9 out of 21 (43 %) compounds inhibited LgtC more 
than 50 % by the PCA. The results at this stage indicated that the compounds are low affinity 
inhibitors by the LDA and false positives by the PCA or the percentage inhibition is real and 
the compounds are not competitive inhibitors. However, there were no suitable controls that 
could be used in both assays to prove which results were correct.     
 
 
Figure 4.10. Percentage inhibition/fluorophore displacement at 25 µM of the compound against LgtC 
obtained by the LDA and the PCA 
 
The percentage inhibition was used for the investigation of the structure-activity relationship 
by assuming that the results obtained with the PCA were real. The benzylidene moiety 
attached to the methylpyrazolone scaffold was essential for the inhibition. In the absence of 
benzylidine (p1) or when benzylidine moiety was replaced with a vinyl furan group (p2), a 
limited inhibition was observed. These preliminary results suggested that, a carboxylic acid 
group is not relevant to the inhibition when non-carboxylated and carboxylated compounds, 
p6 and p15 or p10 and p11 respectively, were compared. In contrast, the position of the 
functional group and the characteristics of the functional group of the aryl (R2) ring seem to 
affect to inhibition. High polarity and large size of the functional groups seem to decrease 

























































































The compound screening results obtained by the LDA and the PCA did not correlate as 
assumed. Therefore, further investigations were required in order explain the difference in 
the results. The type of inhibition was of particular interest as if the compounds inhibited 
LgtC with mixed mode then the low percentage fluorophore displacement and the high 
percentage inhibition could be explained.   
 
4.3.1 Enzymological characterisation of hits from the focus-target library 
 
Nine compounds were identified on the screening assay by the PCA that inhibited LgtC more 
than 50 %. However, compounds which displaced more than 50 % of the fluorophore (related 
to 100 % fluorophore displacement with UDP) were not identified by the LDA. Because the 
results obtained with these two assays did not correlate and the fluorescence intensity was 
partly recovered (7 to 27 %) by the LDA, it was suggested that the inhibition may occur in a 
mixed mode.   
 
Reversible enzyme inhibition can be competitive, un-competitive or mixed. Competitive 
inhibitors binds specifically to the active site of a free enzyme and compete with the 
substrate.257 Un-competitive inhibitors bind at a separate site than the substrate and they 
bind only to the enzyme-substrate complex.257 Mixed inhibitors (and non-competitive) bind 
either to free enzyme or enzyme-substrate complex (Figure 4.11) with the same affinity (non-
competitive inhibition) or different affinity (mixed inhibition).257 Mixed inhibition is a mixture 
of partial competitive and pure non-competitive inhibition, and in the presence of inhibitor, 
some of the enzyme is always in non-active enzyme-substrate-inhibitor complex. 
 
 
Figure 4.11. Non-competitive/ mixed inhibition. Inhibitor (I) binds at a separate site and may bind 
either to E (enzyme) or/and to ES (enzyme-substrate) complex (on the left). Lineweaver-Burk plot of 
mixed inhibition (on the right) 
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The inhibition mode can be determined by double-reciprocal plot (Lineweaver-Burk). The 
rate experiments are carried out in various substrate concentrations in the absence and in 
the presence inhibitor, with the enzyme concentration held constant. The results are plotted 
1/reaction rate versus 1/substrate concentration.257 In the presence of competitive inhibitor, 
increasing inhibition concentration results in a set of lines with a common intercept on the 
1/V axis but with different slopes (Vmax is unchanged). In the case of a mixed inhibitor, both 
intercept changes, resulting in changes in Vmax and Km (Figure 4.11). 
 
The compound screening was carried out at a single compound concentration and the 
percentage inhibition was trend-setting. Therefore, further investigations were required to 
confirm the activity of the compounds. Five of the compounds: p5, p6, p13, p15 and p18 
(Table 4.6) were chosen for the determination of inhibition constant (Ki) by the PCA. After the 
Ki determination, the fluorophore displacement in higher compound (p5 and p18) 
concentrations was investigated (IC50) by the LDA and finally the mode of inhibition was 
determined for p5 and p18, in order to explain why the percentage of fluorophore 
displacement was low.   
 
4.3.1.1 Determination of Ki  
 
The PCA was used for the determination of the Ki values of the identified hits from the 
compound screening. Five of the compounds were selected based on their activity against 
LgtC. In order to investigate whether the compound specifically inhibited LgtC, the Ki values 
were determined in the presence and the absence of TX-100 evaluating the ability of the 
compounds to form aggregates and against β1,4-GalT. Ki values were determined as in the 
previous chapters for p5, p6, p13, p15 and p18.  
 
Firstly, the control test was carried out to ensure that the phosphatase was not inhibited by 
the pyrazolones prior to the activity experiments. A correlation between compound 
concentration and UDP formed in the phosphatase catalysed reaction was not observed 





Figure 4.12. Phosphatase control by the PCA. The functionality of the phosphatase was not affected by 
UDP formation in various concentrations of p5 or p18. Experiment was carried out at fixed 
concentrations of UDP (6.25 µM) and phosphatase (10 U/mL) 
 
All tested pyrazolones, p5, p6, p13, p15 and p18, inhibited LgtC in the range of 0.25 to 4.3 
µM (Table 4.7).  The Ki values remained constant in the presence of TX-100 indicating that 
the pyrazolones were not sensitive to the surfactant and specifically inhibited LgtC. In 
addition, the experiment performed against β1,4-GalT, confirmed the specific inhibition 
because the compounds did not show activity even at high compound concentration (Figure 
4.13).    
 
 
Figure 4.13. Dixon plot of reciprocal initial velocity (v) versus p5 concentration to calculate the Ki value. 









































All the Ki experiments were performed without addition of Mn
2+ to the assay buffer. As 
shown in Chapter 3.4.2 (Figure 3.22), Mn2+ increases the catalytic activity of LgtC, therefore, 
the Ki was performed for p18 also in the excess of Mn
2+. Ki values were identical in the excess 
and without addition of Mn2+ (Table 4.7), indicating the inhibition was not affected by low 
Mn2+ concentration. 
 
Table 4.7. Percentage inhibition by the PCA at 25 µM and Ki values against LgtC and β1,4-GalT in the 
presence and in the absence of TX-100 
Compound %INH  
Ki (LgtC), µM 
Ki (β1,4-GalT), µM 0 %a 0.01 %a 
p5 94 ± 3 1.2 2.9 
No inhibition 
observed 
p6 86 ± 6 0.25 1.0 
No inhibition 
observed 
p13 79 ± 4 4.3 3.8 
No inhibition 
observed 
p15 88 ± 1 1.3 1.2 
No inhibition 
observed 






Ki values determined in the presence of 5.0 mM MnCl2  
 
 
The results strongly suggested that the pyrazolones specifically inhibited LgtC. Therefore, the 
structure-activity relationship was evaluated with p5, p6, p13, p15 and p18 based on the 
obtained Ki values. Based on the percentage inhibition results, it was suggested that 
carboxylic acid group is was not relevant to the inhibition and the similar Ki values of p6 and 
p15 confirmed this. In the absence of the carboxyl group at R1 (p13, p15 and p18) the 
compounds’ activity against LgtC was not changed. The carboxylic acid group was 
demonstrated to be essential for the activity of the pyrazolones against WaaC,250 due to the 
polar interaction with Arg on the acceptor binding site. However, Arg is not present on the 
acceptor binding site of LgtC16 which possibly explains why the pyrazolones were active in the 
absence of the carboxylic acid group. The results suggested that the remaining part of 
pyrazolone structure interacts with LgtC. However, all the tested pyrazolones inhibited LgtC 





4.3.1.2 Determination of IC50 
 
The Ki experiments by the PCA demonstrated that the pyrazolones were real LgtC inhibitors. 
The percentage fluorophore displacement by the LDA was significantly lower than in 
percentage inhibition by the PCA (Figure 4.10). Therefore, in order to investigate whether the 
pyrazolones were low affinity binders, the IC50 values were determined in the large 
concentration range. The experiment was performed in various p5 and p18 concentrations 
(up to 1.0 mM), and fixed LgtC and fluorophore concentrations. In addition, various pre-
incubations were performed to investigate whether the observed inhibition is time-
dependent: 
 Incubation 1: p5 or p18 and fluorophore incubated for 10 minutes then LgtC added 
 Incubation 2: p5 or p18 and LgtC incubated for 10 minutes then fluorophore added  
 Incubation 3: LgtC and fluorophore incubated for 10 minutes then p5 or p18 added 
The final reading was taken 20 minutes after the last component was added. 
 
Time, min











































Figure 4.14. IC50 and pre-incubation study with p5 and p18 by the LDA in the presence of TX-100. A) 
Incubation 1, B) Incubation 2, C) Incubation 3, D) Incubation 3, the displacement of the fluorophore 


















































































































As illustrated in Figure 4.14, A, B and C, approximately 60 % of the fluorophore was displaced 
from the active site and the complete fluorescence recovery was not achieved at high 
concentration of p5 or p18. A plateau was reached approximately at 70 µM of p5 or p18. The 
fluorophore displacement by p18 was followed for 30 minutes (Figure 4.14, D) and the 
fluorophore was first incubated with LgtC to ensure that fluorescence is fully quenched before 
p18 was added. The curves demonstrated that p18 slowly replaced the fluorophore reaching 
the plateau approximately after 15 minutes at high p18 concentrations (> 64 µM).  
 
The results indicated that p5 and p18 do not bind specifically to the donor binding site of LgtC. 
Possibly p5 and p18 binds to LgtC non-specifically causing a conformational change that 
releases the fluorophore from the active site. However, if p5 and p18 are mixed inhibitors then 
the partial fluorophore displacement could be explained because the compounds are capable 
of binding to free LgtC and the LgtC-fluorophore complex. If the pyrazolones were donor 
competitive inhibitors then the fluorescence would be restored completely. In the case of un-
competitive inhibitors, the fluorescence would remain quenched as the inhibitor and the 
fluorophore share different binding sites. The LDA was unsuitable for the determination of the 
IC50 or the inhibition mode, however, the results strongly suggested that the pyrazolones were 
mixed inhibitors against the donor.  
 
4.3.1.3 Determination of inhibition mode of pyrazolones 
 
The inhibition of LgtC by the pyrazolones was confirmed with the Ki experiments. The 
percentage fluorophore displacement obtained by the LDA was significantly lower than the 
percentage inhibition obtained by the PCA (Figure 4.10) suggesting that the inhibition mode is 
more likely mixed than competitive inhibition. The partial fluorescence recovery was possibly 
due to the capability of pyrazolones to bind to substrate free (fluorophore) LgtC and the 
fluorophore-LgtC complex.  
 
The mode of inhibition was first evaluated by performing Michaelis-Menten and Lineweaver-
Burk plots in the absence and in the presence of p5 or p18 (at 2.0 and 5.0 µM).  The same set 
of data was re-plotted (Lineweaver-Burk) and the type of inhibition was determined from the 






Figure 4.15. Michaelis-Menten and Lineweaver-Burk plot in the absence and in the presence of p5 (A 
and B) or p18 (C and D) 
 
Both inhibitors followed Michaelis-Menten kinetics (Figure 4.15, A and C).  The Lineweaver-
Burk plot (Figure 4.15, B and D) illustrated that the straight lines had the same intercept above 
x-axis and changes in the x- and y-axis intercepts indicated mixed mode inhibition. Michaelis-
Menten constants where determined at two different inhibition concentrations (Table 4.8). 
The Km was 2.5 µM and Vmax was 0.39 µM/min in the absence of inhibitor. Km increased and 
Vmax decreased with both p5 and p18 suggesting that less free enzyme is available, thus less 
substrate binding sites. The change in both, Km and Vmax values, supported the hypothesis that 




















































Table 4.8. Km (µM) and Vmax (µM/ min) of UDP-Gal in the presence of p5 or p18 at 2.0 µM and 5.0 µM 
[p5 or p18], µM p5 p18 
Km Vmax Km Vmax 
2.0 6.0 ± 1.7 0.25 ± 0.02 2.6 ± 0.8 0.37 ± 0.03 
5.0 7.6 ± 0.8 0.20 ± 0.01 3.3 ± 1.6 0.28 ± 0.04 
Km= 2.5±1.0 µM and Vmax= 0.39±0.04 µM/min in the absence of p5 or p18 
 
Two graphical methods, Cornish-Bowden and Dixon plots,258 were used in order to determine 
the Ki’ for mixed inhibitors (p5 and p18) and further investigate the mode of inhibition. By 
comparing these two plots in parallel for the same set of data, the mode of inhibition can be 
found from the pattern of the straight lines. Dixon plot (1/v versus inhibitor concentration) 
does not distinguish between competitive and mixed inhibitors. The intersection is found 
above x-axis in both cases and the inhibition constant is [I] = -Ki. The Cornish-Bowden plot 
([S]/v versus inhibitor concentration) provides measure for enzyme-substrate-inhibitor (ESI) 
complex and, in case of competitive inhibitor the lines are parallel (no intersection) and for 
mixed inhibitors, the data for each substrate concentration fall on straight lines that intersect 




Figure 4.16. Cornish-Bowden plot (A and C) and Dixon plot (B and D) in various p5 and p18 
concentrations. The intersection point on both plots suggests p5 and p18 are mixed mode inhibitors 
[p18]










































































The Cornish-Bowden and the Dixon plots were performed at 20 µM and 50 µM of UDP-Gal in 
various inhibitor concentrations. In the Cornish-Bowden plot, the intersection of two straight 
lines was below the x-axis and in the Dixon plot the lines intersected above the x-axis, 
indicating that p5 and p18 are mixed inhibitors.258 The intersections of p5 were near the x-axis 
which possibly indicates that p5 is a non-competitive inhibitor instead of mixed inhibitor. 
However this was unlikely because all the results have indicated mixed inhibition thus far. 
Based on the Cornish-Bowden plots (intersection point is -Ki’) the calculated Ki’ values were 5.8 
µM and 6.5 µM for p5 and p18, respectively.  
 
The Michaelis-Menten kinetics indicated reversible, mixed inhibition and also the Cornish-
Bowden plots indicated mixed inhibition. Therefore, p5 and p18 were mixed inhibitors and the 
re-calculated Ki values changed from 1.2 µM to 5.8 µM and 6.5 µM, respectively based on the 
preliminary results (Table 4.7). The mixed inhibition mode explains the results obtained with 
the LDA: the fluorescence was not restored in high p5 or p18 concentration, approximately 60 
% of the fluorophore was displaced (Figure 4.14). Hypothetically, the fluorophore (p5 and p18) 
can bind either to free LgtC or LgtC-fluorophore complex. If the LgtC-fluorophore-inhibitor 
complex is formed then part of the fluorophore remains on the donor binding site and cannot 
be displaced, i.e. LgtC-fluorophore-inhibitor complex, LgtC-fluorophore complex, free 
fluorophore and possibly LgtC-inhibitor complex are present at the same time. 
 
4.4 Summary and conclusions 
 
The LDA described in chapter 2 was used successfully for the screening of a large compound 
library. Nearly 400 compounds were screened in one day by one person which is in the HPLC-
based assays due to their complex and time consuming protocols. The compound library 
screening included a significant number of pipetting steps which effected the accuracy of the 
results. The Z’ factor (Figure 4.17) was approximately 0.8 or above for the six microplates 
prepared and after the sixth microplate, the Z’ factor decreased. The decrease on the Z’ is 
clearly due to the multiple pipetting steps and this error could be prevented if the screening 








Figure 4.17. Z’ factor reduced during the compound screening. Micro plate number 1 was prepared first 
and so forth to the last microplate number 9 
 
Positive hits were identified from the DOS library screening. The surfactant sensitivity and non-
specific inhibition investigations indicated that the hit compounds (PP analogues) were 
molecular aggregators. The particle size, determined by DLS confirmed that the hits 
compounds formed small particles in the assay conditions. These results supported the 
hypothesis that the small molecular aggregators non-specifically inhibited LgtC. Overall, these 
screening results showed that it is important to introduce a surfactant to the screening assay 
protocol to prevent the molecular aggregation. 
 
Prior to the characterisation studies a small compound library of PP analogues was 
synthesised. The synthesis was affected by the poor solubility, specifically, the solubility of the 
impurities hampered the purification step. Two novel compounds were synthesised (1e and 1f) 
and 1e reached acceptable purity for further enzymological analysis. However, all the 
synthesised compounds were molecular aggregators. Generally, PP analogues were not drug-
like molecules due their high molecular weight and high lipophilicity (LogP). 
 
The focus-target library based on pyrazolones was screened and positive hits were found.  The 
hits (p5 and p18) inhibited LgtC at micro molar range and the further investigations indicated 
that they were mixed inhibitors. Therefore, these pyrazolones are not model drug-like 
molecules because they did not bind to the catalytic site of LgtC which may increase non-
























inflammatory drugs and they have been reported causing hypersensitivity.259 For example, a 
well-known pain killer, metamizole, poses a risk inducing an agramulocytocis.260 However, 
these pyrazolones could be potential targets for further development of specific LgtC 
inhibitors.    
 
The target-focused library was screened parallel with the LDA and the PCA, in order to validate 
the LDA. The comparison of the results demonstrated that the percentage fluorophore 
displacement was lower with the LDA than the percentage inhibition with the PCA. Initially, a 
lack of shared control hampered the comparison. UDP was a suitable control in the LDA, 
however, not in the PCA because UDP is a recorded component and recognised by the 
phosphatase. A possibility to use the same control in both assays was investigated, however, 
either of the compounds tested were unsuitable for the purpose.  5CF3-UDP-Gal inhibited the 
phosphatase in the PCA and tunicamycin (a studied N-glycosylation inhibitor252) did not show 
activity against LgtC. The hits (pyrazolones) from the screening were used to investigate the 
difference between the results obtained with the LDA and the PCA. The hits were found to 
inhibit LgtC by a mixed inhibition mode which explained the low percentage fluorophore 
displacement. Hypothetically, the pyrazolones could bind to the free LgtC and also to the 
fluorophore-enzyme complex. Therefore, pyrazolones displace part of the fluorophore 
resulting in an increase in the fluorescence signal, however, because the pyrazolones can bind 
to the fluorophore-enzyme complex, part of the fluorophore remains on the donor binding site 
and fluorescence cannot be completely restored.  
 
Overall, the compound library screenings showed that the LDA was simple and rapid to 
perform, therefore, it is suitable for HTS. Fluorescence interference of the tested compounds is 
low because the fluorescence intensities of the compounds and the fluorophore are compared 
before recording the final reading. The LDA is designed for the discovery of competitive 
inhibitors that displace the fluorophore from the donor binding site and it is unsuitable for the 
identification of un-competitive or mixed inhibitors. However, the LDA could be used for the 
characterisation inhibition mode in parallel with a biochemical assay because the fluorescence 
intensity could be fully recovered or fluorescence intensity would remain low for competitive 







A multi-mode BMG Labtech PolarStar microplate reader which has both, absorbance and 
fluorescence intensity detection modes was utilised for the compound screening and the 
characterisation experiments. All the compound screening and IC50 experiments by the LDA 
were carried out in black NUNC F96 MicroWell polystyrene plates or black Greiner 384 well 
micro polypropylene microplates. The fluorescence intensity was measured at 430 nm with 
excitation at 350 nm which were relevant to the fluorophore, 5FTUDP-Gal. The flashes per well 
was set to 10 and the gain was performed on blank well (fluorophore in buffer) and adjusted at 
85 % on each experiment. All the compound screening and Ki experiments by the PCA were 
carried out in clear NUNC F96 MicroWell polystyrene plates and absorbance was recorded at 
620 nm. Malachite reagents were prepared as described in experimental chapter 3.6.3. All 
reagent used in this chapter are listed in App. 2. 
 
The compound screening was performed against LgtC and in the characterisation section, the 
hit compounds were tested against β1,4-GalT and the results were utilised as a control. The 
calculations were performed with excel and Michaelis-Menten kinetics always with GraFit 
version 7.0.3. 
 
4.5.1 Diverse compound library screening 
 
The compounds were received in 96 well microplates at 100 mM in 100 % DMSO. The 
compounds from the original plates were diluted to final concentration of 1.0 mM in 100 % 
DMSO to make “daughter plates”.  
 
All the experiments were carried out in 13 mM HEPES (pH 7.0) buffer at final concentrations of 
LgtC (E), fluorophore (F) and DMSO at 10 µM, 0.2 µM and 10 % respectively (Table 4.9). The 
compounds were tested at 100 µM. Each microplate contained a negative control (F + E, low 
fluorescence), a positive control (F + E + 5.0 mM UDP, high fluorescence), a control (F + E + 50 







Table 4.9. Concentration of the components in the DOS library screening (96 well microplate) 
Component [Stock] [Final] Volume, µL 
Inhibitor/ UDP control  1 mMa/ 0.5 and 50 mMa 100 µM /50 and 5000 µM 10 
Fluorophore 1.0 µM 0.2 µM 20 
LgtC 50 µM 10 µM 20 
HEPES buffer 13 mM 13 mM 50 
a
In 100 % DMSO (v/v) 
 
All the compounds and controls were run in duplicate (Figure 4.18). The compounds were 
incubated at 30 ˚C for 10 minutes without LgtC and first reading was taken. 10 minutes after 
the incubation LgtC or buffer to blank was added (total volume on the well 100 µL) and 
incubation was continued for 20 minutes before taking the final reading. The first and the final 
readings were used for calculation the percentage fluorophore displacement. The percentage 
fluorophore displacement was calculated as presented in chapter 4.1.1. 
 
 
 1 2 3 4 5 6-12 
A Blank Comp 1 Comp 1 Comp 9 Comp 9 Comp 16-40 
B Blank Comp 2 Comp 2 Comp 10 Comp 10 Comp 17-41 
C Neg Ctrl Comp 3 Comp 3 Comp 11 Comp 11 Comp 18-42 
D Neg Ctrl Comp 4 Comp 4 Comp 12 Comp 12 Comp 1943 
E Pos Ctrl Comp 5 Comp 5 Comp 13 Comp 13 Comp 20-44 
F Pos Ctrl Comp 6 Comp 6 Comp 14 Comp 14 Comp 21-45 
G Ctrl Comp 7 Comp 7 Comp 14 Comp 14 Comp 22-46 
H Ctrl Comp 8 Comp 8 Comp 15 Comp 15 Comp 23-47 
Figure 4.18. Layout of the microplate on the compound screening 
 
4.5.2 Target-focused library screening 
 
The target-focused library was screened in a similar fashion to the DOS library. The main 
difference was that TX-100 was included in the assay buffer (Table 4.10) and 384 well 
microplates were utilised instead of 96 well microplates. The reaction total volume was 20 µL 
and all compounds and controls were run in triplicate. The stock solutions (10 mM) of the 
tested compounds were prepared in 100 % DMSO and diluted to the desired concentration in 
100 % DMSO. The compounds were tested at 25 µM. Otherwise, the assay set up was identical 





Table 4.10. Concentration of the components on the target-focused library screening (384 well 
microplate) by the LDA 
Component [Stock] [Final] Volume, µL 
Inhibitor/ UDP control 250 µMa /0.25 and 50 mMa 25 µM /25 and 5000 µM 2 
Fluorophore 1 µM 0.2 µM 4 
LgtC 17 µM 5 µM 6 
HEPES buffer 13 mM 13 mM 6 
TX-100 0.1 % (v/v) 0.01 % (v/v) 2 
a
In 100 % DMSO (v/v) 
 
The target-focused library was also screened with the PCA. All the experiments were carried 
out in 13 mM HEPES buffer (pH 7.0) at final concentrations of lactose (2.0 mM), CIP (10 U/mL), 
CEL (1.0 mg/mL), TX-100 (0.01 % (v/v)) and LgtC (60 nM), (Table 4.11). All the compounds were 
tested at 25 µM and the final DMSO concentration was 10 %. 
 
Table 4.11. Concentration of the components on the target-focused library screening (96 well 
microplate) by the PCA 
Component [Stock] [final] V in well, µL 
Lactose 10 mM 2 mM 30 
CIP 100 U/mL 10 U/mL 15 
CEL 10.0 mg/mL 1.0 mg/mL 15 
TX-100 0.1 %a 0.01 %a 15 
Inhibitor/ DMSOb 250 µM/ 100 %a 25 µM/ 10 %a 15 
LgtC / Bufferb, c 300 nM/ - 60 nM/ - 30 
UDP-Gal/ UDPb 150 µM/ 0- 62.5 µM 30 µM/ 0- 12.5 µM 30 
Malachite regent A    30 
Malachite regent B   30 
a(v/v), bin the UDP calibration/phosphatase control and negative control, cin the background 
hydrolysis 
 
The master mixture (M) which contained lactose, CIP, CEL and TX-100 (total 75 µL) was added 
to each well followed by the compound addition. Pure 100 % DMSO was added to the negative 
control (no inhibition) and to the calibration/phosphatase control wells. LgtC was added all the 
wells except to the background and UDP calibration/phosphatase control wells, where HEPES 
buffer was added instead (Figure 4.19). Finally UDP-Gal or UDP (for the calibration) was added 
to initiate the reaction. The reaction mixture was incubated for 20 minutes at 30 °C and 
stopped by adding malachite reagent A. After malachite reagent B addition, the colour 
development was recorded for 30 minutes. The colour development was finished after 




 1 2 3 4 5 6 7 8 
A         
B  M M M+G+E M+G+E M+G M+G  
C  M+U1 M+U1 M+G+E+I1 M+G+E+I1 M+G+I1 M+G+I1  
D  M+U2 M+U2 M+G+E+I2 M+G+E+I2 M+G+I2 M+G+I2  
E  M+U3 M+U3 M+G+E+I3 M+G+E+I3 M+G+I3 M+G+I3  
F  M+U4 M+U4 M+G+E+I4 M+G+E+I4 M+G+I4 M+G+I4  
G  M+U5 M+U5 M+G+E+I5 M+G+E+I5 M+G+I5 M+G+I5  
H         
Figure 4.19. Layout of the microplate in compound screening by PCA. Columns 2-3; UDP calibration, 
columns 4-5; various compounds and negative control on row B, columns 6-7; background for each 
compound. Master mixture (M), UDP in various concentrations, 0, 0.78, 1.56, 3.13, 6.25 and 12.5 µM 
(U1-U5), UDP-Gal (G), LgtC (E) and various compounds (I) 
 
The UDP calibration curve was used for the calculation the amount of UDP was formed in the 
reaction. Before calculating the percentage inhibition the background hydrolysis signal (no 
LgtC) was subtracted from the main signal. The percentage inhibition was calculated by 
normalising the amount of UDP formed to the negative control (100 % LgtC activity).   
 
4.5.3 The hit characterisation studies  
 
The LDA, the HPLC-based assay and the PCA were used for compound characterisation. The 
final DMSO concentration was 10 % (v/v) in all experiments. All inhibitor dilutions were in 100 
% DMSO and pure DMSO was added to controls as a substitute. All the assay settings were the 
same as in the screening assays: the LDA was set as in chapter 4.5.1 and the PCA as in chapter 
4.5.2.  
 
LgtC was activated in 5 mM dithiothreitol (DTT) assay buffer for 30 minutes at 37 °C prior to 
use in the biochemical assays (HPLC and PCA). The final concentration of LgtC was fixed in each 
assay used in characterisation studies, however, the concentration varied depending on the 
assay, batch of LgtC and presence of Mn2+. Concentration of LgtC was optimised on each assay 
prior the experiments by performing a calibration curve of LgtC and ensuring that the turnover 
of UDP-Gal to UDP was less than 10 %. Generally, the concentration of LgtC was 5 µM in LDA, 
182 
 
1.3 nM in HPLC, 60 nM and 25 nM in the absence and in the presence of Mn2+, respectively in 
the PCA experiments.  
 
4.5.3.1 Determination of IC50 and pre-incubation study by the LDA 
 
IC50 experiments were performed at fixed concentration of LgtC and fluorophore (5FTUDP-Gal) 
and in the absence and in the presence of TX-100 (0.01 % (v/v)). The highest concentration of 
inhibitor (p2_27 or 1c) was 100 µM and diluted to 0.2 µM by 2 fold to obtain requisite data 
points to the curve. Negative (no UDP, low fluorescence intensity) and positive (5 mM UDP, 
high fluorescence intensity) controls were included on every microplate.  
 
IC50 experiments were performed for p5 and p18 similarly as described above except the 
highest concentration of inhibitor was 1000 µM and diluted to 4.1 µM by 2.5 fold. The 
experiment was performed in the presence of TX-100 (0.01 % (v/v)).   
 
The following pre-incubations were performed with (p5 and p18): 
 Incubation 1: Inhibitor and fluorophore incubated for 10 minutes then LgtC added 
 Incubation 2: Inhibitor and LgtC incubated for 10 minutes then fluorophore added 
 Incubation 3: LgtC and fluorophore incubated for 10 minutes then inhibitor added 
 The final reading was taken 20 minutes after the last component was added. 
 
4.5.3.2 Determination of percentage inhibition by HPLC-based assay 
 
HPLC settings were as in chapter 3.2.3. The experiment was carried out in eppendorf tubes 
containing UDP-Gal (10 µM), lactose (2.0 mM) and 50 µM inhibitor in 50 mM MOPS buffer (pH 
7.0) including BSA (1.0 mg/mL) and MnCl2 (20 mM). The reactions were initiated by adding 
activated LgtC (see experimental chapter 2.7.5 for activation). The total reaction volume was 
100 µL. The reaction mixture was incubated at 37 °C for 10 minutes and stopped by placing the 
tubes in dry ice. The percentage inhibition was calculated by normalising the peak area of the 
inhibitor containing samples to the peak area of the negative control (maximum reaction 




4.5.3.3 Determination of activity of phosphatase in the presence of inhibitor 
 
A phosphatase test of the PCA was carried out in in the absence of GT reaction, at fixed 
concentration of UDP (6.25 µM) and at 0, 6.25, 12.5, 25, 50 and 100 µM of required inhibitors. 
The reaction was initiated by adding UDP. (see Table 4.11 how the UDP calibration/ 
phosphatase control was performed, DMSO displaced with the compounds) 
 
4.5.3.4 Determination of Ki by PCA 
 
Ki was determined in various TX-100 concentrations (0, 0.001 and 0.01 %, (v/v)), in the absence 
and in the presence of Mn2+ (5.0 mM), and with LgtC and β1,4-GalT. All assay components 
were fixed except the inhibitor concentration (see Table 4.11). The initial velocity was 
determined at 0, 1.56, 3.13, 6.25, 12.5, 25, 50 and 100 µM of inhibitor. The measured data was 
converted to the reaction velocity and 1/v versus inhibitor concentration was plotted (Dixon 
plot). The Ki was determined at singe UDP-Gal concentration (30 µM assuming that the 
compounds were competitive inhibitors (           )               )      )). 
 
The experiments utilising β1,4-GalT were different from LgtC experiments. The experiments 
were carried out in 13 mM HEPES + 50 mM KCl buffer (pH 7.0), including GlcNAc (10 mM), CIP 
(10 U/mL), CEL (1.0 mg/mL), MnCl2 (5.0 mM), β1,4-GalT (0.4 mU/mL) and UDP-Gal (18 µM). 
Otherwise, the assay was performed as PCA with LgtC (see Table 4.11 for the assay set up). 
 
4.5.3.5 Determination of mode of inhibition by PCA 
 
Km was determined in the absence and in the presence of inhibitor, p5 or p18 (2.0 or 5.0 µM) 
and the same data was used in Lineweaver-Burk261 plots (1/v vs. 1/[S],          
   ))           ) )           )                 )). The experiment was carried 
out in the presence of MnCl2 (5.0 mM) and UDP-Gal at 0.7, 1.6, 4.0, 10, 26 and 64 µM (see 





The Cornish-Bowden258 (1/[S] vs. [I]) and the Dixon262 (1/v vs. [I]) plots were performed in 
various inhibitor concentrations (0, 0.078, 0.156, 0.313, 0.625, 1.25, 2.5 and 5 µM) and at 20 
µM and 50 µM of UDP-Gal. Ki was calculated from the intersection of the two straight lines 
(UDP-Gal 20 µM and 50 µM) in the Cornish-Bowden plot. 
 
4.5.4 Synthesis of PP compounds 
 
All reagents used in the compound synthesis were obtained commercially and used as 
received. All the reactions were followed by TLC in 6 % MeOH in CHCl3 and the spots were 
visualized under UV light at 254/365 nm.  The TLC plates were pre-coated slides of Silica Gel 60 
F254 (Merck).  
 
The synthesised compounds were identified and the preliminary purity was obtained by 1H-
NMR on a Bruker BioSpin GmbH at 400 MHz. The accurate purity was determined by HPLC 
(Chapter 4.5.5). 13C-NMR spectra was recorded a Bruker BioSpin GmbH at 100 MHz and the 
accurate ESI-MS were obtained on a Finnigan MAT 900 XLT mass spectrometer at the EPSRC 
National Mass Spectrometry Service Centre, Swansea.  
 
 




Ethylbenzoyl acetate (1.8 g, 9.583 mmol), guanidine hydrochloride (1.0 g, 10.5 mmol), 
isovaleraldehyde (1.02 mL, 9.5 mmol), sodium bicarbonate (2.93 g) and 100 mL DMF were 
loaded in a round bottom flask and refluxed at 70 °C for 16 hours. The reaction mixture 
including an orange precipitate was then poured over ice. After the ice had melted, the 
product was filtered and dried overnight in a desiccator.  The yield of the freeze-dried solid 
185 
 
was 49 % (1.4 g). The compound was pure by 1H-NMR. The purity was not obtained by HPLC 
because the compound was not visible by UV. 1H-NMR (400 MHz; DMSO) δ= 7.38-7.10 (5H, m, 
aryl, CH), 6.18 (2H, br, s, NH2), 4.26 (1H, dd, J 3.4, 9.3 Hz, N-CH), 3.87-3.67 (2H, m, CH2CH3), 
1.85-1.71 (1H, m, CH(CH3)2), 1.49 (1H, ddd, J 4.1, 9.4, 13.4 Hz, CHCH2CH), 1.17 (1H, ddd, J 3.5, 
9.6, 13.2 Hz, CHCH2CH), 0.93 (6H, dd, J 4.1, 6.5 Hz, (CH3)2), 0.85 (3H, t, J 7.1 Hz, CH2CH3), NH 
signal was not observed; 13C-NMR (100 MHz; DMSO) δ= 166.0 (C), 155.5 (C), 144.9 (C), 142.4 
(C), 128.2 (CH), 126.8 (CH), 126.7 (CH), 98.2 (C), 57.9 (CH2), 47.5 (CH), 45.5 (CH2), 23.9 (CH3), 
22.4 (CH), 21.5 (CH3), 13.8 (CH3); HRMS (ESI









Ethylbenzoyl acetate (1.0 g, 5.208 mmol), guanidine carbonate (0.47 g, 5.222 mmol) and 100 
mL EtOH were loaded in a round bottom flask and refluxed at 70 °C for 6 hours. The clear 
solution was reduced to dryness in vacuum, then EtOAc added and white precipitate formed. 
The product was then was reduced to dryness in vacuum and the solid material was washed 
with hot MeOH. The white precipitate was filtered and dried overnight in a desiccator.  The 
yield of the freeze-dried solid was 36 % (346 mg). Pure by 1H-NMR and HPLC (100%). 1H-NMR 
(400 MHz; DMSO) δ= 10.8 (1H, br, s, NH), 7.99-7.92 (2H, m, aryl CH), 7.49-7-41 (3H, m, aryl CH), 
6.64 (2H, br, s, NH2), 6.13 (1H, s, CH); 
13C-NMR (100 MHz; DMSO) δ= 163.3 (C), 162.7 (C), 155.7 
(C), 137.3 (C), 129.9 (CH), 128.4 (CH), 126.6 (CH), 97.4 (CH); HRMS (ESI+) m/z found 188.0817 
[M-H]+, C10H10N3O













1a (50 mg, 0.166 mmol), 6-bromo-3-formylchromone (42 mg, 0.166 mmol) and 5 mL EtOH 
were loaded in a round bottom flask and refluxed at 70 °C for 5 hours. The precipitate was 
filtered hot and washed with hot EtOH. The precipitate was dried overnight in a desiccator.  
The yield of the freeze-dried solid was 46 % (41 mg) that was pure by 1H-NMR and HPLC (96 %). 
1H-NMR (400 MHz; DMSO) δ= 10.67 (1H, br, s, OH), 7.87 (1H, d, J 2.5 Hz, aryl, CH), 7.75 (1H, dd, 
J 2.4, 8.7 Hz aryl, CH), 7.51-7.26 (7H, m, aryl, CH), 7.08 (1H, d, J 8.9 Hz, aryl, CH), 4.84 (1H, br, s, 
N-CH), 3.97-3.80 (2H, m, CH2CH3), 1.70 (3H, br, s, CH(CH3)2, CHCH2CH), 1.08-0.89 (6H, m, 
(CH3)2), 0.85 (3H, t, J 7.2 Hz, CH2CH3); 
13C-NMR (100 MHz; DMSO) δ= 192.2 (C), 176.6 (C), 164.7 
(C), 160.8 (C), 153.5 (C), 148.4 (CH), 141.7 (CH), 138.1 (CH), 134.7 (C), 129.1 (CH), 128.8 (CH), 
128.7 (CH), 127.7 (CH), 121.0 (C), 113.6 (CH), 102.6 (C), 97.9 (C), 94.1 (C), 59.5 (CH2), 49.5 (CH), 
23.7 (CH), 23.4 (CH3), 13.8 (CH3); HRMS (ESI











1a (50 mg, 0.166 mmol), 6,8-dichloro-3-formylchromone (40 mg, 0.166 mmol) and 5 mL EtOH 
were loaded in a round bottom flask and refluxed at 70 °C for 5 hours. The precipitate was 
filtered hot and washed with hot EtOH twice. The precipitate was dried overnight in a 
desiccator.  The yield of the freeze-dried solid was 39 % (34 mg) that was pure by 1H-NMR and 
HPLC (95 %). 1H-NMR (400 MHz; DMSO) δ= 10.52 (1H, br, s, OH), 7.95 (1H, s, aryl, CH), 7.72 
(1H, s, aryl, CH), 7.66-7.23 (7H, m, aryl, CH), 4.95 (1H, br, s, N-CH), 4.02-3.80 (2H, m, CH2CH3), 
1.72 (3H, br, s, CH(CH3)2, CHCH2CH), 1.05-0.94 (6H, m, (CH3)2), 0.89 (3H, t, J 7.1 Hz, CH2CH3); 
13C-NMR (100 MHz; DMSO) δ= 186.7 (C), 177.0 (C), 170.9 (C), 158.0 (C), 154.7 (C), 147.5 (CH), 
137.8 (CH), 134.7 (C), 129.0 (CH), 128.3 (C), 127.7 (CH), 123.7 (CH), 123.1 (C), 121.3 (CH), 101.1 
(C), 103.8 (C), 100.8 (C), 81.9 (CH), 59.5 (CH2), 59.1 (CH2), 50.4 (CH), 23.2 (CH3), 22.6 (CH3), 22.0 
(CH), 13.5 (CH3); HRMS (ESI
+) m/z found 526.1287 [M-H]+, C27H25Cl2N3O4
+ required 526.1295. 
 
 





1a (50 mg, 0.166 mmol), 6-chloro-3-formylchromone (35 mg, 0.166 mmol) and 5 mL EtOH 
were loaded in a round bottom flask and refluxed at 70 °C for 5 hours. The precipitate was 
filtered hot and washed with hot EtOH twice. The precipitate was dried overnight in a 
desiccator.  The yield of the freeze-dried solid was 55 % (45 mg) that was pure by 1H-NMR and 
HPLC (99 %). 1H-NMR (400 MHz; DMSO) δ= 10.67 (1H, br, s, OH), 7.74 (1H, d, J 2.6 Hz, aryl, CH), 
7.64 (1H, dd, J 2.4, 8.6 Hz aryl, CH), 7.53-7.28 (7H, m, aryl, CH), 7.14 (1H, d, J 8.7 Hz, aryl, CH) 
4.85 (1H, br, s, N-CH), 3.97-3.79 (2H, m, CH2CH3), 1.70 (3H, br, s, CH(CH3)2, CHCH2CH), 1.10-0.91 
(6H, m, (CH3)2), 0.85 (3H, t, J, 7.1 Hz, CH2CH3); 
13C-NMR (100 MHz; DMSO) δ= 193.8 (C), 177.5 
(C), 164.9 (C), 160.4 (C), 153.8 (C), 148.1 (CH), 142.5 (CH), 137.4 (CH), 135.4 (C), 129.1 (CH), 
128.8 (CH), 127.7 (CH), 125.6 (CH), 120.6 (C), 118.6 (CH), 103.9 (C), 93.1 (C), 83.2 (C), 59.5 
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(CH2), 47.2 (CH), 23.4 (CH3), 23.2 (CH), 13.4 (CH3); HRMS (ESI
+) m/z found 492.1674 [M-H]+, 
C27H26ClN3O4
+ required 492.1685. 
 
 





1a (50 mg, 0.166 mmol), 6,8-dimethyl-3-formylchromone (34 mg, 0.166 mmol) and 5 mL EtOH 
were loaded in a round bottom flask and refluxed at 70 °C for 5 hours. The precipitate was 
filtered hot and washed with hot EtOH twice. The precipitate was dried overnight in a 
desiccator.  The yield of the freeze-dried solid was 51 % (41 mg) and pure by 1H-NMR and HPLC 
(96 %). 1H-NMR (400 MHz; DMSO) δ= 10.48 (1H, br, s, OH), 7.49-7.29 (9H, m, aryl, CH), 4.49 
(1H, d, J 8.6 Hz  N-CH), 4.01-3.79 (2H, m, CH2CH3), 1.84-1.63 (3H, m, CH(CH3)2, CHCH2CH), 1.19-
0.85 (15H, m, (CH3)2, CH2CH3); 
13C-NMR (100 MHz; DMSO) δ= 191.3 (C), 179.1 (C), 174.9 (C), 
169.2 (C), 165.5 (C), 152.4 (CH), 149.2 (CH), 145.9 (C), 137.4 (CH), 135.3 (C), 131.0 (CH), 129.0 
(CH), 127.5 (CH), 127.0 (C), 126.8 (CH), 124.3 (C), 116.6 (C), 105.6 (C), 59.4 (CH2), 51.1 (CH), 
41.5 (CH2), 23.6 (CH3), 23.3 (CH), 22.0 (CH3), 22.1 (CH3), 13.6 (CH3); HRMS (ESI
+) m/z found 
486.2380 [M-H]+, C29H31N3O4
+ required 486.2387. 
 









7-(5-bromo-2-hydroxybenzoyl) -2-phenyl-4H-pyrimido [1,2-a]pyrimidin-4-one (2b), 




2a (50 mg, 0.267 mmol), 6-bromo-3-formylchromone (67 mg, 0.267 mmol) and 5 mL EtOH 
were loaded in a round bottom flask and refluxed at 70 °C for 5 hours.  The precipitate was 
filtered hot and washed with hot MeOH twice. The precipitate was dried overnight in a 
desiccator.  The compound was pure by 1H-NMR and the yield of the freeze-dried solid was 2 % 
(2 mg). 
 
7-(3,5-dichloro-2-hydroxybenzoyl) -2-phenyl-4H-pyrimido [1,2-a]pyrimidin-4-one (2c), 
C20H11Cl2N3O3, Mw 411.02 
 
 
2a (80 mg, 0.428 mmol), 6,8-dichloro-3-formylchromone (104 mg, 0.428 mmol) and 8 mL EtOH 
were loaded in a round bottom flask and refluxed at 70 °C for 5 hours. The reaction was 
followed by TLC. This indicated that the reaction was incomplete. Another 1 eq of the 
chromone was added and the reaction was refluxed for a further 4 hours, resulting in no 
further conversion to the product. The precipitate was filtered hot and washed three times 
with hot EtOH and once with hot MeOH.  The yield of the final freeze-dried solid was 26 % (45 
mg) that was impure by 1H-NMR and HPLC (24 %).  
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Ethyl 7-(3,5-dibromo-2-hydroxybenzoyl) -4-isobutyl-2-phenyl-4H-pyrimido [1,2-a]pyrimidine-




1a (50 mg, 0.166 mmol), 6,8-dibromo-3-formylchromone (55 mg, 0.166 mmol) and 5 mL EtOH 
were loaded in a round bottom flask and refluxed at 70 °C for 5 hours. The precipitate was 
filtered hot and washed with hot EtOH twice. The precipitate was dried overnight in a 
desiccator. The yield of the final freeze-dried solid was 43 % (44 mg) that was impure by 1H-
NMR and HPLC (41 %). 
 
Ethyl 7-(2-hydroxy-5-methoxybenzoyl) -4-isobutyl-2-phenyl-4H-pyrimido [1,2-a]pyrimidine-3-
carboxylate(1g), C28H29N3O5, Mw 487.21 
 
 
1a (50 mg, 0.166 mmol), 6-metho-3-formylchromone (34 mg, 0.166 mmol) and 5 mL EtOH 
were loaded in a round bottom flask and refluxed at 70 °C for 5 hours. White crystals were 
formed after keeping the reaction mixture in the refrigerator for four days. The crystals were 




4.5.5 Determination of λmax and purity of the synthesised PP compounds 
 
Prior to the purity measurements, the λmax was determined for each compound by Varian Cary 
50 Bio UV-VIS spectrophotometer with Cary Scan application. The compounds were analysed 
at 100 µM and diluted in water:ACN:DMSO (50:40:10, v/v). The measurements were carried 
out in quartz (1 cm) cuvettes and the compounds were scanned from 800 nm to 200 nm. 
Measured λmax (Table 4.12) was utilised as a detection wavelength in the HPLC experiment. 
 
Table 4.12. λmax, HPLC gradient utilised and the purity of the synthesised compounds 
Compound λmax (nm) HPLC method Purity (%) 
1a  - - - 
1b  420 G1 98 
1c  420 G1 95 
1d  380 G1 99 
1e 380 G1 96 
1f  380 G1 41 
2a  310 G2 100 
2c  310 G2 24 
 
 
The purity of the synthesised compounds was determined by Perkin Elmer Series 200 HPLC, 
with Alltech Alltima C18 column (3 µm particle size, 15 cm x 4.6 mm), a DAD with desired 
detection wavelengths, a flow rate 1.0 mL/min and a column oven at 30 °C. The percentage 
purity of the compounds was calculated based on the peak area of the compound and the 
impurities. Two different gradient methods, varying water and ACN contents (Table 4.13) were 
developed and depending on the physical properties of the synthesised compounds, one of 
the two was utilised for analysis of purity. 
 
Table 4.13. HPLC gradients utilised in the determination of the purity of the compounds 
Time (min) 
G1 G2 
Water (%) ACN (%) Water (%) ACN (%) 
3 20 80 80 20 
10 20-0 80-100 80-0 20-100 
5 0 100 0 100 
1 0-20 100-80 0-80 100-20 





4.5.6  Determination of particle size by DLS 
 
All compounds were analysed with Malvern Zetasizer Nano ZS instrument and particle size 
calculations were performed by Maplethorpe data analysis software. Measurements were 
carried out in disposable 12 mm square polystyrene cuvettes. The compounds were measured 
at a final concentration of 25 µM and compounds were diluted in 13 mM HEPES (pH 7.0) buffer 
and the DMSO concentration was 10 % (v/v), mimicking the in the LDA and the PCA assay 
conditions. Each particle size and intensity value represents three independent measurements. 
The measurements were carried out at 25 °C, the refractive index and viscosity of the diluent 
(10 : 90; water : DMSO) were set up to 1.346247 and 1.06,247 respectively. Refractive indexes 
were 1.580, 1.671, 1.642, 1.639, 1.632 and 1.614 for 1a, 2a, 1b, 1c, 1d and 1e respectively 























5 Summary and future work 
 
In this project, assays for the discovery of novel GT inhibitors and for the investigation of GT 
activities have been developed. The LDA was successfully optimised and validated for the 
screening of compounds against LgtC. The PCA was demonstrated to be a time- and cost-
effective method for the enzymological inhibitor characterisation compared e.g. with the 
HPLC-based method.    
 
The LDA proved to be a robust and repeatable method during the assay optimisation. The 
enzyme and MnCl2 concentrations had a significant influence on the IC50 values obtained. The 
optimised LDA was performed without MnCl2 addition because the stock solution of LgtC 
contained MnCl2 and a high concentration of MnCl2 reduced the sensitivity of the assay. If the 
LDA is applied to other GTs than LgtC then it is important to optimise the MnCl2 concentration 
with the desired enzyme. The surfactant, TX-100, had a positive influence for the assay 
performance: in the absence of TX-100, the fluorescence signal was not completely restored in 
the ligand displacement experiments and after introducing TX-100, the fluorescence was 
completely restored, resulting in an improvement in the assay signal window (S/B ratio) and in 
the reproducibility (Z’ factor) of the LDA. The practicability of the LDA was demonstrated by 
screening a library of 393 diverse compounds in one day.  Although, the LDA is operationally 
simple to perform, the adaptation to the automated system would be advantageous because 
errors during a manual operation could be avoided and screening a large compound library 
would be more practical. The compound library screening also demonstrated that the LDA can 
be only used for the identification of competitive inhibitors and that it is important to include a 
surfactant in the assay protocol in early stages to prevent possible false positives. Currently, 
the LDA is suitable for searching potential inhibitors against LgtC, GTB and α1,3-GalT. After this 
study, it is unknown how the fluorescent UDP-Gal analogue (5FTUDP-Gal) binds to the catalytic 
site of these GTs and which interactions upon binding results in the fluorescence quenching. 
Hypothetically, a conformational change of the fluorophore occurs upon binding and causes 
the drop in fluorescence signal. A crystal structure of the fluorophore in the complex with LgtC 
or α1,3-GalT would provide useful information about the possible conformational changes of 
the fluorophore, which amino acids are involved, as well as how many fluorophore molecules 




A novel fluorescence-based glycosidase coupled assay was designed by coupling the GT 
reaction with fluorescent unnatural acceptor (Rgal) and glycosidase reaction. The major 
drawback during the development of this assay was the possible activity of LgtC on α1,4-linked 
galactose in the absence of the natural acceptor, lactose. The results obtained with the HPLC-
based method indicated that UDP-Gal was consumed rapidly compared with Rgal. The further 
investigations with LC-MS/MS showed the formation of multiple polygalactosylated products, 
Rgal-gal and Rgal-gal-gal, based on their molecular weights and retention times. The LC-
MS/MS experiments were performed in the absence of Rgal-gal and Rgal-gal-gal standards. 
Standards would provide important information regarding accurate retention times of the 
products and the correct parent and product ions which assists on compound identification. In 
conclusion, these results indicated that it is essential to design the LgtC assay using lactose as 
the acceptor preventing the α1,4-linked galactose serving as an acceptor. Alternatively, if an 
unnatural fluorescent acceptor is required, then designing an acceptor with binding affinity 
that is higher than the α1,4-linked galactose is essential for the assay performance. A 
limitation of the assays where a fluorescent acceptor is used is the narrow linear concentration 
range of the fluorescent molecule.   
 
The PCA was successfully applied to LgtC and the robustness of the method was demonstrated 
with enzymological studies. The PCA was also demonstrated as having a high tolerance to 
DMSO and being an operationally simple method which was advantageous for inhibitor 
characterisation. A disadvantage of the PCA is that the microplates fill up with controls. In 
addition to the background hydrolysis and phosphatase controls, the wells on the outer edge 
are left empty which means that the Km experiment only can be performed at seven different 
UDP-Gal concentrations (+ background hydrolysis) in triplicate. This is only a concern when the 
assay is used for the determination of the mode of inhibition and the Km is performed in 
various inhibitor concentrations. To avoid performing the assay multiple times to obtain the 
desired results it would be advantageous to apply the PCA to 384 well microplates.    
 
Two compound libraries were screened and two classes of hits were identified. One class 
proved to be molecular aggregators that resulted in non-specific inhibition and the other class 
was a real inhibitor against LgtC. The further investigations demonstrated that the compounds 
(pyrazolones) inhibited LgtC at micromolar range, however, they were mixed inhibitors. The 
results obtained by the ligand displacement assay suggested that the pyrazolones bind to the 
donor binding site because the fluorescence was partly recovered. Initially, the pyrazolones 
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were designed as acceptor analogue inhibitors of WaaC.250 Therefore, hypothetically, if the 
pyrazolones bind to acceptor binding site then the fluorophore remain on the donor binding 
site and fluorescence cannot be recovered (Figure 5.1, A). This hypothesis could be 
investigated by performing the assay in the presence of acceptor (Figure 5.1, B).  A mixture of 
acceptor, fluorophore and LgtC would be incubated first, to ensure that the fluorescence signal 
is quenched. Then incubation in the presence of inhibitor would result a high fluorescence 
signal if the pyrazolones binds to the acceptor binding site and to the donor binding site. 




Figure 5.1. A) Possible outcome of the LDA when the fluorophore is displaced with pyrazolones. B) The 
principle of the fluorophore displacement in the presence of acceptor in order to investigate if 
pyrazolones bind to the acceptor binding site. Abbreviations: A; acceptor, F; fluorophore, I; inhibitor  
 
If the pyrazolones bind to the donor and to the acceptor binding sites, or if one pyrazolone 
molecule binds to the donor-acceptor binding site then they could be modified to a specific 
competitive inhibitors. However, further developments require a detailed docking study or a 









1. Phosphatase coupled assay development with β1,4-GalT 
 
During the course of this project, a novel phosphatase coupled assay was reported85. 
Difficulties to reproduce this assay in house were encountered. Dr Evitt carried out this 
optimisation study with β1,4-GalT. Because the assay conditions used in this thesis are not yet 
published they are presented here. 
 
Dr Evitt discovered an alternative phosphatase which cleavages the phosphate group 
specifically only from UDP and which was financially more viable than the phosphatase used in 
the reported PCA:85 a calf intestinal alkaline phosphatase (CIP) that catalyses the cleavage of 
terminal phosphate from the 5’phophorylated ends of DNA or RNA and is widely used in 
molecular biology.263 The optimum CIP concentration was examined by varying CIP and UDP 
concentrations (App. 1, A) and formed phosphate was detected by malachite reagents.85 The 
plateau was reached approximately at 10 U/mL of CIP at 12.5 and 25 µM of UDP whilst at 
lower UDP concentrations less CIP was required to release phosphate. In order to determine 
how many phosphates CIP at 10 U/mL hydrolyse from UDP, a standard curve of UDP and 
inorganic phosphate at the same concentrations were compared.  At the tested range 10 U/mL 






App. 1. A) Optimisation of CIP concentration in various UDP concentrations. B) Formation of phosphate 
by hydrolysis of UDP vs. phosphate standard curve 
 
Dr Evitt investigated if UDP-Gal behaves as a substrate for CIP by performing a standard curve 
of UDP-Gal. The results indicated that if CIP releases phosphate from UDP-Gal it is from an 
impurity or hydrolysis product, UDP (App. 2, A). This was further investigated at fixed 
concentration of UDP-Gal with increasing concentration of CIP (App. 2, B). The results clearly 
demonstrated that UDP-Gal was not a substrate of CIP because 43 µM of phosphate at most 
was released from 600 µM of UDP-Gal, indicating that UDP-Gal contained approximately 7 % 
phosphate impurity. The phosphate impurity was then subtracted from the main signal by 
including a control in each UDP-Gal concentration in the absence of acceptor. In addition, the 































y = 0.0615x + 0.2116 
R² = 0.9986 
y = 0.0302x + 0.2063 



















App. 2. A) Formation of phosphate by hydrolysis of UDP-Gal. B) Increasing concentration of CIP at 600 
µM UDP-Gal  
 
β1,4-GalT was used as a model enzyme to develop suitable conditions for enzymatic kinetic 
studies. Dr Evitt applied the assay to determine Km of the donor substrate UDP-Gal. However, 
under the current assay conditions Vmax vary significantly (App. 3, A, red curves). The results 
were reasoned that under the assay conditions, β1,4-GalT may be susceptible to attach to 
plastic surfaces (i.e. microplate wells, pipette tips etc.) and consequently to affect the active 
enzyme concentration which can be significant as β1,4-GalT is present in low concentrations in 
the assay. The active concentration of the enzyme and the length of exposure to the plastic 
can vary, therefore, affecting the assay results. This problem is often improved by the adding 
of a carrier protein such as BSA to the assay buffer. However, Dr Evitt discovered that BSA 
significantly prevents the colour development of the malachite reagents thus an alternative 
carrier protein was required.   
 
 
App. 3. A) Replicates of Michaelis-Menten plots for β1,4-GalT varying UDP-Gal substrate concentration. 
B) Time course data for β1,4-GalT in the presence and in the absence of hen egg white-cell lysozyme, 
CEL. Red curves: experiments conducted in the absence of carrier protein CEL. Blue curves: identical 
experiments conducted in the presence of 1 mg/mL CEL 
y = 0.0025x + 0.1937 



























































































Various compounds such as single amino acids (e.g. Cys, Leu), surfactants (e.g. TX-100) and a 
selection of proteins (e.g. BSA) were tested as potential carrier proteins. Hen egg white-cell 
lysozyme (CEL) was a potential option because the colour development of the malachite 
reagents was not hindered in its presence. The further investigations showed significant 
improvement in the reproducibility of Vmax (App. 3, A, blue curves) in the presence of CEL and 
in the time-course experiment, the activity of β1,4-GalT dropped by half over 200 minutes in 
the absence of CEL (App. 3, B). The results clearly showed that CEL acted as a carrier protein 
and β1,4-GalT preserved full activity in the presence of CEL. Dr Evitt improved the PCA 
significantly by using CIP and CEL in the assay set up and during the optimisation the assay 
demonstrated to be a useful tool for GT activities.  
 
The optimised phosphatase coupled assay conditions are presented in App. 4. All the β1,4-GalT 
reactions were carried out in 13 mM HEPES + 50 mM KCl (pH 7.0) buffer, including MnCl2 (5 
mM), DMSO (10% (v/v)), CEL (1 mg/ml), CIP (10 U/ml), β1,4-GalT (0.4 mU/mL), GlcNAc (10 
mM). UDP-Gal was added as a starter to the β1,4-GalT reactions and UDP to the calibration 
curve/phosphatase control. The reactions were incubated for 20 minutes at 30 °C and stopped 
by adding malachite reagent A and mixed thoroughly, and then malachite reagent B was added 
and again mixed thoroughly. The colour development was monitored for 30 minutes. 
 
App. 4. Phosphatase coupled biochemical assay set up 
Assay step Component [Stock] [reaction] Volume in 
well, µL 
1 GlcNAc/ Buffer 50 mM 10 mM 30 
CIP  100 U/ mL 10 U/ mL 15 
MnCl2 50 mM 5.0 mM 15 
CEL 10 mg/ mL 1.0 mg/ mL 15 
 DMSO 100 % 10 %a 15 
2 β1,4-GalT/ Buffer 5x 1x 30 
3 UDP-Gal/ UDP 5x 1x 30 
4 20 min incubation at 30 °C    
5 Malachite reagent A 5x 1x 30 
6 Malachite reagent B 5x 1x 30 






2. List of reagents 
 
Reagent Purity Supplier 
ACN HPLC grade 
Fisher 
Scientific 
Ammonium Acetate  98.7 % VWR 
Ammonium molybdate (para) 
tetrahydrate  




6-bromo-3-formylchomone 99 % Sigma 
BSA >98 % Sigma 
Casamino acids - 
MP 
Biomedicals 
CEL (Hen egg white lysozyme) - Merck 
6-chloro-3-formylchomone 97 % Acros 
CIP (calf intestinal phosphatase) - 
New England 
Biolabs 
Dialysis tubing - Sigma 
6,8-dibromo-3-formylchomone 99 % Sigma 




DMF (dimethylformamide) ≥99.5 % Sigma 
DTT >99 % Sigma-Aldrich 
Enolpyruvate kinase - Sigma 
EtOH 99.9 % VWR 
galactosidase (β-D-Galactoside 
galactohydrolase, Lactase from 
Aspergillus oryzae) 
- Sigma 
GlcNAc 99 % Fluka 
Glucose - Lab M Limited 




HCl 37 % Sigma-Aldrich 
HEPES ≥99.5 % Sigma-Aldrich 





- Bioline Ltd. 
isovaleraldehyde  Sigma 
KCl 99 % BDH 
Lactate dehydrogenase - Calbiochem 
Lactose (α-D-Lactose monohydrate) 97 % Alfa Aesar 
M9 Minimal Salts, 5X - Sigma 
Malachite green oxalate - Alfa Aesar 
MgCl2 ≥98 % Sigma 
6-metho-3-formylchomone 
 
99 % Sigma 
201 
 
Reagent Purity Supplier 
MeOH HPLC grade 
Fisher 
Scientific 
MnCl2·4H2O ≥99 % Acros 
MOPS 99 % Acros 
NaCl Extra pure Acros 
NADH (β-nicotinamide adenine 
dinucleotide, reduced form) 
≥95 % Sigma 
NuPAGE 4-12% Bis-Tris 12well gel - Invitrogen 
NuPAGE antioxidant solution - Invitrogen 
NuPAGE LDS sample buffer (4X) - Invitrogen 
PAGE ruler prestained protein marker - Fermentas 
Nutrient Agar - 
Fisher 
Scientific 
Phosphoenolpyruvate 99 % Sigma 
Potassiumphosphate dibasic, (K2HPO4) ≥99.0 % Fluka 
Potassiumphosphate monobasic, 
(KH2PO4) 
≥99.5 % Fluka 
PVA (Polyvinyl alcohol) 99% Alfa Aesar 
Rgal (Resorufin-β-D-galactopyranoside) ≥95 % Fluka 
Resorufin 95 % Sigma-Aldrich 
SimplyBlue safestain - Invitrogen 
TBAHS (tetrabutylammonium hydrogen 
sulphate) 
≥99.0 % Sigma-Aldrich 
TRIS 99.8 % Acros 




UMP 98 % Acros 
UDP  ≥99.5 % Sigma 
UDP-Gal 97.1 % CalbioChem 
uridine >99 % Sigma 
Vitamin-B1 (thiamine) - 
MP 
Biomedicals 
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